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INTRODUCTION
Acute renal failure (ARF) on the basis of acute tubular necrosis (ATN) was defi ned in the 
early days of the 20 th century by the German pathologist Hackstadt. His observations were 
based on the clinical evaluation of soldiers who sustained severe traumatic injury. However 
its signifi cance was more or less neglected until the second world war, when Bywaters des-
cribed the crush injury syndrome in victims of the London Blitz (1). Initially the underlying 
morphological changes in this kind of renal failure was thought to be related to distal tu-
bular injury due to pigment toxicity and the term lower nephron nephrosis was introduced 
for this clinical condition (2). Later classic micro dissection studies in kidneys of rats showed 
that the dominant side of injury in ATN was the straight segment of the proximal tubules 
(S3 segment, pars recta) (3). 
Diversities of acute renal failure
The diversity of defi nitions has hampered the analysis with regard to the incidence of ARF, 
as it may present with or without oliguria. Some studies defi ned ARF on the basis of ele-
vated serum creatinine concentration; others referred to the increments above baseline 
serum creatinine levels or included only patients with ARF who required dialysis. ARF is 
caused by a variety of different etiologies and occurs in a variety of clinical settings. In daily 
clinical practice, ARF due to hypo-perfusion is one of the most common forms of ARF, it 
may account for 40 to 80 per cent of all cases of ARF, and if prolonged, pre-renal ARF may 
develop into ATN. Postrenal causes of ARF by ureter-, bladder neck or urethral obstruction, 
are less common causes of ARF and are encountered in only 2 to 10 per cent of all cases. 
Renal causes of ARF are diseases like acute and crescentic glomerulonephritis, hemolytic 
uremic syndrome, interstitial nephritis and ATN.
Acute tubular necrosis
Studies on patients with ARF due to ATN illustrate that different insults to renal function can 
be present simultaneously. The most common predisposing factor in the development of 
ATN appears to be renal ischemia resulting from prolonged oxygen deprevation resulting 
clinically in pre renal azotaemia. Sepsis is a major predisposing factor and nephrotoxins 
account for about 25 per cent of all cases of ATN (amino-glycosides, radiocontrast media, 
organic solvents, NSAID’s and heavy metals). ATN can also be the result of heavy loads of 
haem pigment to be excreted by the kidney, such as in rhabdomyolysis or haemolysis (4). It 
has been estimated that some 40 to 60 per cent of cases of ATN occur in a postoperative or 
trauma related setting, while the remainders emerge in a medical setting. The causes of the 
renal failure in these circumstances are often multifactorial in origin. High-risk settings are 
abdominal aortic aneurysm surgery, severe burns, pancreatitis, and advanced chronic liver 
disease. Mortality associated with ATN was reported to be between 37 % and 79 % (5).
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Pathophysiology of renal failure in ATN
One of the possible mechanisms of the decreased GFR in ARF due to ATN is related to 
tubular damage resulting from ischemia/reperfusion injury. Degeneration, necrosis and 
exfoliation of tubular epithelium, interstitial edema and interstitial cellular infi ltration are 
usually observed in biopsies in ARF (6). There are two possible explanations for the im-
paired glomerular fi ltration rate. 
One of the possible mechanisms of decreased GFR is tubular obstruction and tubular 
backleakage or there is a maladaptive response of the tubuloglomerular feedback loop.
Tubular obstruction and backleakage: In the early phase of ATN, tubular obstruction by ex-
foliated tubular cells and protein precipitates results in tubular obstruction and elevated 
proximal and distal intratubular pressures and a low net fi ltration pressure (7). Although 
obstruction is morphologically hard to demonstrate, since it can be present on many levels 
of the nephron, high intratubular pressures can be demonstrated in animal models (8,9). 
Increased intratubular pressures are always present in cases of ischemic ATN but they do 
not sustain, as they decline in a period of days to normal or even low levels. Lowering of 
intratubular pressure is not uniformly associated with recovery of renal function. Another 
possibility, associated with the obstruction theory, is the existence of backleakage. Backlea-
kage of glomerular fi ltrate was demonstrated and associated with severe tubular dysfunc-
tion in animal models (10,11). Myers et al demonstrated the existence of backleakage in 
human ATN (12). The underlying pathophysiological mechanism is the disruption of the 
intercellular tight junctions in damaged tubular cells. Although it explains the impaired 
glomerular fi ltration rate in more severe ATN cases (12) it does not explain the decline of 
GFR in milder cases of ATN.
Decreased tubuloglomerular feedback: Another explanation for the relation between de-
cline in glomerular fi ltration and tubular damage, is the reduction in renal bloodfl ow under 
the infl uence of decreased sodium and chloride reabsorption. The supply of chloride and 
sodium to the juxtaglomerular apparatus leads to an afferent and efferent vasoconstriction 
and diminished renal blood fl ow and glomerular fi ltration pressures (13,14). This can be 
seen as a maladaptive mechanism of a teleologically appropriate mechanism of the kidney 
to prevent excessive loss of fl uid and electrolytes (15). 
ARF in renal transplantation
In renal transplantation a delayed start of graft function (DGF) is found in 10-50% of cases 
(16-21). Literature on the pathophysiology and morphology of ARF in transplanted kidneys 
is scarce. Although risk factors for DGF and ARF in native kidneys are different in transplan-
ted kidneys than in native kidneys, the underlying morphological and pathophysiological 
characteristics are often considered to be similar. The prevailing views are mainly based on 
studies of acute tubular renal failure in experimental animals (22). 
In renal transplantation risk factors for delayed renal function immediately after transplan-
tation are well known. They can be divided into donor linked factors, factors related to the 
transplantation procedure and factors related to the post-transplant period. These clinical 
conditions are unique for the transplantation setting and therefore differ substantially from 
the conditions in which ARF occurs in native kidneys. This makes the comparison with ARF 
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in native kidneys hazardous. Experimental data on ischemia and reperfusion injury are also 
diffi cult to interpret since in these conditions the kidney usually is totally deprived from 
perfusion by clamping the renal artery. Despite these limitations, the literature on ischemic 
ARF in native kidneys and on experimental ATN could contribute to our understanding of 
the pathophysiology of DGF and its meaning for graft outcome and for the development 
of specifi c therapeutic interventions. 
Defi nition of DGF
In most studies DGF is defi ned as the need of dialysis treatment in the fi rst week. This is a 
criterion that is easy to register objectively and to obtain from large databases. However, 
dialysis during the fi rst week after transplantation is also performed for other reasons than 
DGF, like hyperkaliemia and fl uid overload. Others defi ne for that reason DGF as a functi-
onal parameter distinct from the need of dialysis and use the time needed to achieve an 
arbitrarily defi ned creatinine clearance as a marker for DGF. Since, the pathogenesis of DGF 
is supposed to be of ischemic origin it is relevant to defi ne DGF as a functional abnormality 
distinct from the need of dialysis treatment. In addition acute rejection should be excluded 
as a cause of DGF. We propose to use a functional defi nition using the decrease of serum 
creatinine of more than 10% per day for at least 3 consecutive days for more than 1 week 
after transplantation and excluding acute rejection and calcineurin inhibitor toxicity as a 
possible cause of this DGF. Using this defi nition, it is possible to analyze the risk factors and 
consequences of ischemic damage and associated reperfusion injury that is supposed to be 
the underlying cause of DGF and excluding changes of serum creatinine concentration by 
other causes like dilution, surgical complications, cyclosporin toxicity and acute rejection. 
DGF and long-term graft survival
The effect of DGF on short term and long term patient and graft survival is still controver-
sial. Some authors found a deleterious effect effect of DGF on graft survival (20,23) and 
others did not or only found this effect when it coincided with acute rejection episodes 
(24). These discrepancies may be related to the criteria used to defi ne DGF or to differen-
ces in data analysis. Most authors used the need for dialysis within the fi rst week as the 
diagnostic inclusion criterion but this does refl ect the various causes of DGF such as ische-
mia- reperfusion injury, early acute rejection episodes or calcineurin inhibitor toxicity. In 
the UNOS registry, DGF was defi ned as the need for dialysis in the fi rst week after trans-
plantation. It had a signifi cant and independent impact on graft half-life. This effect was 
independent from cold ischemia time, occurrence of acute rejection episodes, donor age 
and serum creatinine levels (25). Others found a detrimental effect of DGF, also defi ned as 
the need for dialysis in the fi rst week, on graft survival only when it was complicated by one 
or more acute rejection episodes (24,26,27). When the time required to reach a Cockroft 
renal clearance of more than 10 ml/min was used, DGF lasting for more than 6 days had a 
deleterious effect on graft survival whereas DGF of shorter duration did not infl uence graft 
survival (28). 
Looking at the different survival curves it is striking that one year after transplantation the 
survival curves essentially run parallel. This suggests an effect of DGF on graft survival wit-
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hin the fi rst year but no effect beyond. This is supported by studies that analyzed the risk 
factors on graft survival at different time intervals after transplantation and found that pro-
gression of chronic graft failure is mainly associated with donor age, creatinine clearance at 
1 year after transplantation, proteinuria and the presence of hypertension in the recipient 
and not with the occurrence of DGF.
Risk factors of DGF
Risk factors for DGF can be divided in donor-related factors, transplantation-related factors 
and recipient related risk factors. The cadaveric kidney is subject to damage at every step 
along the way from procurement to reperfusion whereas kidneys from living donors rarely 
develop DGF.
Donor related risk factors
Well-known donor related risk factors for DGF are donor age over 50 years and an elevated 
serum creatinine or decreased renal function of the donor. In human adults total metabo-
lism and renal function in terms of glomerular fi ltration rate and renal blood fl ow and mus-
cle mass decrease with age. This implies that for the same serum creatinine concentration 
GFR in the elderly can be severely impaired in comparison to younger adults. Kidneys from 
older individuals may have several structural and functional changes compared with kid-
neys from younger donors. Longitudinal studies of elderly individuals have shown a dimi-
nution in renal reserve, along with functional constraints on the kidney’s ability to respond 
appropriately to challenges of either excesses or defi cits (29). Studies of kidneys obtained 
at autopsies demonstrated a progressive decrease in the number and size of glomeruli 
with age, resulting in a progressive decrease of the glomerular fi ltration volume (30,31). 
In addition to the loss of glomeruli, there is an age-dependent increase in the cortical in-
terstitial volume as a result of progressive interstitial fi brosis (31,32). Most renal biopsies 
from kidney donors who are older than 40 yr show intimal fi brosis in the smaller arteries, 
arteriolar hyalinosis, and interstitial fi brosis (33).
Not only factors intrinsically related to the donor, but also the events prior to brain death 
and harvest of the kidney contribute to the occurrence of DGF. Before the establishment of 
brain death of the potential donor, the kidney may be damaged by the underlying disease 
process, or by the therapeutic maneuvers instituted in an attempt to revive the patient or 
to maintain circulation after brain death, like the use of dopaminergic medication and re-
suscitation procedures. Decreasing platelet count and disseminated intravascular coagu-
lation are frequent and suggest that endothelial injury or dysfunction may already be pre-
sent in the postmortal donor. During episodes of cardiac arrest or prolonged hypotension, 
the kidney will suffer from warm ischemia and reperfusion injury. Catecholamine release 
and pharmacological inotropes may contribute to intrarenal vasospasms leading to rela-
tive hypoperfusion. The donor will be in a catabolic state, making recovery from ischemic 
damage more diffi cult. Finally many donors have evidence of intravascular coagulation, 
which may be either a cause or a consequence of endothelial injury in the microcirculation. 
In addition after brain death but before explantation, the patient may not be considered a 
high priority for surgery at a busy intensive care unit and resuscitation may be delegated 
to those with limited experience in appropriate care (34).
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Risk factors related to the transplantation procedure
Organ procurement also contributes to the development of DGF. This starts with hypo-
perfusion after circulation of the donor has stopped (warm ischemia time (WIT)). With the 
multi organ procurement procedures this WIT is limited to several minutes. However, with 
the raising interest of non-heart beating procedures, WIT becomes a serious contributor to 
DGF (35,36). During surgery errors in line placement can result in inadequate fl ushing of 
blood and cooling, and undue manipulation of renal arteries can induce vascular spasm. 
The most important independent and robust risk factor is cold ischemia time (CIT) (18,37-
42). During preservation the kidney is exposed to ATP depletion probably enhanced by re-
perfusion induced vasoconstriction, resulting in apoptosis and necrosis of individual cells 
and leading to severe functional damage (43). The type of preservation fl uid also has been 
recognized as a risk factor for DGF in a study in the Eurotransplant area, in which the pre-
servation fl uid developed by the University of Wisconsin (UW) appeared to be superior to 
Euro Collins (EC) (44). Cold pulsatile perfusion in which organs are perfused with a pulsatile 
preservation machine are described to have a lower incidence of DGF than organs that are 
preserved with a cold fl ush (40).
After perfusion is re-established several mechanisms exist that can damage the renal allo-
graft including the generation of free radicals, mechanical injury to blood vessels from sud-
den high blood fl ow, vasomotor derangement from prostaglandins and other regulatory 
peptide imbalances and cytokine release from infl ammatory infi ltrates (45)
Recipient related risk factors 
Recipient age is a risk factor for DGF especially when kidneys from pediatric donors to adult 
recipients are involved (20). The relation between the occurrence of DGF and the discre-
pancy between donor and recipient Body Mass Indexes (BMI) supports this hypothesis (46). 
Secondary hyperparathyroidism is also associated with a higher incidence of DGF (47,48). 
The lower occurrence rate of DGF with zero HLA mismatch and low levels of panel reactive 
antibodies (PRA) (49), suggests that immunology related factors are involved in the develop-
ment of DGF. Since the studies that describe this effect, used dialysis treatment in the fi rst 
week as their defi nition of DGF, it is very likely that early acute rejection activity is the missing 
link (20,40,50). In addition, the use of calcineurin inhibitors is a riskfactor because their vaso-
constrictive properties infl uence renal perfusion and enhance ischemic damage (51). 
Morphological characteristics of ATN in native kidneys and grafts
Changes in renal morphology that accompany ARF in native kidneys are subtle (52,53). In 
renal biopsies from patients suffering ARF, regeneration and necrosis coexist, suggesting 
that the injury and repair process coincide. Solez studied 57 biopsies from patients with 
ARF and defi ned twelve characteristic morphological items for ATN (52,53). These items 
represent the morphological consequences of necrosis and regeneration respectively. 
Markers for necrosis were: the presence of individual necrosis, loss of brush border, tubular 
dilatation and the presence of tubular casts, signs of interstitial infl ammation and edema, 
hyperplasia of the juxta glomerular apparatus, dilatation of Bowman’s space, tubulariza-
tion of the parietal epithelial cells of Bowman’s capsule. As signs of recovery the presence 
of mitotic fi gures and signs of tubular regeneration were studied. Also the accumulation of 
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leukocytes in the vasa recta were scored as signs of ATN. All items were scored on a 4 point 
scale from score 0 representing the absence of the item to score 3+, representing abun-
dant presence of the item. Only the presence of necrosis of individual tubular cells and the 
loss of the brush border were specifi c for oliguric ARF compared to biopsies from patients 
that had recovered recently from ARF (52). ARF after renal transplantation has a distinctly 
different etiology than ARF in native kidneys. Therefore the same group of investigators 
compared the above mentioned 57 biopsies with 13 allograft biopsies from patients with 
DGF and 5 biopsies from grafts with a stable function. The most striking difference bet-
ween the graft biopsies with DGF and the biopsies from native kidneys with ARF due to 
ATN was that the non-replacement phenomenon was seen more often in the grafts. They 
also had larger interstitial infi ltrates than the native kidneys with ATN. Furthermore grafts 
with DGF showed slightly less frequent disappearance of the tubular brush border, fewer 
tubular casts, less dilation of the Bowman’s space but a greater number polarizable oxalate 
crystals (6,54). Another striking feature in biopsies of ATN is the presence of an interstitial 
infi ltrate. It is supposed to be related of the process of brain death (55) and ischemia/reper-
fusion injury leading to a local infl ammatory reaction which is possibly associated with the 
production of free oxygen radicals (56,57). Ischemia and reperfusion injury is associated 
with an upregulation of pro-infl ammatory cytokines like interleukines (IL-1, IL-6, IL-8 and IL-
10) and monocyte chemoattractant protein 1 (MCP-1) (58-60). As a consequence adhesion 
molecules that are important in the migration of leucocytes, like intercellular adhesion mo-
lecule-1 (ICAM-1), vascular adhesion molecule (VCAM) and endothelial leukocyte adhesion 
molecule-1 (ELAM-1) (61,62) also are upregulated. 
Marcussen concluded there were no differences between biopsies with ATN of native and 
transplanted kidneys, as far as the composition of the interstitial infi ltrates is concerned 
(6) but that in contrast to acute rejection episodes the infi ltrate in ATN consisted mainly of 
granulocytes. Haug and Dragun showed in animal models that the detrimental effects of 
ischemia and reperfusion could be minimized with neutropenia and the use of blocking 
anti-bodies against ICAM-1, LFA-1 and P-selectin (63) or ICAM-1 antisense oligodesoxynu-
cleotides (64).
Pathogenesis of acute ischemic renal injury and subsequent recovery
In the pathogenesis of acute ischemic failure 3 stages can be recognized. The fi rst stage 
is the ischemic phase in which ischemic and reperfusion injury takes place and in which 
renal epithelial and endothelial cells are subjected to lethal insults leading to apoptosis 
and /or necrosis (65). The maintenance phase represents a phase of stabilization of injury 
by intrinsic or upregulated defense mechanisms. During this phase events leading to cellu-
lar repair, proliferation and redifferentiation. lead to the recovery phase in which epithelial 
en endothelial function improve, leading to the recovery of renal function. 
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1. Ischemia and reperfusion in ATN
a. Molecular biological characteristics
Ischemic phase
During the ischemic phase, renal tissue suffers from the lack of oxygen and nutritional sub-
strates whereas cell metabolism continues, resulting in decreased adenosine triphosphate 
(ATP) levels and a decreased supply of adenosine diphosphate (ADP) to the mitochondria 
(66). The shift to anaerobic metabolism results in the accumulation of lactic acid and a de-
crease in pH. One of the most energy intensive cell functions is sodium and water homeos-
tasis via the sodium–potassium pumps (67). When these pumps fail cellular, mitochondrial 
and nuclear swelling occurs. Increased extracellular potassium stimulates calcium ion chan-
nels, increasing cytosolic and mitochondrial calcium concentrations (68). Cytosolic calcium 
levels activate calcium dependent enzymes like cystein proteases, the phospholipases and 
endothelial nitric oxide synthetase (e-NOS) (69). Calpain is an example of a calcium de-
pendent cystein protease capable of disrupting the cellular polarity by breaking down the 
integrity of the organizational proteins spectrin and ankyrin whereas caspase-3 is a calcium 
dependent cystein protease playing a major role in programmed cell death. Phospholi-
pase-2 is able to change tubular cell polarity by breaking down cytoskeleton matrix and it 
plays a role in the synthesis of reactive oxygen species (ROS). The role of e-NOS is dual since 
it has been proven to be tubulotoxic (70), but also causes vascular dilation (71). 
In this ischemic condition, hypoxanthine is the most damaging degradation product. It 
accumulates in the cell as a byproduct of the conversion of ATP to inosine. Under aerobic 
conditions hypoxanthine is metabolized via the production of xanthine to uric acid but 
in anaerobic conditions hypoxanthine accumulates in the endothelial and tubular cells. 
Xanthine oxidase is produced by proteolysis of the xanthine dehydrogenase under the 
infl uence of calcium dependent proteases (72). 
Reperfusion phase
After the reinstitution of perfusion several factors contribute to the damage. The sudden 
increase of perfusion pressure causes endothelial damage and infl ammation. Because of 
unequal distribution of perfusion, ischemia may persist in underperfused areas. Two ty-
pes of molecules have been widely studied and have been implicated in ischemia and re-
perfusion injury; i.e. endothelin and Nitric Oxide (NO), which both modulate vascular tone. 
During ischemia systemic endothelin levels are elevated whereas anti-endothelin antibo-
dies or endothelin receptor antagonists protect against ischemia and reperfusion injury 
(73,74). Many of the actions of endothelin are counteracted by constitutively expressed 
and endothelin induced Nitric Oxide (NO). NO causes vasodilatation which protects against 
ischemic renal injury (75), but on the other hand it also is toxic for tubular cells (70,71). This 
toxicity is probably caused by one of its metabolites, peroxynitrite, , which is a highly reac-
tive oxidant resulting from the interaction between NO and the superoxide anion. During 
reperfusion molecular oxygen (O
2
) is reintroduced (fi g.1). O
2
 reacts with the hypoxanthine 
that has accumulated in the cells during the ischemia phase. This reaction is mediated by 
xanthine oxidase and produces xanthine and reactive oxygen species (ROS). ROS refers to 
any compound derived from molecular oxygen that has acquired less than 4 electrons. The 
free radical members of ROS are Superoxide (.O
2
) and the hydroxyl radical (.OH). They are 
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probably the most important biologically active free radicals..O
2
 is formed by transfer of a 
single electron to O
2




). The latter reaction 
is spontaneous but is accelerated in the presence of a catalyzing transitional metal ion, for 
example Iron (Fe 3+) or Copper (Cu 2+). 
The free radicals lead to an oxidative reduction of the poly unsaturated fatty acids (PUFA’s) 
in the plasma membranes, known as lipid peroxidation. This lipid peroxidation leads to the 
production of fatty acid radicals and by reacting with oxygen to fatty acid peroxyl radicals 
(LOO.) These LOO.’s are the central players in a chain reaction that leads to further lipid 
peroxidation and the formation of reactive aldehydes. The harmful effect of the production 
of free radicals lies in the extensive damage to the cell membrane, leading to decreased 
function and/or cellular apoptosis or cell death (76-79)
b. Cell biological characteristics
Ischemia and reperfusion eventually lead to tubular cell death. Two types of cellular death 
can be distinguished: cells may die either by necrosis or by apoptosis. The morphological 
characteristics of apoptosis and necrosis are both quite distinct and remarkably constant 
among all kind of different cell types. 
Figure 1. Schematic representation of the ischemia and reperfusion injury cascade 
A period of oxygen deprivation results in a deprivation of cellular ATP. Hypoxanthine accumulates 
in the cell as a byproduct of the anaerobic conversion of ATP to inosine. Xanthine oxidase cata-
lyses the reaction of hypoxanthine and oxygen to form reactive oxygen species (ROS). The free 






OH are the most harmful ones. They lead to lipid peroxidation 
in the cellular membrane, eventually leading to cell death by destruction of the cellular walls. 
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Apoptosis
In contrast to necrosis, apoptosis is an active, energy dependent process with morpholo-
gical characteristics that differ markedly from necrosis. Epithelial cells dying by apoptosis 
detach early from the underlying matrix and from each other. They become progressively 
smaller in size and their nuclear chromatin becomes condensed and fragmented. The plas-
ma membrane remains intact and undergoes a process called blebbing. Ultimately, the 
apoptotic cell disintegrates into many membrane-bound vesicles, some of which contain 
fragments of condensed chromatin, the so-called apoptotic bodies. Apoptosis is a form of 
programmed cell death which is used physiologically to remove unwanted cells. The es-
sence of apoptosis is a process of cellular auto-digestion. 
Three stages can be recognized in the process of apoptosis (fi g.2). 
The fi rst stage is the regulator stage. Regulator molecules control adaptor proteins by di-
rectly interacting with them. For example FADD (Fas associated death domain) activation 
can be inhibited by cellular FLIP (FLICE (Fas associated death domain like IL-1 beta conver-
ting enzyme) inhibitory protein). Apaf-1 (apoptotic protease activating factor 1) activation 
can be prevented by binding to the anti-apoptotic members of the Bcl-2 families. Further-
more inhibitors of apoptosis proteins (IAP) can directly prevent caspase activation.
The second stage in the apoptosis process is the adaptor stage. The adaptor molecules are 
able to activate the caspases by binding to specifi c sides and therefore leading to prote-
olysis of the pro-enzyme. Adaptor molecules are up-stream caspases, like caspase 8 and 
caspase 9, that activate caspase 3 as the fi nal common caspase. Caspase-8 becomes acti-
vated by binding to the FADD adaptor protein and caspase-9 is activated by it’s adaptor 
protein Apaf-1.
Figure 2. Schematic representation of the apoptotic cascade
Apoptosis can be initiated by multiple signals. The strength of the apoptotic signal is evalu-
ated by specifi c control proteins which can either inhibit or promote cell death. When the 
apoptotic signal is strong enough, caspase activation degrades cytoskeletal and nuclear pro-
teins. This results in a cascade of intracellular degradation, eventually leading to the forma-
tion of apoptotic bodies and the engulfment of apoptotic material by phagocytic cells. 
Apoptotic stimulus Cytotoxic T cells; Injury; Growth factor withdrawal;  Death receptors
Regulator Phase FADD Apaf-1 Bax; BAD
FLIP Bcl-2; Bclxl















The last stage is the effector stage. The key effector molecules are proteases named cas-
pases of which the caspase-3 is the effector enzyme. Caspases are present in an inactiva-
ted form. Once they are activated the target of these activated caspases is ICAD (inhibitor 
of caspase activated D-nase (CAD). CAD is an endogenous endo-nuclease that fragments 
DNA of cells. Once activated CAD leads to fragmentation of the cellular DNA. Hence DNA 
fragmentation can be used as a marker of apoptosis. 
Necrosis
Frank necrosis is seen in experimental animal models but only in a minority of the human 
cases. It is usually patchy involving individual cells or small clusters of cells sometimes re-
sulting in small areas of denuded basement membrane (non-replacement phenomenon). 
Tubular cell necrosis is associated with a rapid metabolic collapse, cell swelling and early 
loss of plasma membrane integrity and the loss of polarity. Integrity of their tight junctions 
is disrupted, perhaps as a consequence of alterations in the cytoskeletal network (67,80). 
Because of the redistribution of the Na/K-ATPases, tubular function is disturbed and cells 
die. This in turn leads to the release of proteolytic enzymes and other injurious cytosolic 
components into the extracellular space that not only directly damage surrounding cells 
but also incites an infl ammatory response. More subtle changes include loss of brush bor-
der, fl attening of the epithelium, detachment of cells, intra-tubular cast formation and di-
lation of the tubules (fi g.3).
Figure 3. 
Cell biological characteristics 
of acute tubular necrosis 
Cells undergoing acute tubular 
necrosis are morphologically 
characterized by loss of brush 
border, fl attening of the epithe-
lium (distalisation of proximal 
tubular cells) and detachment 
of necrotic cells leading to in-
tratubular cast formation and 
dilation of the tubules. This 
makes distal tubules hard to be 
discriminated from the proximal 
ones on morphological grounds. 
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2. Maintenance phase of ATN
The maintenance phase represents a phase of stabilization of injury in which lethal factors, 
characteristic for the ischemic stage, on the one hand and repair and survival factors, cha-
racteristic for the regeneration phase, on the other hand, are interacting and subsequent 
leading to cellular repair, division and redifferentiation. 
a. Molecular biological characteristics
The kidney has naturally occurring anti-oxidant enzymes to counteract the effects of the 
free radicals. The catalases and gluthathion peroxidase act by safely decomposing the per-
oxides. Catalase is located mainly in the peroxisomes of the cells and therefore acts mainly 
upon hydrogen peroxidase whereas gluthation peroxidase is located in the cellular cytosol 
and therefore acts mainly on the hydroperoxides, that are derived from membrane’s fatty 
acids. The superoxide dismutases act by scavenging the free radicals especially the .O
2
. In 
humans it is present in at least two forms, the cytoplasmatic copper/zinc (CuZn)-SOD and 
the mitochondrial manganese (Mn)-SOD. Superoxide dismutases are enzymes that cata-
lyze the dismutation of .O
2




), which is decomposed, by other en-
zymes like catalase and gluthation peroxidase (76). The presence and the (down regulated) 
activity of these SOD’s seem to be related to the amount of damage induced by ROS in rat 
kidneys (81,82). However, the clinical use of human recombinant superoxide dismutase, did 
not protect against DGF in human kidneys (83,84), although a decrease of acute rejection 
episodes (ARE) and chronic rejection was observed during follow up (85).
b. Cell biological characteristics
During the maintenance phase tubular cells share characteristics of the ischemic phase in 
which necrosis, apoptosis and the interstitial infi ltrate are present and characteristics of the 
recovery and regeneration phase in which proliferation and redifferentiation are present.
3. Recovery phase of ATN
a. Molecular biological characteristics
This process is regulated by the expression of a number of transcription factors, structural pro-
teins and growth factors and recapitulates many aspects of renal organo-genesis in respect to 
the high rate of DNA synthesis, like PCNA, the expression of apoptosis and the expression of 
genes that encode for processes during renal organogenesis like keratin and vimentin (86-88). 
The latter is a fi lament protein expressed in mesenchymal cells but not in mature nephrons. 
Whether these cells are derived by regression of surviving epithelial cells or by the activation 
of resident, but quiescent renal stem cells is not clear yet. The role of the induction of this 
gene expression after acute renal injury lies probably in their involvement in determining cell 
fate (survival versus apoptosis or necrosis) and the transcription of growth factors and their 
receptors that ultimately mediate tubular cell division and proliferation. Upon ischemia and 
reperfusion injury growth factors like the hepatic growth factor, insulin like growth factors 
and fi broblast growth factors are upregulated (89,90). Others like epidermal growth factors 
are down regulated in injured proximal tubules (91). Treatment with these growth factors in 
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animal models were promising (89,92,93) but the use in humans is still limited (94).
b. Cell biological characteristics
During recovery from ischemia and reperfusion injury, surviving tubular epithelial or renal 
stem cells, differentiate and proliferate, eventually replacing the irreversibly injured tubular 
epithelial cells and restoring tubular integrity (56). Morphologically this is characterized 
by the presence of mitotic fi gures and signs of cell proliferation. This process enables the 
replacement of the damaged epithelium and is maximal at 24 to 48 hours after ischemic 
injury in the rat (95). Initially proximal tubules reappear in a fl attened fashion covering the 
tubular basement membrane, followed by the reappearance of the brush border. As the 
number of cells increase the tubular cells become more cubic in shape.
Aim of the thesis
The purpose of this thesis is to evaluate the mechanisms behind DGF and their impact on 
long-term graft function and survival. Since the main cause of DGF is ischemia and reperfu-
sion injury, we use a functional defi nition of DGF, excluding other causes for DGF, like acute 
rejection, cyclosporin toxicity and surgical complications.
In chapter 2 we analyze the risk factors for DGF in a cohort of patients receiving a cadaveric 
transplant between 1983 and 1996, using this functional defi nition. Furthermore we study 
the impact of DGF on long-term events like graft function and graft loss.
Why some grafts develop DGF and others do not is unclear and needs to be elucidated. The 
mechanisms how DGF develops and therefore how DGF infl uences long-term graft faith 
also is unclear. To answer this question, there is need for a marker of functional renal mass 
that is easy assessable and can be repeated frequently.
In chapter 3 we use a parameter developed in the 99mTechnetium-mercaptoacetyltriglycine 
(MAG-3) renal scintigraphy, the Tubular Function Slope (TFS), as a marker of this functional 
renal mass. The differences in TFS between grafts reacting with DGF or not are analyzed, 
immediately after transplantation and during follow up.
The response of a graft on ischemic reperfusion injury depends on its protective and rege-
nerative capacities. Some factors like donor age and donor gender are determinants of the 
functional renal mass and can not be manipulated. Others risk factors, however can. There 
is no doubt that cold ischemia time (CIT) and warm ischemia time (WIT) infl uence the oc-
currence of DGF and can be manipulated. Other factors like serum PTH levels and calcium 
levels and the use of calcium channel blockers (CCBs) are more controversial with regard 
to this aspect. However, the infl uence of serum calcium levels and the use of CCBs on the 
development of DGF has regained interest since many processes that take place during 
ischemia and reperfusion injury and subsequent processes like necrosis, apoptosis and cy-
closporin toxicity, are thought to be directed by calcium dependent processes. Elucidating 
the role of serum calcium and PTH levels on the occurrence of DGF, may have clinical impli-
cations for the management of potential allograft recipients.
In Chapter 4 the impact of serum calcium levels and the use of CCBs on the development 
of DGF are analyzed. Serum calcium levels are not only correlated with the occurrence of 
DGF but also with the presence of calcium deposits in renal biopsies taken within the fi rst 
week after transplantation. Furthermore the effect of CCBs is taken into consideration.
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In chapter 5 we describe a study in which the expression of protective enzymes is correla-
ted with the occurrence of DGF and the presence of ATN in biopsies taken within the fi rst 
week after transplantation.
Chapter 6 reviews the literature on DGF in renal transplantation. 
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Background In renal transplantation, the impact of delayed graft function (DGF) on prog-
nosis is controversial. We analyzed the risk factors of DGF and its impact on graft function 
and prognosis.
Methods 734 cadaveric renal transplants performed between 1983 and 1997 were ana-
lyzed. DGF was diagnosed when serum creatinine levels increased, remained unchanged 
or decreased less than 10 % per day in three consecutive days, in the fi rst week after trans-
plantation. Creatinine clearances of more or less than 50 ml/min or 30 ml/min at 1 year 
were used as cut-off points for optimal and suboptimal graft function, respectively. The 
logistic regression model was used to identify independent risk factor related to DGF and 
renal function 1 year after transplantation. The Cox regression model was used to examine 
the infl uence of DGF on long-term graft survival.
Results Multivariate analysis revealed the following risk factors for DGF (Odds Ratio, 95% 
Confi dent Interval): recipient pre-transplantation mean arterial blood pressure of less than 
100 mmHg: 2.08 (1.43 –3.03), female donor to male recipient combination: 1.55, 1.02 – 2.35, 
donor age of more than 50 years: 2.21, 1.49 – 3.26, cold ischemia time of more than 28 
hours: 1.78, 1.19 –2.63 and peak panel reactive antibodies of more than 50 %: 1.7, 1.15 - 2.55. 
The incidence of DGF was one of the independent risk factors for suboptimal graft function 
at 1 year: 1.68, 1.14 – 2.48 together with donor age of more than 50 years: 2.39, 1.61 – 3.57, 
female donor gender: 1.99, 1.42 –2.78, the occurrence of acute rejection episodes 2.66, 1.87 
– 3.78, peak panel reactive antibodies of more than 50 %: 1.67, 1.15 –2.47 and sharing of 1-3 
vs. 4-8 CREGs 1.65, 1.09 –2.49. Moreover, DGF was one of the two independent risk factors 
for acute rejection episodes, but it had no independent effect on graft survival.
Conclusion Several risk factors for DGF were identifi ed of which a low recipient pre-trans-
plant mean arterial blood pressure, the transplantation of kidneys from female donors to 
male recipients and a prolonged cold ischemia time are potentially avoidable. Although 
DGF is one of the several risk factors of acute rejection and suboptimal function at 1 year, it 
is not independently associated with an increased rate of graft loss.
Delayed graft function infl uences renal function, but not survival
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INTRODUCTION
In renal transplantation there is controversy regarding the impact of delayed graft function 
(DGF) on long-term outcome. This may relate to different criteria used to defi ne DGF or to 
differences in data analysis. Most authors use the need for dialysis within the fi rst week 
as the diagnostic inclusion criterion but this does not differentiate the various causes of 
DGF such as ischemia- reperfusion injury or early acute rejection episodes. In addition, the 
degree of renal damage is often not taken into consideration. In the UNOS registry, DGF 
defi ned as the need for dialysis in the fi rst week after transplantation had a signifi cant and 
independent impact on graft half-life. This effect was distinct from cold ischemia time, oc-
currence of acute rejection episodes, donor age and serum creatinine levels (1,2). Others 
found a detrimental effect of DGF, also defi ned as the need for dialysis in the fi rst week, 
on graft survival only when it was complicated by one or more acute rejection episodes 
(3,4). Using the time required to reach a Cockroft renal clearance of more than 10 ml/min, 
DGF lasting for more than 6 days had a deleterious effect on graft survival whereas DGF 
of shorter duration did not infl uence graft survival (5). In the present paper, we analyzed 
the risk factors of DGF defi ned by stringent criteria, independent from the need of dialysis. 
Moreover, as graft function at 1 year is a strong surrogate marker of late graft outcome 




All patients who received a cadaveric renal transplant in our center between April of 1983 
and December of 1996 were included in the study. Kidneys were allocated according to 
the matching and allocation criteria of Eurotransplant. We aimed to accept kidneys with no 
more than two HLA-mismatches with a priority for HLA-DR matching. 
Immunosuppressive regimen 
The standard immunosuppressive regimen consisted of prednisone and Cyclosporine-A 
[Sandimmune (CsA)]. Sixty-two patients (8,4%) did not receive CsA and were initially tre-
ated with azathioprine (Aza) in a dosage of 2 mg/kg/day. Two hundred and seven (28%) 
patients initially treated with CsA were randomly or on clinical grounds converted to Aza 
within the fi rst six post-transplant months. CsA was administered intravenously in a dose of 
3 mg/kg /day for the fi rst 48 hours, starting at the onset of surgery. The initial oral dose of 
CsA was 10 mg/kg/day from day 2 onward, divided in three daily doses and subsequently 
tapered. Doses were adjusted according to CsA trough levels. After 6 weeks, the total dose 
was given as a once daily dose. In the fi rst three months, the target 24-hour CsA trough level 
was between 250 and 500 μg/l. We targeted to a 24-hour trough level range after 3 months 
between 50 and 150 μg/l. All patients received 20 mg of prednisone starting on day one; 
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this dose was reduced by 2.5 mg every fortnight until a daily maintenance dose of 10 mg 
was reached. Rejection episodes were treated with 1 gram of methylprednisolone intrave-
nously for 3 days or rabbit anti-thymocyte globulin for 10 days, as previously described (8).
Defi nitions
To exclude patients who were dialyzed for reasons other than impaired graft function, we 
diagnosed delayed graft function (DGF) retrospectively if the serum creatinine level incre-
ased, remained unchanged or decreased by less than 10% per day immediately after sur-
gery during three consecutive days for more than 1 week. If a graft biopsy taken within the 
fi rst post-transplant week showed rejection, it was assumed that the graft did not have DGF 
and it was categorized as primary function. Primary Non-Function (PNF) was defi ned as the 
absence of a decrease in the serum creatinine level that ultimately resulted in graft nephrec-
tomy. Primary Function (PF) was defi ned as a decrease of the serum creatinine level of more 
than 10% per day over three consecutive days within the fi rst week after surgery.
Graft loss was defi ned as resumption of dialysis treatments. Early graft loss was defi ned as 
graft loss within the fi rst year after transplantation. Graft survival was censored for patient 
death with functioning graft. Renal Function at one year was calculated using the Cockroft-
Gault Formula (9):
Creatinine clearance = ((140-age) x weight (kg) x A) / (Serum creatinine (μmol/l) x 0, 8))
In which A = 1 in males and A = 0, 85 in females.
Study Design
Risk factors of DGF and the impact of DGF on renal function within the fi rst year were ana-
lyzed and compared with grafts experiencing PF. Moreover, a broad spectrum of donor-
, recipient- and transplantation related variables were studied (Table 1). Acute rejection 
episodes were diagnosed on clinical grounds and confi rmed by biopsy, unless a biopsy 
could not be obtained. Rejections were classifi ed as predominantly interstitial or vascular, 
although most vascular rejections had variable degrees of interstitial infl ammation. Mean 
arterial blood pressure (MAP) was calculated, using the following formula:
MAP = (Diastolic Blood Pressure x 2 + Systolic Blood Pressure)/ 3
Cross-Reactive Groups (GREG) are defi ned as the HLA public epitopes of the class-I MHC-
antigens, based on the amino acid residue system as proposed for UNOS allocation (10). 
Not only the degree of mismatching, but also the effect of sharing between donor and re-
cipient of HLA antigens was studied. The term “mismatch” was used for the number of HLA 
antigens that donor and recipient did not have in common, whereas the term “shares” was 
used for the number of corresponding HLA antigens between donor and recipient. 
In our study population, the mean endogenous creatinine clearance at 1 year is approxi-
mately 50 ml/min (fi g.1). Arithmetical graft half-life is 70 years for grafts with a creatinine 
clearance of more than 50 ml/min and 18,5 years for grafts with a 1-year creatinine clea-
rance of less than 50 ml/min. Therefore, patients having a creatinine clearance of more or 
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less than 50 ml/min were categorized as optimal or suboptimal function respectively. We 
furthermore analyzed the data using a graft function of more or less than 30 ml/min as the 
dependent variable. This cut-off point represents the mean minus one standard deviation 
and is a more stringent outcome parameter. Arithmetical graft half-life is 53 years for grafts 
with a creatinine clearance of more than 30 ml/min and 7 years for grafts with a 1-year crea-
tinine clearance of less than 30 ml/min. To predict outcome at 1 year, patients experiencing 
graft-loss within this year, were categorized as having suboptimal function at 1 year. To 
study the additional impact of DGF on outcome after the fi rst year, we analyzed its effect in 
different strata of renal function after 1 year.
Statistical analysis 
The logistic regression model was used to determine the factors signifi cantly related to DGF, 
early graft loss, acute rejection and renal function at one year in an uni-variate way. The 
signifi cant predictors of each parameter of renal function were next fi tted in a multivariate 
model. Step forward selection techniques were used to determine signifi cant risk factors. 
The risk is expressed as Odds Ratio (OR) + 95% Confi dence Interval (95% CI). The impact of a 
suboptimal Cockroft clearance at 1 year on late graft loss was studied using the Cox regressi-
on model. By using this model we were able to correct for the time of follow up to graft loss. 
The risk is expressed as a Relative Risk (RR) + 95% Confi dence Interval (95% CI). We used the 
Kaplan Meier survival analysis (Log-rank test) to compare graft failure in the different strata 
of Cockroft clearance at 1 year. We used the SPSS software package (9.0) for all analyses.




















Seven hundred and ninety patients were included in the study; 24 (3.0%) were not ana-
lyzed because of primary non-function and 32 (4.1%) because of missing data on DGF. 
Demographic data are shown in Table 1. DGF was diagnosed if the serum creatinine le-
vel increased, remained unchanged or decreased less than 10% per day immediately after 
surgery during three consecutive days for more than 1 week. Twenty eight (11.8%) of the 
patients experiencing renal dysfunction in the fi rst week, making dialysis treatment neces-
sary, had a biopsy proven acute rejection episode and were classifi ed as PF.










Age (years)  46 (13)  46 (12)  47 (14)
Gender (% female)  38  38  39
Peak panel reactive antibodies (PRAH) (%)  31 (32)  29 (31)  36 (35)
Current panel reactive antibodies (PRAC) (%)  12 (23)  11 (22)  14 (26)
MAP before transplantation (mmHg) 109 (16) 110 (17) 106 (16)
Donor
Age (yrs.)  37 (14)  36 (14)  42 (14)
Gender (% female)  41.7  44.9  40.5
Cause of death:
Trauma / Cardio-vascular (%)  47.5 / 52.5  49.5 / 50.5  41.8 / 58.2
Transplantation related
Gender Mismatch
No mismatch (%)  54  56  46
Donor male-Recipient female (%)  21  20  24
Donor female-Recipient male (%)  25  23  30
Transplant status
First transplant (%)  83  76  79
>1 transplant (%)  17  24  21
Cold Ischemia Time (hours)  29 (7)  28 (7)  30 (7)
Warm Ischemia Time (min.)  28 (9)  28 (9)  28 (9)
Immuno-suppression at transplantation
Aza/pred. (%)  8  9  6
Immuno-suppression at 6 months
Aza/pred. (%)  28.1  29.6  23.5
HLA
Mismatch  1.9 (1.1)  1.9 (1.1)  1.9 (1.2)
Shares  3.7 (1.0)  3.6 (1.0)  3.6 (1.1)
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GREG
Mismatch  1.2 (1.1)  1.2 (1.1)  1.1 (1.0)
Shares  4.5 (1.2)  4.5 (1.2)  4.5 (1.1)
Number of rejection episodes < 1 year
1 (%)  23  23  24 
2 (%)  23  20  30 
>2 (%)  11  10  13 
Type of rejection < 1 year
Interstitial (%)  36  34  41
Vascular (%)  14  12  21
Clinical (%)  8  8  7
Graft Loss within 1 year (%)  13  11  19
Clearance at 1 year (ml/min)  53 (20)  55 (20)  47 (21)
Data are expressed as mean ± SD unless otherwise stated
Risk Factors for Delayed Graft Function
In an univariate analysis, donor age of more than 50 years, mean arterial blood pressure 
(MAP) of less than 100 mmHg, cold ischemia time (CIT) of over 28 hours, transplantation 
of a kidney from a female donor to a male recipient and peak panel reactive antibodies 
of over 50 % were associated with DGF. All these factors were subsequently entered in a 
multivariate analysis and remained signifi cant (table 2). 
Risk factors for sub-optimal graft function after one year 
To analyze the impact of DGF and other factors on graft function after 1 year we used the 
creatinine clearance of more or less than 50 ml/min as the dependent variable. The univari-
ate analysis revealed DGF as a risk factor for a sub-optimal graft function after 1 year. Other 
risk factors for suboptimal function included donor age of more than 50 years, female do-
nor gender, donor cause of death (cardio-vascular versus trauma), total warm ischemia 
time, peak panel reactive antibodies of more than 50%, current panel reactive antibodies, 
sharing of less than 3 cross reactive antigens groups (CREG) and the number of acute rejec-
tion episodes within the fi rst year. All these factors were entered in a multivariate analysis 
and as shown in table 3, remained signifi cant with the exception of donor cause of death 
and the warm ischemia time. 
As a creatinine clearance of 30 ml/min is a more stringent outcome variable for graft func-
tion, we also analyzed 30 ml/min at 1 year as the dependent variable. In the uni-variate ana-
lysis, DGF remained a signifi cant risk factor, as were donor age of more than 50 years, female 
donor gender and sharing of 3 or less CREGs. The use of an initial Aza-based immunosup-
pressive regimen, the occurrence of acute rejection episodes and vascular rejection, were all 
associated with suboptimal outcome. Table 4 shows the results of the multivariate analysis. 
The incidence of DGF (OR 1.81; 95% CI 1.17 – 2.81), the use of kidneys from donors older 
than 50 years (OR 2.11; 95% CI 1.35 – 3.29), the initial use of an Aza-based immunosuppressi-
ve regimen (OR 2.53; 95% CI 1.32 – 4.83), the sharing of 3 or less CREGs (OR 2.53; 95% CI 1,30 
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– 3,35) and the incidence of acute rejection episodes (OR 4.00; 95% CI 2.41 – 5.65) remained 
signifi cantly and independently related to a graft function of less than 30ml/min after 1 
year. We were not able to analyze recipient’s age, weight and gender as risk factors, because 
these variables were used in the Cockroft-Gault method to estimate graft function.
Table 2: Risk factors for Delayed Graft Function a
Variable Odds Ratio 95% CI b
Donor age
>50 years 2.21 1.49 – 3.26
Recipient MAP before transplantation
<100 mmHg 2.08 1.43 – 3.03
Cold Ischemia Time
>28 hours 1.78 1.19 – 2.63
Gender Mismatch
No mismatch 1
Donor male- Recipient female 1.09 0.69 – 1.73
Donor female- Recipient male 1.55 1.02 – 2.35
Peak Panel Reactive Antibodies 
> 50% 1.7 1.15 – 2.55
a Multivariate analysis b 95% CI: 95% Confi dence Interval 
Table 3: Risk factors for suboptimal function (creatinine clearance < 50-ml/min) at 1 year after trans-
plantation, including graft-loss in the fi rst year a
Variable Odds Ratio 95% CI b
Delayed graft function 1.68 1.14 – 2.48
Donor age
> 50 years 2.39 1.61 – 3.57
CREG-sharing
1-3 shares vs. 4-8 shares 1.65 1.09 – 2.49
Number of acute rejection episodes
>1 2.66 1.87 - 3.78
Donor Gender
Female vs. male 1.99 1.42 – 2.78
Peak panel reactive antibodies
>50% 1.67 1.15 – 2.47
a Multivariate analysis; b 95% CI: 95% Confi dence Interval
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Table 4: Risk Factors for a1-year creatinine clearance <30 ml/min including graft-loss within 1 year a
Variable Odds Ratio 95% CI b
Delayed graft function 1.81 1.17 – 2.81
Donor Age
> 50 years 2.11 1.35 – 3.29
Immuno-suppressive regimen at time of transplan-
tation
Aza/Pred. Vs. CsA/Pred. 2.53 1.32 – 4.83
CREG- sharing
1-3 vs. 4-8 shares 2.53 1.30 – 3.35
Number of acute rejection episodes
>1 4.00 2.41 – 5.65
a Multivariate analysis; b 95% CI: 95% Confi dence Interval
Occurrence of acute rejection episodes within one year after transplantation. 
DGF was associated with an increasing likelihood of acute rejection episodes in an univa-
riate analysis as were female donor gender, HLA-DR mismatch, peak panel reactive anti-
bodies of more than 50% and retransplant status of the recipient. HLA-sharing correlates 
inversely with the incidence of acute rejection episodes. Table 5 shows the independent 
risk factors for acute rejection in the fi rst year, in the multi-variate analysis. The incidence 
of acute rejection episodes was independently associated with DGF (OR 1.61; 95% CI 1.11–
2.33), an increase of HLA-DR mismatch (OR 2.36; 95% CI 1.68– 3.31) and peak panel reactive 
antibodies of more than 50 % (OR 1.60; 95% CI 1.12 – 2.30). 
Table 5: Riskfactors for the occurrence of acute rejection episodes within 1 year a
Variable Odds Ratio 95% CI b
Delayed Graft Function 1.61 1.11 – 2.33
Mismatch HLA DR 
>=1 2.36 1.68– 3.31
Peak Panel Reactive Antibodies
> 50% 1.60 1.12 – 2.30
a Multivariate analysis; b 95% CI: 95% Confi dence Interval
Infl uence of DGF on graft loss 
Fig.2 shows the univariate Kaplan Meier graft survival estimates, of patients with primary 
function and patients with delayed graft function. There is a signifi cantly decreased graft-
survival in patients with DGF, with an arithmetical graft half-life of 12.8 years, compared to 
21.7 years for patients not experiencing DGF. The main effect of DGF on graft loss seems to 
take place in the fi rst year, whereas after the fi rst year, especially after 6 years there is no dif-
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ference in outcome (data not shown). The short-and long-term graft losses were analyzed 
separately.
In an univariate analysis, DGF was correlated with graft loss within the fi rst year, as were 
female donor gender, an Aza-based immunosuppressive regimen, CIT of more than 24 
hours and the number and type of rejection episodes. Sharing of HLA Class-1 antigens 
correlated inversely with graft loss. However, when the data were entered in a multiva-
riate analysis neither DGF (OR 1.52; 95% CI 0.92 –2.53) nor cold ischemic time (OR 1.17; 
95% CI 0.72 –1.88) remained a risk factor for graft-loss within the fi rst year. Acute rejec-
tion episodes, especially vascular rejection (OR 9.32; 95% CI 4.77 – 18.2), female donor 
gender (OR 1.70; 95% CI 1.07 – 2.68), and an Aza-based immunosuppressive regimen (OR 
2.07; 95% CI 1.05 – 4.09) remained independently associated with graft loss within the 
fi rst year (Table 6). 
Graft loss after the fi rst year was associated in a univariate analysis with recipient age of 
less than 50 years and donor age of more than 50 years, the occurrence of acute rejec-
tion episodes in the fi rst year and a cold ischemia time of more than 34 hours. Increased 
sharing of HLA antigens, sharing of 4-8 vs. 3 or less CREGs and higher creatinine clearance 
at 1 year correlated inversely with graft loss. DGF was not an independent risk factor for 
graft loss after the fi rst year (OR 1.58; 95% CI 0.98 – 2.54). Table 7 shows the results of the 
multivariate analysis. The occurrence of acute rejection episodes (OR 1.38; 95% CI 1.11 – 
1.71), recipient age of less than 50 years (OR 1.70; 95% CI 1.00 – 2.86) and a cold ischemia 
time of more than 34 hours (OR 1.90; 95% CI 1.20 – 3.05) were all independent risk factors 
for late graft loss. As soon as the Cockroft clearance after 1 year was fi tted in the model as 
a continuous parameter, CIT and recipient age were no risk factors anymore. Therefore, 
graft function at 1 year was a strong predictor of late graft outcome (RR 0.96; 95% CI 0.95-
0.97 per ml/min). When graft function after 1 year was divided in 4 strata of clearance of 
> 50 ml/min, clearance of 40-50 ml/min, clearance of 30-40 ml/min and clearance of < 30 
ml/min, DGF had no additional effect on graft survival in any stratum (fi g.3). 
Fig. 2 Graft survival according 
to the incidence of DGF. 
Kaplan-Meier estimates for trans-
plants experiencing PF (solid rule; 
N=550); half-life: 21.7 years and expe-
riencing DGF (dashed rule; N= 183); 
arithmetical half-life: 12.8 years. Log-
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Table 6: Risk factors for graft loss within 1 year a
Variable Odds Ratio 95% CI b
Donor Related
Gender of donor 1
Female vs. Male 1.70 1.07 – 2.68
Transplantation related
Immunosuppressive Regimen
Aza / Pred. vs. CsA / Pred. 2.07 1.05 – 4.09
Type of rejection < 1 year
No 1
Interstitial 2.64 1.33 – 5.22
Vascular 9.32 4.77 – 18.2
Clinical (no biopsy) 3.61 1.45 – 8.99
a Multivariate analysis; b 95% CI: 95% Confi dence Interval
Table 7: Riskfactors of graft loss after 1 year a
Variable Relative Risk 95% CI b
Recipient age
<50 years 1.70 1.00– 2.86
Cold Ischemia Time
> 34 hours 1.91 1.20 – 3.05
Occurrence of acute rejection episodes 1,38 1.11 – 1.71




In this retrospective study we examined the risk factors and prognostic signifi cance of DGF 
in renal transplantation. In contrast to most other studies that examined this, we used a 
more stringent defi nition of DGF and analyzed the effect of DGF on graft function and 
survival independently. When DGF was diagnosed if the serum creatinine level increased, 
remained unchanged or decreased less than 10% per day immediately after surgery during 
three consecutive days for more than 1 week, 183 (23.2%) patients experienced DGF and 
551 (69.7%) had primary graft function. If we defi ned DGF as the need of dialysis in the fi rst 
week, 244 (33.9%) of the patients would have been classifi ed as having DGF. This means 
that 26 % of patients that were dialyzed post-operatively required dialysis treatment for 
other reasons than DGF and that 10% of the patients experiencing DGF did not need dia-
lysis treatment.
Studies on transplant outcomes have traditionally focused on patient- and graft survival 
as end-points without consideration of graft function. Although graft loss is the worst type 
of graft dysfunction, grafts with an impaired function require the most intense follow-up 
and therapeutic management and are economically most costly (11). For this reason graft 
function as a parameter in studies on outcome of kidney transplantation, should be con-
sidered. 
One of the possible mechanisms of the decreased GFR in DGF seems related to tubular 
damage resulting from ischemia/reperfusion injury. Tubular epithelial cell degeneration, 
tubular cell exfoliation, interstitial edema and interstitial cellular infi ltration are usually ob-
served in biopsies in DGF (12). In the early phase, tubular obstruction by exfoliated tubular 
cells results in a low net. fi ltration pressure (13). Later, decreased sodium reabsorption re-
sults in afferent vasoconstriction and diminished glomerular fi ltration pressures through 
the tubulo-glomerular feedback mechanism (14). Another factor related to DGF is brain 
Fig. 3 Graft survival according to graft function 1 year after transplantation. 
Kaplan-Meier estimates for trans-
plants experiencing a 1-year cre-
atinine clearance of >50 ml/min 
(solid rule; N= 339); arithmetical 
half-life: 70 years; 40-50 ml/min 
(short dashed rule N= 135); arith-
metical half-life: 30 years; 30-40 
ml/min (long dashed rule; N= 79) 
arithmetical half-life: 25 years and < 
30 ml/min. (long, short, long dashed 
rule; N= 56), half-life: 7 years.
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death (15), but all the patients studied received a cadaveric transplant.
In the present study we found that DGF was signifi cantly associated with the use of kidneys 
from older donors, particularly donors of more than 50 years of age, with the use of female 
donor kidneys transplanted into male recipients, a cold ischemia time of more than 28 
hours, historic panel reactive antibodies of more than 50% and a recipient’s pretransplant 
MAP of less than 100 mmHg. Other authors have also reported an increased incidence of 
DGF in grafts from older donors (1,16-18). In human adults, total metabolism and renal 
function in terms of glomerular fi ltration rate and renal blood fl ow, decrease with age. This 
is associated with a decrease in the number of glomeruli, a decrease in the mean glomeru-
lar volume (19) and interstitial fi brosis (20, 21). It is conceivable that such kidneys are more 
susceptible to additional insults such as brain death and the transplantation procedure.
The higher incidence of DGF in female donor to male recipient combinations could be ex-
plained by the absence of estrogens in the male environment. In-vitro studies have shown 
that the administration of estrogens leads to dilation of aortic rings (22) as has been descri-
bed in-vivo in human coronary arteries (23). It is therefore conceivable that female kidneys 
when transplanted into a male environment experience more vasoconstriction and thus 
are more prone to DGF. An interesting observation is the fi nding that a low pretransplant 
blood pressure level in the recipient confers a signifi cant risk to DGF (Table 2). A stable 
hemodynamic condition and possibly some degree of extra-cellular volume expansion are 
associated with good perfusion of the graft immediately after recirculation (24,25). Mo-
reover, invasive hemodynamic studies have shown that a high pulmonary artery (26) or 
central venous pressures (27) before, during and after the transplantation surgery corre-
lates inversely with the incidence of DGF. As ischemia-reperfusion injury results in the loss 
of auto-regulation (28), the benefi cial effect of hypervolemia may result in an increased 
glomerular perfusion fl ow and pressure. It is unknown, whether the reduced incidence of 
DGF in patients treated with peritoneal dialysis, as found by some authors (29,30,30), is also 
based on an increased total extracellular fl uid volume. A CIT of longer than 28 hours was 
also independently associated with an increased risk of DGF, as found by others (31-34). 
This is probably also the result of increased vasoconstriction (35) and renal damage as a 
result of ischemic injury. Peak panel reactive antibodies constitute another independent 
risk factors for DGF, as was noted by others (5). In studies in which DGF was defi ned as the 
need of dialysis within the fi rst week after transplantation, DGF could theoretically have in-
cluded acute rejection episodes. Although we corrected for acute rejection episodes, peak 
panel reactive antibodies remained independently correlated with DGF. It is thus concei-
vable that we missed some very early rejection episodes, as we did not biopsy every graft 
experiencing DGF, within 1 week. In contrast to another study (5), we found no effect of the 
initial immunosuppressive regimen on early graft function.
The transplanted nephron mass and subsequent graft damage determine renal function 
and many of the riskfactors for graft loss operate very likely through these factors (36,37). 
We found that the number of acute rejection episodes, donor age, donor gender, DGF and 
decreased sharing of CREGs are correlated independently with graft function at 1 year. 
Using either 50 or 30 ml/min as the cut-off point, DGF remained a risk factor for poor graft 
function at 1 year. Although DGF is a strong risk factor for acute rejection episodes (OR 1.63 
95% CI 1.11 – 2.33), the effect of DGF on graft function was independent from the number 
of rejection episodes. Long term follow-up studies of native kidneys that have experienced 
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ATN suggested a decrease in renal function in most cases, albeit it was not associated with 
chronic failure (38,39). However, experimental studies in rats have shown that ischemia 
added to ongoing injury results in more severe tissue damage (40). Some authors found an 
effect of DGF on graft survival only in combination with acute rejection episodes (3,4,41). In 
our model, DGF had no infl uence on graft loss at 1 year or after the fi rst year. Renal function 
at 1 year is probably a more important determinant for late graft loss, as suggested in the 
Collaborative Transplant Study (42). To further study the effect of DGF on late outcome, we 
stratifi ed renal function after 1 year in 4 strata (fi g. 3) and demonstrated that renal function 
at 1 year is a risk factor of late graft-loss. When the contribution of DGF on late graft loss 
was analyzed in these strata, there was no additional effect of DGF on outcome. 
In this retrospective study we found that DGF, defi ned as the absence of a decline in serum 
creatinine of 10% or more in three consecutive days for more than 1 week after transplan-
tation has an independent effect on graft function at one year as well as on the incidence 
of acute rejection episodes, but it does not seem to infl uence early or late graft loss. Graft 
survival after 1 year is mainly determined by the creatinine clearance at 1 year, which sug-
gests that the infl uence of DGF on graft survival is through graft function at 1 year. We also 
found that the incidence of DGF is related to pretransplantation MAP, probably as a marker 
for the effective circulating volume. Furthermore, the use of kidneys from older donors or 
from female donors transplanted into male recipients increases the risk for DGF. It remains 
to be seen whether changing these risk factors improves the rate of DGF as well as long 
term function.
Delayed graft function infl uences renal function, but not survival
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Background The mechanism that underlies delayed graft function (DGF) is still poorly de-
fi ned. Previous studies using tubular function tests have shown that post-ischemic injury 
to the renal transplants results in profound impairment of para-immunohippurate extrac-
tion by the tubules. 
Methods Using 99mTechnetium-mercaptoacetyltriglycine (99mTc-MAG3) renography and 
tubular function slope (TFS) we studied the tubular uptake of 99mTc-MAG3 in a prospec-
tive study of renal transplant recipients with immediate graft function (IGF) and those with 
DGF. 
Results Thirty-seven consecutive recipients of a cadaveric graft and 5 kidneys from living 
donors were evaluated within 48 hours after transplantation and in week 2, month 3 and 
6 and 3 years after transplantation. In addition to the protocol scans, recipients with DGF 
were examined every other day until function was resumed. Repeated measurement two-
way ANOVA and a change point analysis were performed to determine the difference in 
the follow-up of TFS values between the two groups. Fourteen patients were classifi ed as 
having DGF and 28 IGF. In the DGF group, the initial TFS value was signifi cantly lower than 
in the IGF group [0.54 ( + 0.01) and 1.75 ( + 0.16) respectively; P = 0.002], a difference that 
persisted for up to 3 years. Change point analysis revealed that the post ischemic tubular 
excretion improved with time in both groups in the fi rst 3 to 4 weeks, but both groups 
remained different up to 3 years after transplantation. Multi-variate analysis revealed that 
only the cold ischemic time (CIT) was an independent risk factor for a low TFS value. After 
the initial recovery from post-ischemic injury, the TFS may be used as a marker for functi-
onal renal mass.
Conclusion We propose that the tubular defect in DGF defi ned by 99mTechnetium-mercap-
toacetyltriglycine (99mTc-MAG3) renography is irreversible and may be a marker of initial 
graft function.
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INTRODUCTION
Despite increased donor awareness and actions, the actual number of organ donors has 
not increased to any meaningful extend. This disparity has led to an increased interest in 
the use marginal donors, including donors at the extremes of age, non-heart beating do-
nors and donors with a history of hypertension or diabetes (1,2). 
DGF is a common complication after renal transplantation, with a reported incidence of 
up to 50%, especially in recipients of kidneys from marginal donors (3-6). The underlying 
cause is usually ischemic damage, which may be further complicated by an increased li-
kelihood of acute rejection episodes (3,7) or drug-related nephrotoxicity (8). There is still 
debate on the impact of DGF on late graft outcome. Some authors fi nd an effect of DGF 
on renal allograft survival (9,10), but others only fi nd an effect of DGF on graft survival in 
patients who experience acute rejection episodes (11). 
To answer the question whether the occurrence of DGF is merely an expression of an insuf-
fi cient amount of functional renal mass at the time of transplantation or an independent 
risk factor for subsequent graft loss, there is need for a marker of renal mass that is easy as-
sessable and can be repeated frequently. Several studies have been undertaken to defi ne 
the nature of graft dysfunction in DGF. Corrigan et al. found in human renal transplants 
with post-ischemic injury, a severely impaired para-aminohippurate (PAH) extraction, by 
the renal tubules that persisted for up to 7 days (12). The renal handling of 99mTechneti-
um-mercapto-acetyltriglycine ( 99mTc-MAG3) is similar to that of PAH (13). We prospecti-
vely evaluated serial 99mTc-MAG3 renographies in patients with immediate or delayed graft 
function, using a standardized method to estimate the active tubular extraction for up to 
3 years.
MATERIALS AND METHODS
Between August 1997 and January 1998, 37 consecutive recipients of a fi rst or second ca-
daveric renal transplant and 5 recipients of a living related donor transplant gave informed 
consent and were entered into the study. DGF was defi ned based on previously described 
criteria (3) and never functioning grafts were excluded from the study. In short, cases were 
categorized as DGF when the serum creatinine level increased, remained unchanged, or 
decreased by less than 10 % per day immediately following surgery during three conse-
cutive days within the fi rst week. All other situations were designated as immediate graft 
function (IGF). An acute rejection episode as a cause of graft dysfunction was defi ned as a 
decline in renal function by more than 10 % and was confi rmed by a percutaneous renal bi-
opsy unless this could not be obtained. Cyclosporine (CsA) nephrotoxicity was diagnosed 
based on the criteria described in the Banff 1997 classifi cation of renal allograft pathology 
(14) or when there was a normalization of renal function after reduction of the CsA dose. 
Renal function, expressed as the creatinine clearance was estimated using the formula de-
veloped by Nankivell, which showed a good correlation with 99mTc diethylenetriaminepen-




GFR [ml/min] = 6.7 / creat. [mmol/l] + BW [kg] / 4 - urea [mmol / l] / 2 - 100 / (height [m])2 + 
(35 [ male] or 25 [ female]).
All patients had an initial 99mTc-MAG3 study on the fi rst post-transplant day. Protocol scans 
were performed at 2 weeks, 3 and 6 months and at three years after transplantation. In ad-
dition, patients experiencing DGF were followed with 99m Tc-MAG3 studies every other day 
until the serum creatinine concentration decreased by more than 10 % per day on three 
consecutive days. 
99mTc-MAG3 renogram
99mTc-MAG3 studies were done by positioning a large fi eld of a view gamma camera 
(Toshiba GCA 501S) anteriorly over the patient in the supine position. The fi eld of view 
included the transplanted kidney, the lower abdominal aorta and iliac arteries as well as 
the urinary bladder (fi g. 1a). After a bolus injection of 100 MBq of 99mTc-MAG3 into a large 
caliber vein (usually the medial antecubital vein), frames were recorded initially at 1 sec in-
tervals for 120 frames, followed by 90 frames at 20 sec intervals to complete the 32 minute 
study as shown in fi gure 1b and 2a. To calculate the dose activity administered, the syringe 
was counted before and after injection and when there was extravasation, the injection 
site was counted as well. A dedicated nuclear medicine computer (MAPS 10000 Web Link 
Medical, UK) was programmed for processing the data and calculating the Tubular Func-
tion Slope (TFS).
Tubular Function Slope 
To study the radiopharmaceutical uptake by the renal tubular cells the tubular function slo-
pe (TFS) was designed. Two regions of interest were drawn semi-automatically; one around 
the graft (ROI - 1) and one representing the background (ROI - 2) (fi g. 1a). The background 
region of interest was crescentic in shape and it was placed infero-lateral to the kidney, 
avoiding any vascular structures (fi g. 1a). A background subtracted graft curve was gene-
rated during the fi rst two minutes of the study. (fi g. 2 a): it consists of a rapidly ascending 
initial phase until the fi rst pass peak, which results from the initial perfusion, followed by a 
second phase which represents the tubular extraction phase (fi g. 2 b). The graft curve was 
normalized to the injected dose and a measure of the slope was taken using a linear fi t 
(least squared error estimate) of the curve between 50 seconds and 110 seconds (fi gure 2 
b). This slope was defi ned as the TFS. As TFS is determined in the second phase of the time 
activity curves it is proposed to be independent of renal perfusion.
Reproducibility and inter-observer reliability
To assess the intra-observer variability the TFS was calculated twice in two different ses-
sions by one observer in a random set of 33 scintigrams of 10 patients. The average dif-
ference between the TFS values between the fi rst and second processing was 0.062 (SD 
0.016) with a correlation of 0.992. The intra-class correlation was 0.991. The inter-observer 
variability was assessed by processing 59 scans twice by two different operators. The aver-
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Figure 1 
a: 99mTc-MAG3 renogram. The region of 
interest 1 (ROI -1) describes the whole 
kidney activity. The region of interest 2 
(ROI - 2) describes the avascular refer-
ence region.
b: Backgound subtracted and dose ad-
justed 99mTc-MAG3 extraction and se-




















a: Backgound subtracted and dose 
adjusted 99mTc-MAG3 extraction and 
secretion curve of kidney experiencing 
delayed graft function. (Note: time axis 
is until 32 minutes). 
b: First 2 minutes of the 99mTc-MAG3 
extraction and secretion curve in which 
Phase 1 (the rapidly ascending phase) 
represents the renal perfusion phase. 
Phase 2 represents the tubular ex-
traction phase. Using a linear fi t (least 
squared error estimate) the slope of 
this curve is determined and defi ned as 
tubular function slope (TFS).
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age difference in TFS values between the two was 0.011 (SD 0.019) with a correlation of 
0.997. The inter-class correlation was estimated to be 0.997. These excellent correlations 
were not unexpected as the calculations of the TFS, including drawing the regions of in-
terest and the defi ned periods in the second phase of the early dynamic curve, are almost 
entirely automatic. 
Immunosuppressive Regimen
The standard immunosuppressive regimen consisted of Prednisone, Cyclosporine (Neoral) 
and Mycophenolate Mofetil (MMF). Cyclosporine was administered intravenously in a dose 
of 3 mg/kg /day for the fi rst 48 hours, starting at the onset of surgery. The initial oral dose 
of Neoral was 10 mg/kg/day from day 2 onward. Subsequent doses were adjusted accor-
ding to cyclosporine 12-hour trough level monitoring. Mean cyclosporine dose and trough 
levels were not signifi cantly different between the 2 groups. In the fi rst three months, the 
target 12-hour trough level was 300 μg/l (range 250 μg/l –350 μg/l) and beyond 3 months 
it was 150 μg/l (range 100 μg/l - 200μg/l ). All patients started on 20 mg/day of Predniso-
lone followed by a dose reduction of 2.5 mg every fortnight until the maintenance dose 
of 10 mg was reached. MMF, 1 gram b.i.d. was given from day 1 onward. Acute rejection 
episodes were treated with 1 gram of methylprednisolone intravenously for 3 consecutive 
days. Severe or steroid resistant acute rejection episodes or any second rejection episode 
were treated with rabbit anti-thymocyte globulin for 10 days, as previously described (16).
Statistical analysis
Risk factors for a low TFS were analyzed, using linear regression analysis. Differences in TFS 
and creatinine clearance were examined using the two way ANOVA for repeated measure-
ments. Furthermore, the change of the ln(TFS)-parameter during follow-up was modeled 
using a change-point model with two linear regression lines, one involving a rapid increase 
after transplantation, and a second line, following a change-point, involving a slow change 
of the ln(TFS) parameter. The parameters of the regression lines, and the timing of the 
change-point was assumed to vary between patients. These parameters were handled as 
random, drawn from the multivariate normal distribution. The mean and (co)variance of 
this normal distribution were estimated separately for patients with immediate and de-
layed graft function. The change of the ln(TFS) of the “averaged” patient according to the 
model thus defi ned, was calculated and illustrated graphically. A p-value of 0.05 or less was 
considered signifi cant. Statistical analysis was done using the SPSS 9.0 software package 
(Version 9.0; SPSS, Inc., Chicago, IL).
RESULTS
A total of 42 patients were prospectively followed with 99mTc-MAG3 renography; 28 ex-
perienced IGF and 14 had DGF. The characteristics of the study population, grouped ac-
cording to the presence or absence of DGF are summarized in Table 1. In this cohort of 
patients none of the factors summarized in Table 1 were statistically different between 
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the two groups. Although donor age and the number of female donors were slightly hi-
gher in the DGF group, this did not reach signifi cance. The type of rejection episodes was 
not different in the two groups. Three patients in the IGF group experienced recurrence 
of their renal disease (IgA nephropathy, membrano proliferative glomerulonephritis and 
focal segmental glomerulosclerosis) and one lost his graft after 432 days. Two patients in 
the DGF group lost their graft because of recurrence of their renal disease (micro angiopa-
thic nephropathy and membrano proliferative glomerulonephritis) after 43 and 373 days 
respectively. A total of two hundred and seventy three 99mTc-MAG3 renographies were per-
formed: 160 in the IGF group and 113 in the DGF group.








HLA-AB mismatch 1.25 (1.07) 0.92 (0.86) 0.37
HLA-DR mismatch 0.46 (0.51) 0.38 (0.51) 0.67
Panel reactive antibodies (historic) 30 (33) 19 (27) 0.30
Donor age, years 46 (17) 48 (11) 0.81
Recipient age, years 45 (13) 44 (11) 0.80
Gender 
Recipient male (%) 64.3 78.6 0.34
Donor female (%) 50 35.7 0.38
Mismatch: female to male (%) 32.1 35.7 0.91
Cold ischemia time, (hours) 23 (8) 25 (5) 0.46
Warm ischemia time (minutes) 35 (12) 36 (11) 0.80
Pretransplantation MAP, (mmHg) 105 (16) 104 (12) 0.70
Cadaveric transplantation (%) 82 100 0.15
Cause of donor death
Cardiovascular (%) 61 64 1.00
Retransplants (%) 21 14 0.39
Posttransplantation factors
Immunosuppression
Pred / neoral/ MMF (%) 100 100 1.00
Biopsy proven rejection episodes (%) 53 36 0.34





The TFS values after predefi ned time intervals for both the IGF and the DGF group are 
shown in fi gure 3a. In the DGF group the average TFS values (mean ± SEM) in the initial 
scans was 0.54 ± 0.01 and there was an increase to 1.8 ± 0.19 in the week 2 studies. In the 
IGF group the average TFS values (mean ± SEM) at the fi rst examination and the week two 
studies were 1.75 ± 0.16 and 2.52 ± 0.22, respectively. At the month 3 and 6 and year 3 time 
points, the initial difference in TFS values between the two groups persisted; for the DGF 
group the TFS values were 1.83 ± 0.17, 1.84 ± 0.19 and 1.38 ± 0.24 respectively and for the 
IGF group they were 2.91 ± 0.22, 3.17 ± 0.23 and 2.76 ± 0.31. The differences between the 
two groups were highly signifi cant (P < 0.0001). After correction for the initial TFS value, by 
subtracting the initial TFS values from the follow-up TFS values of each group, these diffe-
rences were no longer present (p = 0.85) and the curves were superimposable. These data 
show that in both groups, despite of comparable recovery of tubular function as measured 
by TFS, there is an initial difference in the TFS values that persists for up to 3 years.
Change point model
To further evaluate whether there was a difference in time to reach the maximum TFS 
values between the two groups, all 273 available scans were studied in a change–point 
analysis model. The results of this analysis are plotted in fi gure 4. The slopes of the sharp 
increasing regression lines prior to the change-point were not different for recipients with 
DGF and patients with IGF (0.06 ln(TFS-units)/day and 0.06 ln(TFS-units)/day respectively; p 
= 0.87), but the absolute level achieved was different between the two groups (P = 0.005). 
Interestingly the timing of the change-point was also the same in DGF-and IGF-patients 
(29/21 days, p=0.85) as was the slow ln(TFS)-increase thereafter [-0.0003 ln(TFS) units and 
-0.00002 ln(TFS) units (p=0.24)]. This means that TFS remains at a constant level from about 
3 to 4 weeks onwards both in the presence or the absence of DGF. 
Factors infl uencing the TFS value and renal function
To evaluate the risk factors that correlated with an initial low TFS value and the creatinine 
clearance and TFS values at the predefi ned time-points, several factors concerning the do-
nor and the transplantation procedure were retrospectively evaluated. In the multivariate 
analysis, the only signifi cant risk factor for a low post-transplant TFS value was the cold 
ischemia time (correlation coeffi cient (CC): - 0.27 per hour; -0.54 – 0.00). In the multivariate 
analysis, only the TFS value at 6 months was correlated with the TFS value found after 3 
years (CC: 0.75; 0.58 – 1.16) and the estimated creatinine clearance at 1 year was the only 
variable that was correlated with the graft function at 3 years (CC: 0.875; 0.59 - 0.89). The 
creatinine clearances at 3 and 6 months and 1 and 3 years are plotted in fi gure 3b and were 
56 ml/min, 60 ml/min, 58 ml/min and 58 ml/min for the DGF group and 64 ml/min, 71 ml/
min, 67 ml/min and 63 ml/min for the IGF group. The estimated clearances tended to be 
lower in the DGF group, but this did not reach a statistical signifi cance (p = 0.20), because 
of the limited sample size.
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a: TFS values in the two groups, which are 
different (p = 0.005). After correction for the 
initial TFS value, by subtracting the inital TFS 
values from the TFS values in the follow-up 
of each group, these differences were no 
longer present (p = 0.85) and the curves 
were superimposable, indicating that the 
differences between the two groups were 
determined by the differences already pre-
sent in the early post transplant 99mTc-MAG3 
renographies 
( IGF: dashed rule ; DGF: solid rule )
b: Creatinine clearances at the different 
time points. The values tended to be lower 
in patients that experienced DGF but did 
not reach statistical difference (p = 0.2). 
( IGF: dashed rule ; DGF: solid rule ).

















The change point model, using all 273 availa-
ble renographies. The improving of the tubular 
extraction impairment occurred within the fi rst 
post-transplant month and to the same extend 
in both groups. 
( IGF: dashed rule ; DGF: solid rule ) Time after transplantation
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Use of TFS in detection of acute rejection episodes or cyclosporine toxicity 
In the total study population 24 episodes were identifi ed with a decline of TFS of more than 
20 % in 2 consecutive 99mTc-MAG3 renographies performed within the fi rst three weeks. 
In 17 (71 %) cases an acute rejection episode or cyclosporine toxicity was identifi ed and 
in 7 (29 %) cases no obvious explanation could be found. In the DGF group there were 14 
cases with a decline of TFS of more than 20 % in 2 consecutive scans. In 10 (71%) cases 
an acute rejection episode or acute cyclosporine toxicity was identifi ed, in 4 (29 %) cases 
no obvious explanation was found. Figure 5 shows two representative examples of the 
relation between the decline of TFS and an acute rejection episode (fi g 5a) and he TFS and 
cyclosporine toxicity (5b) in patients who experienced DGF. Both curves show complete 
reversibility of the TFS value after treatment of the acute rejection episode or lowering of 
the CsA dose respectively. 
Figure 5
a: A representative case of an acute re-
jection episode ( Grade II a) in a patient 
experiencing DGF. TFS values are rever-
sible after treatment.
b: A representative case of an episode 
of cyclosporine toxicity (CyA 12 hours 
trough level: 600 μmol/l) in a patient 
with DGF. TFS values are reversible after 
correction of the neoral dose.
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DISCUSSION 
In the present study we demonstrated that transplantation of a renal allograft is associated 
with a low level of active tubular extraction of the radiopharmaceutical 99mTc-MAG3 as as-
sessed by renography. The tubular extraction is expressed as the tubular function slope 
(TFS). The TFS values were particularly decreased in the immediate post-operative days 
in recipients who experienced delayed graft function. Independent of whether the graft 
showed immediate good function or delayed function, this tubular extraction impairment 
of 99mTc-MAG3 showed improvement within the fi rst post-transplantation weeks in both 
groups, but remained always lower in the DGF group. 
After the fi rst post-transplant month, the difference in the absolute TFS values between re-
cipients with immediate function and those with delayed function persisted in subsequent 
99mTc-MAG3 renographies for up to three years. The results where not different when the 
data of the living related transplants or the data of the grafts that showed recurrence of 
their renal disease were left out of the analysis. 
Previously, a fi rm correlation between histological tubulo-interstitial changes and renal 
outcome has been established (17). Since the TFS is a marker of the proximal tubular func-
tion and the tubular compartment represents approximately 80 to 85% of the renal mass, 
we propose that it may serve as a marker of renal mass after the initial recovery from post-
ischemic injury.
It has been diffi cult to quantitate the amount of renal mass transplanted. The degree of 
glomerulosclerosis and glomerular size have been proposed as a measure of functional 
renal mass but these parameters have a poor correlation with outcome (18,19). However 
as stated before, there is a good correlation between tubulo-interstitial changes and out-
come (17). 
Radionuclide renography, using 99mTc-MAG3 is a non-invasive method that can be repea-
ted frequently. To improve its diagnostic accuracy, various quantitative parameters have 
been proposed (20,21). In 99mTc-MAG3 renography the second part of the early phase of 
the curve represents the active extraction of the radiopharmaceutical by epithelial cells of 
the proximal renal tubules (22-26). No objective correlations with graft dysfunction have 
been established yet (23,26,27). Therefore, we defi ned the tubular function slope (TFS) in 
99mTc-MAG3 renography, as a putative objective marker of tubular extraction capacity. The 
hypothesis that the TFS value of the renogram measures active tubular excretion is suppor-
ted by studies using para-aminohippurate (PAH). Since the renal handling of 99mTc-MAG3 
shares the same characteristics with the handling of PAH (13), it is likely that both substan-
ces are handled similarly. In a study of transplanted human kidneys with ischemic injury, 
no correlation between the PAH clearance and renal plasma fl ow, measured by phase con-
trast–cine-magnetic resonance imaging (MRI), was found (12). The authors concluded that 
the severely depressed clearance was explained by the reduced tubular extraction of the 
PAH. Because the tubular extraction of 99mTc-MAG3 is an energy dependent transport me-
chanism and occurs along the entire length of the proximal tubules, it will be affected by 
ischemic injury or infl ammation. These conditions are characterized by the loss of tubular 
cell polarity, which impairs the transport of 99mTc-MAG3 by the dislocation of the Na+-K+ 
-ATP-ase from the basolateral cell membrane into the cytoplasm (28,29). 
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A decrease in TFS value of more than 20% in consecutive 99mTc-MAG3 renographies in the 
early post-transplant period can be helpful in detecting additional complicating factors, 
such as an acute rejection episode or cyclosporine toxicity. As these events also infl uence 
long term graft outcome(3,7,8), we looked at the reversibility of the TFS values after treat-
ment of an acute rejection episode or after adjusting the neoral dose. We found that TFS 
values were completely reversible in both conditions and we therefore assume that these 
events have a no major infl uence on the TFS values, during follow up.
We found that cold ischemic time (CIT) is an independent risk factor for a low initial TFS va-
lue in both groups. CIT has been reported as an independent risk factor for the occurrence 
of DGF(3,30-32). We hypothesize that in the presence of a long CIT, the quality and the 
amount of the functional renal mass transplanted, explains why some grafts experience 
DGF and others do not. It remains to be seen whether other risk factors for the occurrence 
of DGF, like donor age, pretransplant mean arterial pressure (MAP) and gender mismatch 
(3) are correlated with a low initial TFS-value when the numbers are increased.
We conclude that the TFS as defi ned in 99mTc-MAG3 renography may serve as a marker for 
the functional renal mass. Most renal transplants will experience a recovery phase from 
post-ischemic injury, but grafts from marginal donors are more likely to experience delay-
ed graft function. After the initial recovery, grafts experiencing DGF have lower TFS values, 
than grafts without DGF, which remained evident up to 3 years of follow-up. Therefore, the 
TFS after for example 1 month provides information about renal mass that is not obtained 
by measures of glomerular fi ltration rate and may serve as a measure for initial renal mass 
post-transplantation. Furthermore a decrease of TFS in subsequent 99mTc-MAG3 renograp-
hies helps in the management of grafts experiencing DGF by planning additional diagnos-
tic procedures like doing a renal biopsy or adapting calcineurine dose. Previous fi ndings 
showed that DGF was associated with an increased risk of acute rejection episodes and a 
suboptimal function at 1 year but DGF alone was not independently associated with graft 
loss (3). The current study confi rms that delayed graft function is associated with an initially 
decreased renal tubular function that appears irreversible. 
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Background Delayed graft function (DGF) occurs in upto 50% of renal transplants. Hyper-
calcemia and hyperparathyroidism are associated with impaired renal function. Little is 
known on the effects of serum calcium levels on delayed graft function. This issue was ad-
dressed in the current study. 
Methods Patients receiving a cadaveric renal transplant between 1986 -1996 were studied. 
Data on calcium metabolism and histological characteristics of nephrocalcinosis, acute tu-
bular necrosis (ATN) and acute rejection in biopsies taken within the fi rst week, were rela-
ted to the occurrence of DGF. 
Results The incidence of DGF in a cohort of 585 cadaveric transplants was 31%. DGF cor-
related independently with serum calcium levels (OR 1.14 (95% CI 1.04-1.26) per 0.1 mmol/
l). The use of calcium channel blockers before transplantation protected against DGF (OR 
0.5 (95% CI 0.29 – 0.87). In this selected group we found an association with histological 
signs of ATN and DGF. However, most of the biopsies also had features of acute rejection or 
nephrocalcinosis. Nephrocalcinosis was found in 12 of 71 biopsies and was not associated 
with serum calcium levels or the occurrence of DGF. 
Conclusions In this study, serum calcium levels were independently associated with DGF. 
This could not be explained by the presence of microscopic nephrocalcinosis. Therefore 
DGF is attributed to high intracellular calcium levels. As calcium supplementation and vi-
tamin D analogues are commonly used in dialysis practice, hypercalcemia infl uences long-
term graft outcome by its effect on DGF. The pretransplant use of calcium channel blockers 
has a protective effect on the occurrence of DGF.
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INTRODUCTION 
The pathogenesis of acute tubular necrosis (ATN) in human kidneys remains enigmatic 
despite great scientifi c interest and investigative efforts. The poor correlation between the 
clinical occurrence of acute renal failure and the morphological manifestations of ATN in 
the renal biopsy has hampered progress in this fi eld (1). The regular occurrence of delayed 
graft function (DGF) immediately following transplantation of postmortal kidneys has re-
newed this interest. However, the circumstances in which DGF occurs in renal allografts dif-
fer from the conditions in which acute renal failure develops in native kidneys. Conditions 
during explantation and implantation of the donor organ as well as calcineurin inhibitor 
toxicity and rejection episodes immediately following transplantation may be responsible 
for or contribute to the development of DGF (2). The interest in the occurrence of DGF was 
heightened by the fi nding that rejection episodes are more likely to occur in association 
with DGF (3,4). In combination with rejection episodes DGF also infl uences the long term 
prognosis of graft function (4,5).
The study of the morphological manifestations of DGF in renal allografts is facilitated by 
the fact that graft biopsies are more readily obtained than biopsies from native kidneys. It is 
conceivable that the discrepancy between DGF and ATN in allografts is not only explained 
by factors related to the transplantation procedure, including calcineurine toxicity, but also 
by elevated serum phosphate – and / or serum calcium levels at the time of transplanta-
tion. 
The mechanism by which hypercalcemia causes acute renal failure remains largely hypo-
thetical. In dogs and rats, acute renal failure has been reported as a result of experimentally 
induced hypercalcemia (6). In animal models 3 types of nephrocalcinosis are distinguished: 
chemical nephrocalcinosis, microscopic nephrocalcinosis and macroscopic nephrocalcino-
sis (7). The latter is characterized by gross calcium deposits found on radiographic inves-
tigations. Microscopic nephrocalcinosis is characterized by microscopic calcium deposits, 
mainly located in the lumen of the tubules. Its effect on renal function is thought to be cau-
sed by tubular obstruction and tubular back-leak. Chemical nephrocalcinosis, assumed to 
be present when macroscopic and microscopic nephrocalcinosis are excluded, affects glo-
merular fi ltration rate by vasoconstriction and natriuresis induced volume constriction (8). 
Calcium is a co-factor in the activation of proteolytic enzymes that are linked with tubular 
integrity. Several factors have been described to play a role in the development of tubular 
damage caused by oxygen deprivation such as abnormal calcium homeostasis, reactive 
oxygen species and activation of enzymes (9). Hypoxia has been found to reduce the cel-
lular pool of adenosine triphosphate (ATP) leading initially to accumulation of adenosine 
di- and monophosphate and further catabolism to hypoxanthine and xanthine and the 
generation of reactive oxygen species (10). As a consequence of ATP depletion, cells are no 
longer able to extrude calcium. The infl ux of calcium occurs predominantly during reper-
fusion and reoxygenation. High cytosolic concentration of free calcium has been shown 
to activate calcium-dependent enzymes such as phospholipases, nucleases, and cysteine 
proteases (11). The wide spread use of vitamin D analogues in dialysis patients and the ex-
perimental evidence for a nephrotoxic effect of hypercalcemia prompted us to investigate 





Patients who received a cadaveric renal transplant between January 1986 and December 
1996 were included in this study. Twenty-six patients experiencing primary non-function 
(PNF) were excluded from the study. PNF was defi ned as grafts that never functioned and 
led to transplantectomy. A total of 585 transplants were analyzed. DGF was defi ned when 
serum creatinine levels increased, remained unchanged or decreased less than 10% per 
day in three consecutive days in the fi rst week after transplantation. Primary function (PF) 
was present when they did not meet the defi nition of DGF and acute rejection was exclu-
ded. All patients that received anti-rejection treatment in the fi rst week were categorized 
as primary function and acute rejection. Cold ischemia time (CIT) was calculated from the 
Eurotransplant report; warm ischemia time (WIT) was registered by the attending trans-
plant physician. Only three patients received a graft from a non heart beating donor.
The standard immunosuppressive regimen consisted of prednisone and Cyclosporine-A 
(Sandimmune® soft gelatin capsules). CsA was administered intravenously in a dose of 3 
mg/kg /day for the fi rst 48 hours, starting at the onset of surgery. The initial oral dose of CsA 
was 8 - 10 mg/kg/day from day 2 onward, divided in three daily doses and subsequently 
tapered. Doses were adjusted according to CsA trough level monitoring. All patients re-
ceived 20 mg of prednisone starting on day one. Rejection episodes were treated with 1 
gram of methylprednisolone intravenously for 3 days or rabbit anti-thymocyte globulin for 
10 days, as described previously (12). 
Calcium, phosphate, parathormone (PTH) 
Concentrations of calcium, phosphate, parathormone (PTH) and albumin were determined 
on serum samples, obtained on admission for transplantation. Calcium values were cor-
rected for protein binding. Intact PTH was measured with a two-side radioimmunometric 
assay (IRMA) from Nichols Institute, San Juan Capistrano CA, USA.
Histological examination
During the study period 85 biopsies were taken within 7 days after transplantation. 
Fourteen biopsies were excluded because suffi cient material was not available for analysis. 
A total of 71 biopsies could be studied. Transplantectomy specimens were not included in 
the analysis. Needle biopsies were taken to detect or exclude early graft rejection, not to 
confi rm ATN. Three wedge biopsies were taken during surgical re-interventions. 
Kidney sections stained by hematoxylin-eosin (HE), periodic acid-Schiff (PAS) and silver-
methenamine were scored for manifestations of ATN, according to Olsen et al (13). Signs 
and severity of rejection in allograft biopsies were taken from the light microscopic des-
cription of these biopsies in the clinical records. Acute rejection episodes were retrospec-
tively classifi ed based on the criteria described in the Banff 1997 classifi cation of renal al-
lograft pathology (14).
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In order to detect calcium deposits, paraffi n sections were stained according to Von Kossa 
(15) and scored independently by JAB and LES. Nephrocalcinosis was defi ned when Von 
Kossa positive material was seen at the same location in at least two consecutive sections 
(fi g.2).
Statistical analysis
Characteristics among groups were compared using Student’s t-test for independent 
continuous variables and Pearson chi-square test for categorical variables. Binary logis-
tic regression analysis was used to assess the risk for occurrence of DGF for each variable 
separately. Multivariate binary logistic regression was used to adjust for confounding. All 
analyses were performed using SPSS statistical software package (version 10.07;SPSS Inc.
Chicago Ill.)
RESULTS 
DGF occurred in 183 (31%) of the 585 patients studied (Table 1). Sex of either donor or 
recipient did not correlate with DGF, but a higher donor age correlated signifi cantly (p = 
0.0005) with the occurrence of DGF, whereas recipient age had no infl uence. Warm ische-
mia time (WIT) was longer for patients with DGF, but this difference was not signifi cant, 
whereas cold ischemia time (CIT) was signifi cantly longer in recipients with DGF. Recipients 
who used calcium channel entry blockers before transplantation experienced less frequent 
DGF (p = 0.01).
Calcium, phosphate and PTH 
Recipients with DGF had signifi cantly higher total serum calcium (p = 0.001) and albumen 
corrected calcium levels (p = 0.01) than recipients without DGF (Table 1). In a logistic regres-
sion model in which several risk factors for the occurrence of DGF were included the Odds 
Ratio for serum albumen corrected serum calcium was 1.14 for each 0.1 mmol/l increase of 
serum calcium. When serum calcium levels were stratifi ed, calcium levels of 2.75 mmol/l or 
higher were associated with a higher occurrence of DGF compared to levels of less than 2.55 
Figure 2
 
Representative slide showing 
nephrocalcinosis (Von Kossa staining).
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mmol/l (OR: 2.51; 95% CI: 1.59 – 3.98; p < 0.0005) (Table 2). However, the individual calcium 
levels of recipients with and without DGF shows a considerable overlap (fi g.1). The rela-
tion between corrected calcium levels and the predicted probability of DGF did not show 
a critical value above which DGF was more likely to occur. Serum phosphate levels did not 
correlate with the occurrence of DGF and neither did the calcium phosphate product or the 
albumin corrected calcium-phosphate product. Serum PTH levels were higher in recipients 
with DGF, but this difference was not signifi cant (p = 0.81). 
Table 1: Transplantation characteristics and of calcium and phosphate metabolism of 585 kidney 
transplant recipients
 Total 




n = 183 
P-value
Transplantation characteristics
Sex recipient male (%) 63 62 66 0.34
Sex donor male (%) 58 59 56 0.66
Recipient age (years) 46.2 (12.8) 45.9 (12.5) 47.1 (13.5) 0.68
Donor age (years) 38.4 (15.0) 36.7 (14.6) 42.3 (15.2) <0.0005
Number of transplants 1.20 (0.48) 1.22 (0.49) 1.17 (0.46) 0.34
Pre-Tx CCB’s (%) 17.5 20 11.4 0.01
CIT (hours) 28.7 (6.7) 28.0 (6.6) 30.1 (6.7) < 0.00001
Pre-Tx dialysis mode 
 (% HD) 292 (50) 193 (47) 99 (54) 0.70
Time on dialysis (months) 40.5 (69) 43 (80) 35 (31) 0.61
Preservation fl uid (% EC)  41  40  43  0.62
WIT (minutes) 27.8 (9.3) 27.5 (9.1) 28.4 (9.6) 0.58
Laboratory parameters
Serum calcium (mmol/l) 2.57 (0.24) 2.54 (0.24) 2.63 (0.25) < 0.001
Corrected serum calcium (mmol/l) 2.47 (0.22) 2.46 (0.22) 2.51 (0.21) 0.01
Serum phosphate (mmol/l) 1.67 (0.51) 1.68 (0.50) 1.66 (0.52) 0.72
Calcium*Phosphate product 4.27 (1.28) 4.23 (1.24) 4.34 (1.35) 0.39
Corrected Calcium* Phosphate 
product
4.11 (1.26) 4.10 (1.23) 4.14 (1.33) 0.72
Serum PTH (pmol/l)* 18.5 (23.6) 18.3 (24.8) 19.1 (21.1) 0.81
*Since February 1993 (n = 179); () mean (SD) () Mean (SD); CCB’s : calcium channel blockers; 
EC: Euro Collins
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Table 2: Independent risk factors for DGF in the cohort 585 patients transplanted in the period 1986 - 1996
OR 95% CI p-value
Adjusted serum calcium 
< 2.54 1
2.55 – 2.74 1.54 0.98 – 2.43 0.062
> 2.74 2.51 1.59 – 3.98 < 0.0005
CIT > 28 h 1.70 1.16 – 2.48 0.007
Donor age >=50 years 1.48 0.975 - 2.23 0.07
Use of CCB 0.49 0.28 – 0.85 0.01
*CCB: Calcium Channel Blocker
Histological examination 
To determine whether the results could have been infl uenced by the biopsy strategy used 
to take graft biopsies, characteristics of biopsied (n = 85) and non-biopsied (n = 500) pa-
tients were compared (Table 3). No differences were found, except for the serum phospha-
te levels (p = 0.05). Despite the signifi cant higher phosphate levels in the biopsied patients, 
hyperphosphatemia was not associated with DGF.
In a total of 71 biopsies, 34 were taken from patients with DGF and 37 were taken from 
patients with PF. DGF correlated signifi cantly with the presence of ATN in the renal biopsies 
(Table 4A). However most biopsies, except six had other morphological changes such as 
acute rejection or nephrocalcinosis. The association of these changes with DGF was there-
fore analyzed (Table 4B and 4C). DGF did not correlate with histological signs of acute rejec-
tion, except when it was accompanied with ATN (Table 4B). Nephrocalcinosis did not corre-
late with DGF, but it could have been associated with other histological abnormalities. It did 






































The distribution of albumen cor-
rected serum calcium levels, 
showing a considerable overlap 










Sex recipient male (%) 65 63 0.82
Sex donor male (%) 57 59 0.91
Age recipient 44 (13) 47 (13) 0.14
Age donor 38 (15) 39 (15) 0.58
CIT (hours) 23.0 (6.6) 28.6 (6.8) 0.67
WIT (min.) 26.8 (8.5) 28.0 (9.4) 0.26
DGF 29 (36 %) 178 (36%) 0.94
Use of CCB’s (%) 18 17 0.77
Serum calcium (mmol/l) 2.54 (0.22) 2.58 (0.25) 0.21
Corrected Calcium (mmol/l) 2.44 (0.22) 2.48 (0.22) 0.11
Serum phosphate (mmol/l) 1.77 (0.49) 1.65 (0.51) 0.05
Calcium / phospate product 4.47 (1.24) 4.23 (1.28) 0.12
Calcium / phospate product (albumen corr.) 4.32 (1.28) 4.07 (1.26) 0.10
PTH (pmol/l ) * 25.9 (32.2) 17.3 (21.0) 0.16
() = mean (SD); *since February 1993 (N=179); CCB: Calcium channel blocker 
Table 4 A: Histological characteristics of ATN and initial graft function, showing a relation between 







No ATN 33 (89) 19 (56) 0.002
ATN total 4 (11) 15 (44) 0.002
ATN only 2 (5) 6 (18) NS
ATN + rejection 2 (5) 4 (12) 0.04
ATN + NC* 0 5 (18) 0.001
* NC: nephrocalcinosis; (%)
Table 4 B: Histological characteristics of acute rejection and initial graft function, showing a lack of 






No rejection 11 (30) 14 (41) NS
Total rejection 26 (70) 20 (59) NS
Rejection only 21 (57) 12 (35) NS
Rejection + ATN 2 (5) 4 (12) 0.04
Rejection + NC* 3 (7) 4 (12) NS
* NC: nephrocalcinosis; (%)
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Table 4 C: Histological characteristics of nephrocalcinosis and initial graft function, showing a lack of 






No NC 34 (92) 25 (73) 0.05
Total NC 3 (11) 9 (27) 0.05
NC only 0 0
NC + ATN 0 5 (15) 0.001
NC + Rejection 3 (7) 4 (12) NS
 NC: nephrocalcinosis; (%) 
Role of calcineurin inhibitors on DGF
In the current study with the use of continuous infusion of Cyclosporin all patients received 
a standardized systemic exposure to cyclosporin in the fi rst postoperative days. To asses 
a possible confounding effect of this intravenous regimen, we extended our study with a 
cohort of patients transplanted between 1997 and 2002, who received triple immunosup-
pressive therapy with the micro-emulsion formula of cyclosporin (Neoral ®), Prednison and 
Mycophenolate Mofetil (CellCept ®). The oral doses of cyclosporine were adjusted accor-
ding to 12 hours serum trough level monitoring, aiming at 250 – 350 μg/l. Fifty fi ve out of 
222 patients (25%) experienced DGF. Cold ischemia time (CIT) and donor age were again 
signifi cantly associated with DGF. Also in this cohort, the increased pretransplant serum 
calcium levels were associated with the occurrence of DGF (PF vs. DGF: 2.49 mmol/l vs. 2.54 
mmol/l ; p: 0.11). The results of the multivariate analysis are shown in table 5. The increased 
serum calcium levels were associated with an increased occurrence of DGF (OR: 3.12: cal-
cium > 2.75 mmol/l vs. serum calcium < 2.55 mmol/l; 95% CI: 1.18 – 8.26; p: 0.02). Patients 
who used calcium channel blockers prior to and at the time of transplantation were protec-
ted against DGF (OR 0.57; 95% CI: 0.26 – 1.23; p = 0.15), although no statistical signifi cance 
was reached, probably because of the limited number of patients that could be analyzed in 
this additional cohort of patients (Table 5). 
Table 5: Independent risk factors for DGF in the cohort 222 patients transplanted in the period 1997 - 2002
OR 95% CI p-value
Serum calcium 
< 2.55 mmol/l 1
2.55 – 2.74 mmol/l 1.60 0.73 – 3.51 0.24
>2.75 mmol/l 3.12 1.18 – 8.26 0.02
CIT > 28 h 2.00 0.93 – 4.30 0.07
Donor age > 50 yrs 3.49 1.71 – 7.11 0.001
Use of CCB 0.57 0.26 – 1.24 0.16




In this retrospective study, the occurrence of DGF was 35%. We also found that among 
other known risk factors, like donor age and CIT, pre-transplant serum calcium level was 
independently associated with DGF. Although the differences between the two groups 
seem to be small (0.09 mmol/l in serum calcium levels and 0.05 mmol/l for the albumen 
corrected serum calcium levels), the risk of DGF increased 14 %, with each 0.1 mmol/l rise 
in serum calcium level (OR 1.14 [95%CI: 1.04 -1.26]). Dialysis mode, duration of dialysis be-
fore transplantation and the preservation fl uid used on the other hand did not correlate 
with DGF. When a commonly used defi nition for DGF (e.g. the need of at least 1 dialysis 
treatment in the fi rst week), was used similar results were obtained. However the need of 
dialysis treatment in the fi rst week also includes patients that are dialyzed for other reasons 
than DGF (16). In our study 12 out of 358 patients (3.4%) were dialyzed in the fi rst week 
after transplantation for other reasons than DGF.
Also the possibility of calcineurin toxicity as a risk factor for the occurrence of DGF was consi-
dered. Although histological proof of acute cyclosporin toxicity was only found in 2 biopsies 
in the PF group, we cannot exclude a role of cyclosporin in the development of DGF. Howe-
ver differences in cyclosporin assays over time and the high inter patient variability of syste-
mic exposure to cyclosporin preclude any meaningful retrospective evaluation of systemic 
exposure. (17,18). To asses a possible confounding effect of this intravenous regimen, we 
analyzed an other group of patient that was transplanted in the period 1997-2002 and that 
were treated with Neoral® soft gelatin capsules twice daily, assuming that the occurrence 
of high serum levels is limited. Again albumen corrected serum calcium levels tend to be 
higher in the DGF group (OR 3.12; p: 0.02 calcium > 2.75 mmol/l vs. <2.55 mmol/l). We also 
found that the use of calcium channel blockers (CCB) prior to the transplantation protected 
against the occurrence of DGF. Unfortunately the level of signifi cance was not reach, proba-
bly because of the limited number of patients that could be analyzed.
No relation was found between microscopic nephrocalcinosis and serum calcium levels 
(2.43 mmol/l in each group). Acute renal failure in native kidneys has been reported in pa-
tients with serum calcium levels above 3.5 mol/l. In native kidneys, these conditions occur 
in the milk alkali syndrome (19), severe hyperparathyroidism, PTH-related proteins (PTHrP) 
associated conditions(20), multiple myeloma (21) or vitamin D intoxication (22). Although 
the corrected serum calcium exceeded the serum level of 2.7 mmol/l in only 19% of the 
cases, we found an effect of serum calcium levels on initial graft function. Since we did not 
fi nd a critical value above which DGF occurred more often, it is diffi cult to predict DGF on 
the basis of serum calcium levels alone. 
Little is known about the effects of hypercalcemia on the initial graft function. Torregosa et 
al. (23) reported a signifi cant effect of elevated PTH levels on the incidence of DGF, where-
as serum Vitamin D levels and serum calcium levels did not differ. Therefore we analyzed 
the pre-transplant PTH-levels that were routinely measured; 179 pre-transplant PTH levels 
were measured but no signifi cant differences were found between the two groups (PF vs. 
DGF: 18.3 pmol/l vs. 19.1 pmol/l ; p= 0.81). 
Vitamin D analogues and calcium-containing phosphate binders are prescribed on a regu-
lar basis in patients that are on renal replacement therapy to prevent renal bone disease. 
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Serum calcium levels and the total body calcium load therefore will rise. This is associated 
with a higher incidence of calcifi cations of the coronary arteries and possibly with inferior 
patient survival (24,25). Since DGF is associated with inferior long-term graft outcome (26) 
this prophylactic regimen may not only infl uence patient survival but also graft survival. 
Unfortunately Vitamin D levels were not routinely measured in our study. A prospective 
study is required to determine the risk of developing DGF as a consequence of calcium and 
vitamin D supplements in transplant recipients.
Of the 26 biopsied patients with DGF only 13 biopsies showed signs of ATN whereas in 
the other 13 biopsies no signs of ATN were observed. Therefore attempts were made to 
fi nd other morphological explanations for DGF in these patients. ATN was only associated 
with DGF when it coincided with acute rejection or nephrocalcinosis. Acute rejection and 
nephrocalcinosis alone or in combination with other histological features than ATN were 
not associated with DGF. This means that DGF and ATN are fi rmly correlated in this cohort. 
In contrast to the whole group of patients, we found no differences in serum calcium levels 
between the PF and DGF group that had renal biopsies in the fi rst week (p = 0.3).
This study can not explain the effects of high pre-transplant serum calcium levels on initial 
graft function by the development of calcium depositions. Very few clinical studies have 
looked at the morphological substrate of hypercalcemia in the kidney. Prospective studies 
have not been performed and on the basis of the relative benign outcome of DGF it will be 
hard to justify protocolized prospective renal biopsies in recipients with and without DGF. 
In animal models 3 types of nephrocalcinosis can be distinguished: chemical nephrocal-
cinosis, microscopic nephrocalcinosis and macroscopic nephrocalcinosis (7). The latter is 
characterized by gross calcium deposits found on radiographic investigations. As macros-
copic nephrocalcinosis is not present in this study, microscopic and chemical nephrocalci-
nosis might explain the effect of high serum calcium levels on initial graft function. Micros-
copic nephrocalcinosis is characterized by microscopic calcium deposits, mainly located in 
the lumen of the tubules. It is supposed to be a transitional phase between chemical and 
macroscopic nephrocalcinosis. Microscopic nephrocalcinosis is associated with increased 
calcium x phosphate product and with chronic renal failure. Especially high serum phosp-
hate levels seem to trigger this process. Its effect on renal function is thought to be caused 
by tubular obstruction and tubular back-leak. Chemical nephrocalcinosis, assumed when 
macroscopic and microscopic nephrocalcinosis are excluded, affects glomerular fi ltration 
rate by vasoconstriction and natriuresis induced volume constriction (8) and is histological 
characterized by areas of focal necrosis in the distal tubules and medullary collecting duct. 
High calcium content of the medullary area was found and the functional substrate was 
characterized by impaired function of the distal tubules. The role of cytoplasmatic calcium 
as an intracellular messenger in many important cell functions might explain these functi-
onal changes associated with the high cytoplasmatic calcium content. Calcium dependent 
enzymes that were analyzed in vitro in this respect are the cystein proteases, like calpaine 
and the caspases (27). In this study, we found a correlation of DGF with serum calcium 
levels but not with calcium deposits. This suggests that chemical nephrocalcinosis rather 
than microscopic nephrocalcinosis is the underlying cause of the effect of serum calcium 
levels on initial graft function.
In this context our fi nding that the use of pre-transplant calcium channel blockers (CCB’s) 
protects against DGF is interesting. CCB’s are reported to ameliorate initial graft function 
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(28). The mechanisms by which CCB’s have this protective effect may be related to an in-
crease of renal perfusion because of vasodilatation of the glomerular arterioles (29). On the 
other hand it is conceivable that the CCB induced reduction of calcium infl ux into tubular 
cells during ischemic and reperfusion periods and thereby reduce the generation of oxy-
gen-free radicals and activation of cystein proteases (11). 
In this study we found that serum calcium levels were independently correlated with the 
occurrence of DGF. In contrast to other studies a signifi cant correlation was found between 
DGF and ATN, but not with microscopic nephrocalcinosis. Therefore DGF should be attri-
buted to high intracellular calcium levels (chemical nephrocalcinosis). As calcium supple-
mentation and vitamin D analogues are commonly used in dialysis practice, hypercalcemia 
might cause a higher incidence of DGF and therefore infl uence long-term outcome of renal 
transplantation. The use of calcium channel blockers protects against the occurrence of 
DGF.
Calcium levels as a risk factor for delayed graft function
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Background Acute tubular necrosis (ATN) in renal allograft biopsies correlates poorly with 
delayed graft function (DGF). Factors involved in the pathogenesis of DGF were evaluated 
in biopsies in an attempt to refi ne the recognition of DGF.
Methods Of a total of 85 biopsies taken within the fi rst week after transplantation, 41 bi-
opsies were suitable for this study: ten from patients with DGF, and 31 from patients wit-
hout DGF. Anti-cubulin and anti-AE-1/AE-3 antibodies were used to identify proximal and 
distal tubules respectively. The TUNEL technique and staining for active caspase-3 were 
used to demonstrate apoptosis. Antibodies against three types of super oxide dismutase 
(SOD) were used as markers of the protective tubular response. Tubular regeneration was 
evaluated using anti-ki 67 and anti-vimentin antibodies.
Results DGF occurred in 24 % of the transplant recipients. ATN coincided with DGF in 31% 
of the cases. The predictive value of fi nding ATN in the biopsy of a graft with DGF was only 
50 %. Absence of distal caspase-3 staining predicted the absence of ATN in 78 % of cases. 
The presence of caspase-3 predicted ATN in 75 % of cases. The detection of Mn-SOD in dis-
tal tubules predicts the absence of DGF in 78% of the cases. 
Conclusions The use of immuno-histochemical staining on renal biopsies improved its 
predictive value with respect to ATN and DGF: The absence of active caspase-3 in distal tu-
bular epithelium predicts the absence of ATN in 78% of cases, whereas its presence predicts 
ATN in 75% of cases. The presence of Mn-SOD in distal tubules predicts the absence of DGF 
in 78 % of cases.
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INTRODUCTION
The relationship between the functional and the morphological manifestations of acute 
renal failure remains enigmatic. It is generally accepted that acute tubular necrosis (ATN) 
is the morphological expression of acute renal failure due to ischemia-reperfusion injury. 
However, extensive tubular necrosis is not a typical feature of ATN (1). The tubular changes 
in human ATN are subtle and consist of fl attening of proximal tubules with loss of brush 
border and necrosis of individual cells with focal denudation of the tubular basement 
membrane (2). Acute tubular injury therefore might be a better term to describe the more 
subtle morphological markers as a substrate of acute renal failure. In clinical practice renal 
biopsies are rarely performed to confi rm ATN, but rather to exclude other causes of ARF. 
Delayed graft function of renal transplants (DGF) has renewed the clinical and scientifi c in-
terest in the histopathological characteristics of ARF, as it has been described as a possible 
risk factor for acute rejection (3) and for the development of chronic allograft nephropa-
thy (4). Olsen reported, that although there are a lot of similarities between ATN in native 
kidneys and graft ATN, the latter shows more apoptosis and tubular necrosis, sometimes 
extending to whole tubular cross sections (5,6). Although circumstances leading to ATN in 
transplants may differ from those leading to ATN in native kidneys, ischemia/reperfusion 
injury plays a role in both conditions.
Several mechanisms have been described in the development of acute tubular damage 
caused by oxygen deprivation such as abnormal calcium homeostasis, reactive oxygen 
species and activation of enzymes involved in the oxidative stress response. Hypoxia has 
been found to reduce the cellular pool of adenosine triphosphate (ATP) initially leading to 
accumulation of adenosine di- and monophosphate and the generation of reactive oxygen 
species. Moderately elevated levels of reactive oxygen species have been shown to cause 
apoptosis, whereas higher levels cause necrosis of proximal tubules (7). As a consequence 
of ATP depletion, cells are no longer able to excrete calcium. The infl ux of calcium occurs 
predominantly during reperfusion and reoxygenation. High cytosolic concentration of free 
calcium has been shown to activate calcium-dependent enzymes such as phospholipa-
ses, nucleases, and cysteine proteases (8). Activated cysteine proteases are responsible for 
the disruption of the microtubular and cytoskeletal network and are involved in apoptosis 
(9,10) whereas administration of inhibitors of cysteine proteases reduce reperfusion injury 
in rat kidneys (11). Intact structural polarity of proximal tubules is vital for their function. 
Disruption of the cytoskeletal network has been reported to be associated with disturbed 
polarity, apoptosis and delayed graft function (12)
Protection against the toxic effects of reactive oxygen species is mediated by antioxi-
dant enzymes, such as catalase, glutathione peroxidase (GPX) and superoxide dismutases 
(SODs). Extracellular-SOD (Ec-SOD) is mainly present in the extracellular fl uid and matrix. 
Copper–Zinc SOD (Cu/Zn-SOD) is expressed constitutively throughout the body, whereas 
Manganese-SOD (Mn-SOD) is located exclusively in mitochondria (13) and is easily induced 
by oxidant stress and infl ammatory conditions (14). The kidney has a remarkable capacity 
to recover from ischemic injury. Signs of regeneration and proliferation such as mitotic ac-
tivity are characteristic of previous ischemic injury. Renal regeneration recapitulates certain 
aspects of renal development. Renal tubules are of mesenchymal origin, but they normally 
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do not express vimentin, unless they are recovering from ischemia (15). 
Renal biopsies are generally not taken from renal allografts to confi rm ATN; they are taken 
to detect acute rejection in patients with DGF. Since DGF is a transient and treatable dis-
order, prospective studies to investigate the relationship between DGF and ATN are not 
likely to be performed. It is therefore extremely diffi cult to study ATN in human kidneys. 
Therefore we performed a retrospective study in order to determine whether molecular 
markers for cell death, protection against oxidative stress, regeneration and proliferation 




DGF was defi ned as a failure of the graft to reduce serum creatinine concentration by more 
than 10 % over three consecutive days for more than 1 week after transplantation (3). Using 
this defi nition DGF occurred in 24% of the transplantation procedures. Ninety percent of 
the patients were initially treated with prednisone and cyclosporine (Sandimmune) and 
10 % with prednisone and azathioprine. Between 1983 and 1996, 85 biopsies were taken 
within the fi rst 7 days.
To be included in the study, a renal biopsy taken in the fi rst week after transplantation had 
to be available. These biopsies were taken for clinical reasons to detect or exclude additio-
nal acute rejection or cyclosporin toxicity. No biopsies were done to confi rm ATN. When 
acute rejection was not found in the biopsy and cyclosporin toxicity could be excluded on 
clinical data and histology, the biopsy was included in the study. Patients who had a renal 
biopsy taken within the fi rst week and who fulfi lled these criteria were divided into a group 
with DGF and a group with primary function (PF). Forty one biopsies were selected. Eleven 
wedge biopsies were taken during surgical re-interventions and 30 needle biopsies were 
taken for diagnostic purposes. These biopsies were subsequently evaluated using light mi-
croscopy for the presence of acute tubular necrosis (16). 
The pathophysiology of acute tubular necrosis is generally divided in an ischemic phase, 
characterized by tubular cell apoptosis or necrosis, a protective response against super-
oxide radicals, and a recovery phase in which tubular cell regeneration is prominent (17). 
Biopsies were therefore stained for markers of apoptosis, using the TUNEL technique and 
by immunostaining for active caspase-3, as well as for Ki 67 and vimentin, markers for pro-
liferation and regeneration respectively. Staining for Cu/Zn-SOD, EC-SOD and Mn-SOD was 
performed to evaluate the protective response of the graft against reactive oxygen spe-
cies. Differences between the 2 groups were subsequently scored in a blinded protocol. 
Histopathological examination and scoring
Biopsies were fi xed in 3 % formaldehyde and embedded in paraffi n. Tissue sections were 
cut and stained with hematoxylin and eosin (H+E), Periodic acid-Schiff (PAS) and periodic 
acid-silver methenamine (PASM). The biopsies were reviewed by a pathologist without 
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knowledge of the clinical fi ndings (He.Be.). Each biopsy was evaluated for the following at-
tributes: number of glomeruli present, extent of global and segmental glomerulosclerosis, 
interstitial infl ammatory infi ltrate, interstitial fi brosis, tubular atrophy, tubular cell shed-
ding, focal denudation of the tubular basement membrane (“non-replacement phenome-
non”), presence of necrotic tubular cells in the lumen (tubular necrosis), tubular cross-secti-
onal necrosis, tubular nucleolar prominence (tubular cell “activation”), and tubular mitotic 
activity. A semiquantitative evaluation was applied and each characteristic scored on a 
scale of 0 - 3. (16). For a better analysis of the relation between these histological parame-
ters and clinical and immuno-histochemical features, this histological score was simplifi ed 
into 2 point scale The Banff Schema for transplant pathology was applied (18). A biopsy 
was classifi ed as having morphologic changes characteristic of ATN, when tubular cells 
were necrotic or showed cross-sectional necrosis or when at least score 2 was reached for 
tubular regenerative changes (16).
Immunohistochemical techniques
TUNEL Paraffi n sections (4µm) were mounted on Superfrost plus glass slides (Mensel-
Glaser, Omnilabo, Breda, The Netherlands) and deparaffi nized in xylol and ethanol 96% and 
dried overnight at 37 0 C. After inactivation of endogenous peroxidases with 1.2% H2O2 in 
methanol and hydration, sections were pretreated with blocking buffer consisting of 0.1 M 
TRIS, 3% BSA and 20% normal calf serum for 30 minutes at room temperature. After rinsing 
with PBS, TUNEL mix (Roche Diagnostics, Almere, the Netherlands) was applied for only 30 
minutes at 370 C. The prescribed incubation for 60 minutes resulted in our hands in unac-
ceptable level of false positives in normal controls. The reaction was stopped with a mixture 
consisting of 40 cc 0.75 M PBS, 30 cc 0.1 M citrate and 30 cc demineralized water for 15 
minutes. After rinsing with phosphate buffered saline (PBS), horse radish peroxidase (HRP) 
conjugated rabbit anti-FITC was applied in blocking buffer for 30 minutes. After three rinses 
in PBS, the peroxidase reaction was visualized with Novared (Vector Lab Inc., Burlingame; 
CA 940100).
Antibodies Rabbit anti-caspase-3 (Idun Pharmaceuticals, Inc., La Jolla, CA, USA), rabbit 
anti-MnSOD (a gift from dr. H. Verspaget, Dept. of Gastroenterology, LUMC, The Netherlands), 
rabbit anti Cu/Zn - SOD and rabbit anti Extra - Cellular (EC-) SOD (a gift from Dr. S. Marklund, 
Umea, Sweden), rabbit anti-vimentin (Euro Diagnostica, Arnhem, The Netherlands), mouse 
monoclonal anti-Ki 67 (DAKO, Glostrup, Denmark), mouse monoclonal anti cubulin (clone 
2A3)(19)) and rabbit/mouse anti - AE1/AE3 (Neomarkers, LabVision, Fremont, CA, USA) were 
obtained as indicated.





nol. In order to retrieve the antigen in the renal biopsy, sections were either boiled in 0.1 M 
citrate (pH 6) for 1 minute or in 0.01M citrate (pH6) for 10 minutes.
Double staining Specifi c antibodies directed against the brush border antigen cubulin 
of the proximal tubules and against the cytokeratin AE1/AE3 were used to achieve a shar-
per distinction between proximal and distal tubules. When anti-cubulin was used to loca-
lize proximal tubules it was applied fi rst and followed by antigen retrieval with 0.1M citrate 
and incubation with anti-caspase-3, anti- Mn-SOD or anti Ki 67. Double staining for vimen-
tin did not require antigen retrieval. When anti AE1/AE3 antibodies were used to localize 
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distal tubules, kidney sections were incubated overnight with anti-vimentin followed by 
antigen retrieval for 10 minutes with 0.01 M citrate and staining for AE1/AE3. When sections 
were stained for AE1/AE3 and Mn-SOD, antigen retrieval was performed fi rst in 0.01 M ci-
trate followed by incubation with AE1/AE3 and subsequently with anti-Mn-SOD. When an-
tibody binding was visualized by peroxidation of 3.3 diaminobenzidine tetrahydrochloride 
(DAB), either mouse or rabbit envision (Dako, Glostrup, Denmark) was used as a secondary 
antibody conjugated to HRP. When tissue binding was visualized using Fast Red (Klinipath, 
Duiven; The Netherlands) anti-mouse or anti-rabbit IgG antibodies were used conjugated 
to alkaline phosphatase (AF, Sigma, Zwijndrecht, The Netherlands). Finally double stained 
sections were counterstained for 1-2 minutes in hematoxylin.
Immunohistochemical scoring
The intensity of staining in tubular cells was scored semi quantitatively using a 3-point 
scale; 0: negative or weak intensity; 1+: intermediate intensity; 2+: strong intensity. The 
extent of staining was similarly scored as negative: 0-10 % of tubules; focal: 10-50% of tu-
bules or diffuse: > 50% of tubules. This scoring system was performed on proximal as well 
as on distal tubules, which were recognized on their immuno-histochemical or morpho-
logical characteristics. Scoring was performed at a magnifi cation of 200 x. At time of sco-
ring the investigators (LEs & HeBo) were blinded for clinical and histological data. When 
immuno-histochemical markers to identify proximal or distal tubules were absent, their 
morphological characteristics were taken into account. Proximal tubular epithelial cells in 
ATN kidneys show a fl at cytoplasm with few nuclei ,giving them the impression of distal 
tubules or “distalisation”. However, distal tubules have a high nucleus/cytoplasm ratio and 
their nuclei are better preserved in ATN than the proximal tubular cells, giving them a bead 
like appearance.
Statistics
The intensity and extent scores of the immunohistochemical stainings were compared 
between biopsies with and without histological ATN. The groups were compared with re-
gard to the ordinal semiquantative scale of the scoring system of staining intensity and 
- extent, using non-parametric tests (Mantel-Haenzel chi-square test for linear association). 
The Kendall’s tau-b coeffi cient shows the direction of this correlation. A p-value of 0.05 or 
less was considered signifi cant. Statistical analysis was done using the SPSS software pac-
kage (Version 10.0; SPSS, Inc., Chicago, IL).
RESULTS
Clinical characteristics of patients with or without delayed graft function (DGF) and with or 
without acute tubular necrosis (ATN)
A total of 41 biopsies was studied. Ten were taken from patients with DGF (Table 1) The 
remaining 31 were taken from patients with primary function (PF). Donor age for patients 
with DGF was signifi cantly higher (p<0.05) than for patients without DGF (Table 1). Re-
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cipient age and cold ischemia time (CIT) did not differ between the 2 groups. ATN was 
observed in 16 biopsies (table 2), 5 (50%) coincided with DGF, but 11 did not. The inter-
val between transplantation and the timing of the biopsy did not differ between the two 
groups. Patients who experienced DGF but were not biopsied were slightly younger, had a 
younger donor and had lower Panel reactive antibodies (PRA). Other clinical characteristics 
summarized in table 2, did not differ between the ATN and non-ATN group. 
Table 1: Clinical characteristics of recipients with primary function (PF) or delayed graft function (DGF)
PF DGF
Number of patients 31 10
Mean recipient age (yrs.) 45 ( 12) 53 ( 12) 
Mean donor age (yrs.) 35 (14) 48 (11)*
Mean Cold Ischemia Time (hrs.) 23 (12) 28 (11)
Biopsy interval (days) 4.35 (2.2) 3.2 (2.3)
ATN (%) 11 (36) 5 (50)
PRA (%) 29 (28) 57 (43)
Chi-square test *p<0.05; (SD) 
Table 2: Clinical characteristics of recipients with or without histological evidence ATN
Non-ATN ATN 
Number of biopsies 25 16
Mean recipient age (yrs.) 45 ( 11 ) 50 (15) 
Mean donor age (yrs.) 36 (13) 40 (16)
Mean Cold ischemia time (hrs.) 22 (13) 26 (11)
Biopsy interval (days) 3.9 (2.1) 4.4(2.4)
DGF (%) 5 (20) 5 (31)
PRA (%) 38 (35) 31 (35)
Histological parameters
The morphological features of tubular necrosis in the biopsies with or without DGF are 
shown in Table 3. No correlation was found between the occurrence of DGF and the his-
tological changes. Evaluation of the biopsies according to the Banff 1997 classifi cation for 
transplant pathology (18) revealed no differences between the ATN and non-ATN group 
for the acute tubulitis (t)-score, mononuclear cell interstitial infl ammation (i)-score and al-
lograft glomerulitis (g)-score. All biopsies except for 2 biopsies in the non-ATN group and 
one in the ATN group, had grade 0 t-score. Six biopsies in the ATN group and 5 in the non-
ATN group showed a grade 1 interstitial infl ammation (i) - score. No biopsy had a positive 




Table 3: Histological changes observed in renal biopsies classifi ed as Primary Function (PF) or.
Delayed Graft Function (DGF)
PF (n = 31) DGF (n = 10) p
Glomeruli
Mean number (SD) 18.1 (8.0) 20.4 (6.6)
Glomerulosclerosis (SD) 0.61 (0.89) 0.59 (0.71)
Tubules
Tubular necrosis
Present 7 4 0.22
Absent 24 6
Cross sectional necrosis
Yes 3 3 0.14
No 28 7
Tubular Shedding
Present 12 7 0.21
Absent 19 3
Non-replacement phenomenon
Present 8 3 0.86
Absent 23 7
Activated tubular cells
Present 15 8 0.055
Absent 16 2
Mitosis
Present 13 5 0.32
Absent 18 5
* p- value of the Mantel-Haenzel χ2 test for linear association 
Markers for proximal and distal tubules
In eleven out of 16 biopsies of the ATN group and 18 out of 25 biopsies of the non-ATN group, 
the cubulin positive brush border was absent, indicating damage to the brush border also in 
renal allografts without ATN. The presence or absence of cubulin in the brush border of proxi-
mal tubules did not differentiate between the presence or absence of ATN or DGF. The same 
applied to AE-1/AE-3 positivity and ATN or DGF: the AE-1/AE-3 marker for distal tubules was 
not only present in 23 out of 26 non-ATN biopsies, but also in 14 out of 16 ATN biopsies. Ho-
wever, when AE-1/AE-3 positivity was related to histological scores for ATN, it was correlated 
with the absence of necrosis or cross sectional necrosis. Twenty eight of the 37 biopsies with 
a positive staining for AE-1/AE-3, had no signs of necrosis, whereas 2 biopsies with a negative 
staining for AE-1/AE-3 had signs of necrosis (P: 0.02; : -0.23). Thirty three of the 37 biopsies 
with a positive staining for AE-1/AE-3, had no signs of cross sectional necrosis, whereas 2 bi-
opsies with a negative staining for AE-1/AE-3 had cross sectional necrosis (P: 0.03; κ: - 0.33)
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Active Caspase-3 and TUNEL staining
Of the sixteen biopsies classifi ed as ATN, 5 showed no necrosis in the individual score. In 
these cases, the diagnosis of ATN was made on other diagnostic criteria: 3 showed “non 
replacement”, 3 showed shedding of tubular epithelial cells in the lumen and in 3 biopsies 
activated tubular epithelial cells and mitosis were seen. The absence of necrosis prompted 
us to test markers for apoptosis.
 Table 4a shows that ATN was signifi cantly associated with intensive staining for active cas-
pase-3 in the distal tubules (p = 0.04). The negative predictive value of a negative caspase-3 
staining was calculated to be 78 %. On the other hand the positive predictive value was 
only 54%. Five biopsies had ATN and DGF, whereas 21 biopsies were categorized as non-
ATN without DGF (non-ATN/non-DGF). When these categories were analyzed separately, 
the active caspase-3 staining is positive in the distal compartment of all 5 biopsies from the 
ATN/DGF group, whereas 13 out of 20 biopsies in the non-ATN/ non DGF group are nega-
tive (p = 0.010) (Table 4b). No statistical signifi cant difference in the extent of the caspase-3 
staining in these biopsies was found.
Interestingly, in the absence of ATN and subcomponents of ATN like tubular necrosis and 
cross-sectional necrosis, the distal tubules showed more often apoptosis as assessed by 
the staining with the TUNEL technique than in the presence of ATN (p = 0.01). The pre-
sence of TUNEL staining in the distal tubules predicted the absence of ATN in 96 % of ca-
ses, whereas the absence of TUNEL predicted the presence of ATN in 60 % of the cases. 
Furthermore tubular atrophy was positively correlated with the extent of TUNEL positivity 
(data not shown). In the proximal tubules TUNEL staining correlated with the intensity of 
the active caspase-3 staining (p = 0.04; κ: 0.23) (Table 5). This was not the case in the other 
compartments. 
Figure 1 
Active caspase-3 staining differentiating between the ATN (a) and the non-ATN group (b), in the dis-
tal tubules: Figure a shows the more prominent presence of active caspase-3 positive cells in the ATN 
group. The arrow points to a caspase-3 positive cell with histological apoptotic characteristics. (→)
Original magnifi cation: 400x; proximal tubules: p ; Distal tubules: d 
84
Chapter 5





0.04 0.31+ 4 4
++ 6 8
* p- value of the Mantel-Haenzel χ2 test for linear association ; ** Kendall’s tau β- correlation coeffi cient
Table 4b: Expression of active Caspase-3 in distal tubules in relation to ATN in 21 biopsies classifi ed as histolo-





0.010 0.49+ 3 1
++ 5 4
* p- value of the Mantel-Haenzel χ2 test for linear association ; ** Kendall’s tau β- correlation coeffi cient 
Table 5: Correlation between active caspase 3 staining and TUNEL staining in proximal tubules.
TUNEL P κ





* p- value of the Mantel-Haenzel χ2 test for linear association ; ** Kendall’s tau β- correlation coeffi cient
ROS deactivating enzymes
As expressions of a protective response against ischemia, tubular localization of Cu/Zn -
SOD, Ec-SOD and Mn-SOD were compared between the DGF and ATN groups. Cu/Zn-SOD 
localization was found in both proximal and distal tubules and the intensity and extent of 
staining did not differ between the groups. Ec-SOD localization was found in both proximal 
and distal tubules, but it was slightly more present in the distal tubules. However, there 
was no difference in intensity and extent of localization between the two groups (data not 
shown). 
The intensity and extent of the Mn-SOD staining in distal tubules were related with the 
absence of DGF suggesting a protective role of Mn-SOD against the development of DGF 
(Table 6). This relationship was also found in the proximal tubules, but this relation was not 
signifi cant. The predictive value for the absence of DGF, of distally located Mn-SOD was 
calculated to be 76 %, whereas the predictive value of absent Mn-SOD was not associated 
with the presence of ATN.
Caspase-3 and Mn-SOD in Distal Tubules and ATN and DGF
85





+ 11 6 0.05 - 0.30
++ 15 1
Mn SOD (Extent)
Negative 5 3 0.06 -0.31
Focaal 4 4
Diffuse 22 3
* p- value of the Mantel-Haenzel χ2 test for linear association ; ** Kendall’s tau β- correlation coeffi cient 
Vimentin staining
Regeneration was assessed by staining for vimentin. Vimentin localization was seen relati-
vely more often in ATN biopsies than in the non-ATN biopsies. The basolateral localization 
of vimentin was exclusively seen in cubulin positive proximal tubules. However, the diffe-
rence with non ATN biopsies was not signifi cant (p=0.07). 
Ki 67 staining
The proliferation marker Ki 67 was not associated with the occurrence of ATN or DGF. Ho-
wever the extent of the activated Mn-SOD staining in the proximal tubules was associated 
with a higher extent of staining for Ki 67, but this association was not signifi cant (p 0.09; 
data not shown). No signifi cant correlation was found between Ki-67 staining and the ex-
pression of vimentin.
Figure 2 
Distal tubular localization of Mn SOD in the presence (a) and absence (b) of 
DGF. Note the increased staining intensity in biopsies with DGF (→).




This study confi rms earlier reports documenting the poor correlation between the defi ned 
clinical syndrome of delayed graft function (DGF) and the morphological changes of ATN 
in renal allografts (2,20). The ATN score in this study was performed according to the crite-
ria of Olsen and Solez (16) and did not correlate with the presence of DGF (Table 1). When a 
functional defi nition of DGF was used, excluding acute rejection episodes and cyclosporin 
as a cause of DGF, the presence of ATN in renal allografts predicted DGF, in only 50% of the 
cases, whereas the absence of ATN predicted the absence of DGF in 80% of our cases (Table 
2). This prompted us to study molecular markers allegedly involved in the pathogenesis of 
DGF hoping to obtain a more reliable histological marker for the presence of DGF and to 
gain more insight in the pathophysiology of DGF. The markers were selected on the basis 
of the generally accepted pathogenetic events in ATN, consisting of an initiation phase of 
ischemic and reperfusion injury, an extension or a maintenance phase in which the renal 
tubular protective response is important and a recovery phase in which tubular regenera-
tion and proliferation are characteristic (17). 
Necrotic tubular cells have been described to undergo the following morphological chan-
ges: fi rst proximal tubular cells form “blebs” in their apical membranes and lose their brush 
border (21). They lose their polarity and the integrity of their tight junctions is disrupted, 
presumably as a consequence of the redistribution of the Na/K-ATPases, resulting in altera-
tions in the cytoskeletal network and disruption of tubular cells. Dead tubular cells slough 
into the tubular lumina and therefore are responsible for the denuded aspect of the lumen 
(non-replacement phenomenon) and the tubular obstruction (20). The denuded tubular 
basement membrane (TBM) is repopulated by proliferation of adjacent viable cells, under 
the infl uence of growth factors and by dedifferentiated stem cells that fi rst spread out over 
the membrane, giving the proximal tubules the aspect of distal tubules (distalisation of 
proximal tubules). In contrast to normal distal tubules these recovering proximal tubules 
show very few nuclei. After the TBM has been repopulated cells will proliferate and dedif-
Figure 3
 Magnifi cation 200 x   Magnifi cation 400 x
Basolateral vimentin staining in proximal tubules (→), which is present relatively more frequent in 
the presence of ATN. Note the increased staining intensity in biopsies with ATN.
Original magnifi cation: A :200x; B : 400x. Proximal tubules: p ; Distal tubules: d
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ferentiate until normal morphology and function is reinstalled.
Since the morphological identifi cation of damaged renal tubular segments during ATN is 
diffi cult, we tried to improve the recognition of these segments by introducing proximal 
and distal specifi c markers (cubulin and AE-1/AE-3 respectively). These markers enabled us 
to identify the distal tubules in the presence as well as in the absence of ATN. The presence 
of AE-1/AE-3 positivity, allowed us to identify proximal tubules, as tubules that were AE-1/
AE-3 negative in AE-1/AE-3 positive biopsies. In the four AE-1/AE-3 negative biopsies, distal 
tubules were identifi ed on morphological grounds. 
The paradox of severe reduction of glomerular fi ltration rate (GFR) and mild tubular necro-
sis could be explained by cell death via apoptosis instead of necrosis (22). The contribution 
of apoptosis was evaluated using the TUNEL technique and an immuno-histochemical stai-
ning for active caspase-3. In our hands the TUNEL technique had to be modifi ed to obtain 
a higher specifi city at the expense of sensitivity, because of the high percentage of false 
positive results in biopsies of normal kidneys. TUNEL positivity in the proximal tubules of 
both groups did not differ. Proximal tubules were by regular light microscopy either vital or 
necrotic. In the latter case intra-luminal sludging of cubulin positive material was present. 
Necrosis of proximal tubular cells is probably based on the high sensitivity of the proximal 
tubules for oxygen deprivation and ATP-depletion (23). Staining for active caspase-3 on 
the other hand was more prominent in the distal tubules in biopsies with ATN. The presen-
ce of apoptosis instead of necrosis in the distal tubules of the ATN group can be explained 
by a lower susceptibility of the distal tubules to ischemia and reperfusion injury followed 
by subsequent necrosis. Only when ATP depletion becomes more severe distal tubules will 
react with necrosis instead of apoptosis (24). Our fi nding that in selected cases in which ex-
tremes of ATN and DGF and non-ATN and non-DGF are compared, the relation of DGF with 
the extent and intensity of active caspase-3 staining in distal tubules is even stronger, sup-
ports this hypothesis. Experimental studies illustrate that various zones within the kidney, 
are differently susceptible to ischemic damage (25). Since the amount of tissue in human 
biopsies is very limited in a retrospective study, identifi cation of these separate segments 
within the nephron was not attempted. 
Activated caspases affect the cytoskeletal fi laments, including actin. Recent studies have 
shown that the disruption of cytoskeletal proteins may in itself induce apoptosis and cellu-
lar detachment (9). ATN is characterized ultrastructurally by disruption of apical and baso-
lateral membranes of proximal tubules, with redistribution and diminished intensity of cy-
toskeletal proteins of the apicolateral membrane (21). These mechanisms might contribute 
to the pathogenesis of ATN. Because of the resemblance between these features of ATN 
and the mechanisms of action of activated caspases, apoptosis might be the “missing link” 
in the pathogenesis of ATN. Activation of caspase-3 has been described to be the fi nal step 
in the apoptotic pathway (27). When biopsies were stained for active caspase-3, cytoplasm 
of distal tubules stained signifi cantly more intense in the ATN group (Table 4a). This made 
us conclude that the absence of distal active caspase-3 staining predicted the absence of 
ATN in 78% of cases, whereas the presence of caspase-3 predicted ATN in 75% of cases. No 
differences were found in the proximal tubules between the two groups. 
TUNEL positivity was more prevalent in the distal tubules, especially in the non-ATN group. 
This unexpected fi nding could be explained by experimental evidence that apoptosis is 
not only an expression of damage, but also of repair(28,29). The number of apoptotic cells 
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in rat kidneys with experimental ATN were found to peak in the early phase after ischemic 
injury and in a later stage during regeneration. The fi rst phase of apoptosis occurs early on, 
between 12 and 48 hours after the acute ischemic or nephrotoxic insult and is a result of 
the damaging effect of the insult. In contrast, the apoptosis associated with the recovery 
phase has been postulated to contribute to the remodeling of injured tubules and to faci-
litate their return to a normal structural and functional state. The discrepancy between the 
TUNEL and active caspase-3 staining might be explained by the fact that the specifi city for 
apoptosis of the TUNEL staining is not high enough. It is known from experimental models 
that after treatment with carbon tetrachloride (CCl4) or N-nitrosomorpholine (NNM), rat 
livers showed a high percentage of TUNEL positive necrotic liver cells (26)
Since reactive oxygen species play an important role in the pathogenesis of ATN, the ex-
pression of enzymes with a protective effect against these oxygen radicals was studied. 
Superoxide dismutases have been found to be involved in the detoxifi cation of reactive 
oxygen species (30) and have been described to play a role in experimental ischemia re-
perfusion injury (31). In humans at least three isoforms of SOD have been identifi ed, each 
with a distinct metal component: Copper/Zinc-SOD (Cu/Zn-SOD), Manganese-SOD (Mn-
SOD) and Extracellular -SOD (Ec-SOD). We did not fi nd any difference for the Cu/Zn-SOD or 
Ec-SOD expression, between the two groups. Mn- SOD was found to be the only inducible 
form and to be exclusively located in the mitochondria (32). The overexpression of Mn-SOD 
was reported to correlate with the protection against pro-apoptotic stimuli and ischemic 
damage whereas decline of Mn-SOD expression has been associated with disease activity, 
like cancer and transplant rejection and cis-platinum tubulotoxicity (33-35). In biopsies 
from the non-DGF group, we found a more extensive presence of Mn-SOD in the distal tu-
bules, compared with biopsies from the DGF group. Mn-SOD expression was also present 
in the proximal tubules, but there was no difference between the groups. These fi ndings 
suggest that distal tubules are more resistant against Reactive Oxygen Species because 
they are capable of generating protective upregulation of Mn-SOD. The negative predic-
tive value of the presence of Mn-SOD in the distal tubules predicts the absence of DGF in 
76% of cases. This could explain the absence of necrosis but the presence of apoptosis in 
distal tubules: Proximal tubular cells have been reported to be more vulnerable to necrosis 
(36) whereas distal tubules may be protected to some extent against necrosis because of 
their upregulation of Mn-SOD (14). The clinical use of recombinant SOD (rh-SOD), to pre-
vent ischemia reperfusion injury and subsequent DGF was tested in two randomized trials 
(37,38). Both studies showed that with the pharmacological doses that were used, no effect 
on the incidence of DGF was found. However one study showed a lower incidence of acute 
and chronic rejection and a better long-term graft function for patients treated with Rh-
SOD (38). We therefore hypothesize that at the time of transplantation, the presence of Mn 
SOD, either structurally, upregulated or substituted, may be a parameter for the intrinsic 
potential to recover and may be a surrogate marker for long-term outcome of grafts.
After necrosis and/or apoptosis have occurred, tubular cells will regenerate (39). We found 
that the vimentin expression in proximal tubular cells was more prominent in biopsies, 
showing denudation, one of the morphological characteristics of ATN in grafts. However, 
this did not reach the level of signifi cance. Tubular cells are of mesenchymal origin, but 
normal tubular cells do not express the mesenchymal intermediate fi lament protein vi-
mentin. After being damaged, the recovery of the tubular cells is characterized by replace-
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ment of irreversibly injured tubular epithelial cells by surviving tubular cells, renal stem 
cells or cells originating from the bone marrow. These cells differentiate to tubular cells, 
meanwhile expressing antigens, mimicking renal organogenesis (40,41). Vimentin expres-
sion has been described to be increased in damaged tubular cells and in renal carcinomas 
as a sign of tubular dedifferentiation (42,43). However, we could not confi rm their fi ndings 
in our study, because of the lack of signifi cance. The expression of vimentin that we ob-
served in proximal tubules of the ATN group can be interpreted as a sign of regeneration. 
Unfortunately no correlation was found between the presence of the proliferation marker 
Ki 67 in tubular cells and the occurrence of ATN or DGF. However,Ki-67 positivity in proxi-
mal tubules was more extensive in biopsies with a high expression of the protective marker 
Mn-SOD. This means that also the presence of Mn-SOD in proximal tubules correlated with 
its capacity for regeneration and recovery.
Since biopsies of human kidneys with ATN are diffi cult to obtain, we studied allograft bi-
opsies taken to detect rejection during the fi rst week after transplantation. Because acute 
rejection and calcineurine toxicity were excluded, only 41 biopsies were available for this 
study. This study shows that the use of molecular markers in the evaluation of early post-
transplant renal biopsies does not discriminate between patients with DGF and/or ATN. 
However, in distal tubules correlations were found between the expression of active cas-
pase-3 and the presence of ATN. This could explain why half of our patients with DGF did 
not show signs of ATN in their biopsies. Furthermore the expression of Mn-SOD in distal 
tubules is related to a lower occurrence of DGF, suggesting a protective role. Since the 
absence of distal localization of active caspase-3 is associated with the absence of ATN in 
78 % of patients with DGF and the absence of Mn-SOD in the distal tubules is associated 
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Delayed graft function (DGF) in renal transplantation is an enigmatic problem.
Progress in the research after the etiology and consequences of DGF are hampered be-
cause the clinical consequences of DGF on long term graft function are unclear and renal 
biopsies are usually not taken to document the cause of the DGF syndrome but rather to 
exclude additional acute rejection episodes. Our knowledge on DGF is mainly based on 
studies in experimental animals and on clinical data on acute renal failure in native kid-
neys. This comparison has major fl aws, because the risk factors and clinical setting for acute 
renal failure in the transplantation setting are substantially different from the risk factors 
for acute renal failure in native kidneys. 
The interest in DGF has increased with the increased use of marginal donors, including 
non-heart-beating donors, donors at the extremes of age, and donors with hypertension 
and diabetes, in order to resolve the shortage of kidney donors. This group of donors expe-
rience DGF more frequently, with an incidence of upto 50% (1-6). 
The underlying mechanism is considered to be related to ischemic and reperfusion da-
mage, which may be further complicated by an increased likelihood of acute rejection epi-
sodes (3,7) or drug-related nephrotoxicity (8).
There is debate on the impact of DGF on late graft outcome. Some authors reported an 
effect of DGF on renal allograft survival (9,10,10),while others only found inferior graft sur-
vival in patients who also experienced acute rejection episodes (11,12). 
One possible explanation for this apparent difference in outcome may be the defi nition of 
DGF that is used. To study risk factors for DGF and its clinical consequences, it is therefore 
very important to use a defi nition of DGF, in which the contribution of ischemia and reper-
fusion injury is stressed.
Defi nition of DGF
In most studies DGF is defi ned as the need of dialysis treatment in the fi rst week after renal 
transplantation. This is a criterion that is easy to register and to obtain from large databa-
ses (13). However, dialysis during the fi rst week after transplantation is also performed for 
other reasons than DGF, like hyperkaliemia and / or fl uid overload. Another fl aw in this 
defi nition is the inability to exclude acute rejection and calcineurin toxicity as an additional 
cause of impaired graft function. For that reason others have defi ned DGF as a functional 
parameter distinct from the need of dialysis and used the time needed to achieve an arbi-
trarily defi ned creatinine clearance as a marker for delayed graft function (9),(3,14). Using 
this defi nition they found an impact of DGF on short term graft survival and function, when 
DGF lasted for at least 1 week and rejection episodes were excluded. 
Because the pathogenesis of DGF is supposed to be of ischemic origin we propose to de-
fi ne DGF in clinical studies retrospectively on the basis of renal function, distinct from the 
need of dialysis treatment. Using the absence of a spontaneous decrease of serum creati-
nine of more than 10% per day for at least 3 consecutive days within 1 week after trans-
plantation, excluding acute rejection, and calcineurin inhibitor toxicity as a possible cause 
of this DGF, allows a more meaningful analysis of the risk factors and consequences of 
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ischemic damage and associated reperfusion injury that is supposed to be the underlying 
cause of DGF.
Acute ischemic renal injury and recovery
In the pathogenesis of acute ischemic failure 3 stages can be recognized (15). The fi rst 
stage is the ischemic phase in which ischemic and reperfusion injury takes place and in 
which renal epithelial and endothelial cells are subjected to lethal insults leading to apop-
tosis and /or necrosis (16). The maintenance phase represents a phase of stabilization of 
injury by intrinsic or upregulated defense mechanisms. During this phase, events leading 
to cellular repair, proliferation and redifferentiation. lead to the recovery phase in which 
epithelial en endothelial function improve, leading to the recovery of renal function.
1. Ischemic phase of ATN
Ischemia and reperfusion injury in acute tubular necrosis (ATN)
During the ischemic phase, renal metabolism is characterized by severe ATP depletion due 
to a lack of oxygen and a subsequent shift from aerobic to anaerobic metabolism (Fig 1.) 
(17). This leads to a disruption of cellular homeostasis, resulting in failure of the cellular 
sodium-potassium pumps as well as the calcium pumps (18). (19). Because of an increase 
in cytosolic calcium levels calcium dependent enzymes like cystein proteases, phospholi-
pases and endothelial nitric oxide synthetase (e-NOS) will be activated (20). These enzymes 
are able to break-down the cytoskeleton of the cells, eventually leading to cell death. Next 
to this purely ischemic condition, hypoxanthine is formed from xanthine which are degra-
dation products of adenosine triphosphate (ATP) (21). 
After the reinstitution of perfusion several factors contribute to the further damage. First 
of all the sudden increase of perfusion pressure causes endothelial damage and infl am-
mation. Next molecular oxygen (O
2
) is reintroduced, during reperfusion, which reacts with 
hypoxanthine which forms Reactive Oxygen Species (ROS). The free radical members of 
ROS are Superoxide (.O
2
) and the hydroxyl radical (.OH) and are probably the most impor-
tant biologically active free radicals, leading to extensive damage of the cell membranes 
by affecting its integrity. These processes eventually result in cellular apoptosis and / or 
cell death (22-24),(25). The cellular characteristics of this ischemic phase consist mainly of 
apoptosis and necrosis.
Apoptosis or programmed cell death is an active, energy dependent process with mor-
phological characteristics that differ markedly from necrosis. The essence of apoptosis is a 
process of cellular auto-digestion, which is regulated by activation and inhibition of enzy-
mes and which are identical for all human tissues. The key molecules are proteases named 
caspases of which the caspase-3 is the enzyme that is the end of the fi nal common path 
way (Fig.2). Upon activation of caspase-3, DNA is fragmented leading to the characteristic 
apoptotic bodies. Because of subsequent changes in the plasma membranes, the cells are 
removed by phagocytic cells.
Necrosis is seen in experimental animal models but only in a minority of the human cases 
(26-28). It is usually patchy involving individual cells or small clusters of cells sometimes re-
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sulting in small areas of denuded basement membrane (non-replacement phenomenon). 
Tubular cell necrosis is associated with a rapid metabolic collapse, cell swelling and early loss 
of plasma membrane integrity and the loss of the polarity and the integrity of their tight 
junctions is disrupted, perhaps as a consequence of alterations in the cytoskeletal network 
(18,29). Because of the redistribution of the Na/K-ATPases, tubular function is disturbed and 
cells die. This in turn leads to the release of proteolytic enzymes and other injurious cytosolic 
components into the extracellular space that incites an infl ammatory response. More subtle 
changes include loss of brush border, fl attening of the epithelium, detachment of cells, intra-
tubular cast formation and dilation of the tubules (26-28) (Fig. 3).
Figure 1. Schematic representation of the apoptotic cascade
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Figure 2. Schematic representation of the ischemia and reperfusion injury cascade
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2. Maintenance phase of ATN
The kidney has naturally present anti-oxidant enzymes to counteract the effects of the free 
radicals. The catalases and gluthathion peroxidase act by safely decomposing the peroxi-
des. The superoxide dismutases (SOD) act by scavenging the free radicals especially the .O
2
. 
In humans it is present in at least two forms, the cytoplasmatic copper/zinc (CuZn)-SOD and 
the mitochondrial manganese (Mn)-SOD. SODs are enzymes that catalyze the dismutation 
of .O
2




), which is decomposed, by other enzymes like catalase 
and gluthation peroxidase (22). The presence and the (down regulated) activity of these 
SOD’s seem to be related to the amount of damage induced by ROS in rat kidneys (30,31). 
However, the clinical use of human recombinant superoxide dismutase, did not protect 
against DGF in human kidneys (32,33). During the maintenance phase tubular cells share 
characteristics of the ischemic phase in which necrosis, apoptosis and the interstitial in-
fi ltrate are present and characteristics of the recovery and regeneration phase in which 
proliferation and redifferentiation are present.
Figure 3. Cell biological characteristics of the acute tubular necrosis 










3. Recovery phase of ATN
This process is regulated by the expression of a number of transcription factors, structural 
proteins and growth factors and is a copy of kidney organo-genesis in respect to the high 
rate of DNA synthesis, like PCNA, the expression of apoptosis and the expression of ge-
nes that encode for processes during renal organogenesis like keratin and vimentin (34) 
(35,36). On ischemia and reperfusion injury growth factors like the hepatic growth factor, 
insulin like growth factors and fi broblast growth factors are upregulated (37,38). Others 
such as epidermal growth factors are down regulated in injured proximal tubules (39). Tre-
atment with these growth factors in animal models was promising (37,40,41) but the use in 
humans is still limited (42). During recovery from ischemia and reperfusion injury, surviving 
tubular epithelial or renal stem cells, differentiate and proliferate, eventually replacing the 
irreversibly injured tubular epithelial cells and restoring tubular integrity (43,44). Morpho-
logically this is characterized by the presence of mitotic fi gures and signs of cell prolifera-
tion. This process enables the replacement of the damaged epithelium and is maximal at 
24 to 48 hours after ischemic injury in the rat. (45).
Risk factors of DGF
Using the earlier-mentioned functional defi nition of DGF, risk factors for post transplant 
acute renal failure (DGF) can be divided in donor-related factors, transplantation-related 
factors and recipient related risk factors. The cadaveric kidney is theoretically subjected 
to the cumulative damage at every step along the way from procurement to reperfusion 
whereas kidneys from living donors rarely develop DGF.
Risk factors related to the donor 
Well known donor related risk factors for DGF are donors of over 50 years of age and an 
elevated serum creatinine or suboptimal renal function of the donor. In human adults, renal 
blood fl ow (RBF) declines by approximately 10% per decade after the age of 40. This reduc-
tion of RBF is partially explained by a reduction of renal mass but is accompanied by an in-
creased afferent and efferent arteriolar resistance especially in the renal cortex (46,47). This 
change in glomerular fi ltration rate (GFR) is hard to detect when serum creatinine alone is 
taken into account: Muscle mass and consequently urinary creatinine excretion, decreases 
with age. This implies that for the same serum creatinine concentration, GFR in the elderly 
can be severely impaired in comparison to younger adults. Kidneys from older individuals 
have several structural and functional changes compared with kidneys from younger do-
nors. Longitudinal studies of elderly individuals have shown a diminution in renal reserve, 
along with functional constraints on the kidney’s ability to respond appropriately to chal-
lenges of either excesses or defi cits (48). Studies of kidneys obtained at autopsies demon-
strated a progressive decrease in the number and size of glomeruli with age, resulting in a 
progressive decrease of the glomerular fi ltration volume (49,50). In addition to the loss of 
glomeruli, there is an age-dependent increase in the cortical interstitial volume as a result 
of progressive interstitial fi brosis (49,51). Most renal biopsies from kidney donors who are 
older than 40 yr show intimal fi brosis in the smaller arteries, arteriolar hyalinosis, and inter-
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stitial fi brosis (52). Not only factors intrinsically related to the donor, but also events prece-
ding brain death and harvest of the kidney contribute to the occurrence of DGF. Before the 
establishment of brain death of the potential donor, the kidney may be damaged by the 
underlying disease process (e.g. hypotension or shock), or by the therapeutic maneuvers 
instituted in an attempt to revive the patient or to maintain circulation after brain death, 
like the use of dopaminergic medication and resuscitation procedures (53). Decreasing pla-
telet count and disseminated intravascular coagulation are frequently found and at least 
suggest that endothelial injury or dysfunction may already be present before the organs 
are harvested. During episodes of cardiac arrest or prolonged hypotension, the kidney will 
suffer from warm ischemia and reperfusion injury. Catecholamine release and pharmaco-
logical inotrope agents may contribute to intrarenal vasospasms leading to areas in the 
kidney subjected to relative hypoperfusion. Because the donor generally is in a catabolic 
state, recovery from ischemic damage is more diffi cult. After brain death but before explan-
tation, the potential donor may not be considered a high priority for surgery in the setting 
of a busy intensive care unit and resuscitation may be delegated to those with limited ex-
perience in appropriate care (54). 
Risk factors related to the transplantation procedure
Organ procurement also contributes to the development of DGF. This starts with hypoper-
fusion after circulation of the donor has stopped (warm ischemia time [WIT]). However, 
with the multi organ procurement procedures currently this WIT is almost reduced to zero. 
However, with the raising interest of non-heart beating procedures, WIT has nowadays be-
come a serious contributor to DGF (55), (56). During surgery errors in line placement can 
result in inadequate fl ushing of blood and / or cooling, and undue manipulation of renal 
arteries can induce vascular spasm (53). The most important independent and robust risk 
factor is the time that it takes from the explantation of the kidney until its transplantation 
into the recipient , defi ned by the cold ischemia time (CIT) (57-63). The type of preservation 
fl uid also is recognized as a risk factor for DGF in a study in the Eurotransplant area, in which 
the preservation fl uid developed by the University of Wisconsin (UW) appeared to be su-
perior to Euro Collins (EC) (64). After perfusion is reestablished several mechanisms exist 
that can damage the renal allograft including the generation of free radicals, mechanical 
injury to blood vessels from sudden high blood fl ow, vasomotor derangement from prosta-
glandins and other regulatory peptide imbalances and cytokine release from infl ammatory 
infi ltrates (65).
Risk factors related to the recipient
Recipient age is a risk factor for DGF especially when kidneys from pediatric donors to adult 
recipients are involved (6). The relation between the occurrence of DGF and the discrepan-
cy between donor and recipient Body Mass Indexes (BMI) supports this hypothesis (66). 
The lower occurrence rate of DGF with zero HLA mismatch and low levels of panel reactive 
antibodies (PRA) (67), suggests that immune factors are responsible for this relation. Be-
cause the studies that describe this effect, used dialysis treatment in the fi rst week as their 
defi nition of DGF, it is conceivable that early acute rejection activity constitutes the missing 
link (4,6,60). In addition, the use of calcineurin inhibitors is a riskfactor because their vaso-
constrictive properties infl uence renal perfusion and enhance ischemic damage (68).
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 Finally abnormalities in the calcium and phosphate metabolism are not uncommon in 
patients on the waiting list for a renal transplant. For instance secondary hyperparathyroi-
dism has been associated with a higher incidence of DGF (69,70). But studies on the effect 
of hypercalcemia and hyperparathyroidism in renal transplants are lacking.
DGF and long-term graft survival
The effect of DGF on short and long term patient and graft survival is unclear. Some aut-
hors reported an effect of DGF on graft survival (6,71) while others did not or only found 
this effect when it coincided with the occurrence of acute rejection episodes (72). Recent 
data on the outcome of grafts from non heart beating donors have shown, that if strict se-
lection criteria were applied with respect to donor age, warm ischemia time and duration 
of oliguria of the donor, long term graft survival was good, despite the high incidence of 
DGF (2). Brook et al (1).found that when long term graft survival of grafts from heart bea-
ting donors (HBDs) experiencing DGF are compared with grafts from non heart beating 
donors (NHBDs) with DGF, graft survival after 6 years of follow up is even better in the 
NHBD group 
When the survival curves are closely analyzed it is striking that 1 year after transplantation 
the survival curves run parallel. This suggests that DGF has its effect in the fi rst year post-
transplantation, but has no negative impact on graft survival beyond the fi rst year. This 
fi nding is supported by studies that analyzed risk factors on graft survival after 1 year and 
found that progression of chronic graft failure was mainly associated with donor age, cre-
atinine clearance, proteinuria and the presence of hypertension in the recipient and not 
with the occurrence of DGF per se (73).
DGF and renal function
One of the enigmatic problems of DGF is why some grafts react with DGF and others do 
not whereas the risk profi les are comparable Furthermore the effect of DGF on long term 
graft survival is unclear.
Slope and intercept
We proposed a theory on the course of graft function after transplantation. We presumed 
two variables to be important in the fi nal evolution of graft function over time. The inter-
cept determines the boundaries within which graft function develops. We suppose that this 
intercept refl ects the quality of the transplanted organ. The slope exemplifi es the long term 
course of graft function. Using this concept we analyzed renal function of 654 patients that 
were transplanted between 1983 and 1997. The creatinine clearance at 6 months was used 
at the determinant of the intercept of the graph that describes graft function over time 
and was categorized as more or less than 50 ml/min. Chronic decline in function, modeled 
by one or two least square fi tted regression lines after 6 months, was determined as a ne-
gative slope signifi cantly different from zero. We created four patterns of evolution of graft 
function over time (Fig 4). 41% of grafts resumed and maintained optimal function post im-
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plantation (creatinine clearance > 50 ml/min) whereas 28 % achieved a similar function but 
experienced function deterioration afterwards (negative slope) The remaining 31% had a 
creatinine clearance at 6 months of < 50 ml/min, of which half maintained stable function 
and the remaining grafts displayed progressive loss of function. Using logistic regression 
analysis we found that old donors and female gender of the donor, histoincompatibility 
,the incidence of delayed graft function and the incidence of acute rejection episodes in 
the fi rst 6 months were independent risk factors for a low intercept, whereas younger reci-
pient age, previous sensitization, class I histoincompatibility, baseline immunosuppression 
and late acute rejection episodes were associated with a negative slope. In the multivariate 
analysis proteinuria and diastolic blood pressure at 6 months were determinants of graft 
function deterioration. We also found that the rate of deterioration is dependent on graft 
function at 6 or 12 months (73), in which grafts with a function of < 50 ml/min that deteri-
orate have a faster decline in renal function than grafts with a creatinine clearance of over 
50 ml/min.
DGF and short term and long term graft function
In a recent study (3), we analyzed the risk factors and the impact of DGF on graft loss and 
renal function. DGF was diagnosed, when serum creatinine level increased, remained 
unchanged or decreased less than 10% per day immediately after surgery during three 
consecutive days for more than one week excluding acute rejection when anti rejection 
treatment was started within this fi rst week. Grafts that never functioned, ultimately lea-
ding to graft nephrectomy, were also excluded, because this is most often caused by sur-
gical complications like renal vein or artery thrombosis or by hyperacute rejection. The 
incidence of DGF was related to a donor age of more than 50 years (odds ratio [OR] 2.21; 
confi dence interval [CI]:1.49-3.26), cold ischemia time (CIT) of more than 28 hours (OR 1.78; 
CI:1.19-2.63), mean arterial pressure (MAP) of the donor of less than 100 mmHg (OR 2.08; 
CI:1.43-3.03) and the transplantation of a female donor kidney to a male recipient (OR 1.55; 
CI:1.15-2.55).
Analyzing the impact of DGF on graft survival and graft function we found that DGF was 
associated with a suboptimal 1 year graft function but neither with inferior long term nor 
short term graft survival. Suboptimal graft function after 1 year, defi ned as a serum crea-
tinine clearance of less than 50 ml/min was apart from the incidence of DGF associated 
with risk factors that can be classifi ed as non-immunological [donors over 50 years of age 
Figure 4 
Six hundred and four transplants catego-
rized according to intercept (endogenous 
creatinine clearance at 6 months) and slo-
pe of reciprocal creatinine concentrations 
beyond six months post-transplant (73)
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(OR 2.39; 95% CI: 1.61-3.57) or female donors (OR 1.99; 95% CI: 1.42-2.78)] and immuno-
logical (more than 1 acute rejection episodes in the fi rst year [OR 2.66; 95% CI: 1.87-3.78], 
peak panel reactive antibody level of more than 50% [OR 1.67; 95% CI: 1.15-2.47] and the 
number of shared Cross reactive groups major histocompatibility complex class I antigens 
(CREG ) [OR 1.65; 95% CI: 1.09-2.49]. Long term graft survival was related to graft function 
at one year and the number of acute rejection episodes or treatments during this fi rst year 
(Fig.5).
Tubular Function Slope (TFS) in MAG-3 renal scintigraphy 
To analyze the underlying functional mechanisms of DGF, we studied a group of 28 pa-
tients with immediate graft function (IGF) and 14 patients with DGF, with 99mTechnetium-
mercapto-acetyltriglycine (MAG-3) renography. The renal handling of MAG-3 is equivalent 
to paraminohippurate (PAH) (74). We defi ned TFS in a background subtracted MAG-3 graft 
curve: the fi rst 2 minutes consist of a rapidly ascending phase as a result from initial per-
fusion and a second phase representing the tubular extraction phase. The slope of this 
second phase was defi ned as the tubular function slope TFS (Fig.6 ). Because this can only 
be done by active proximal tubular cells we used this TFS as a marker for functional renal 
mass. We found that all grafts had an initial recovery phase of the TFS from the moment 
of transplantation until a maximum level was reached after 3 to 4 weeks, indicating that 
initial damage from the transplantation procedure was comparable in both groups and 
that both groups recovered equally. However, in absolute terms, grafts with Immediate 
Graft Function (IGF) always had a higher TFS as compared with grafts with DGF and this 
difference persisted until the end of follow up at 3 years after transplantation. When cre-
atinine clearance was analyzed for these grafts there also was a clear difference between 
the groups, but this did not reach the level of statistical signifi cance (14). These fi ndings 
suggested that grafts with DGF have an initial lower functional renal mass than grafts with 
IGF. Unfortunately this could not be translated in a difference in renal function, because of 
a lack of power of this study.or lack of accuracy in renal function estimation.
Figure 5. Graft survival according to graft 
function 1 year after transplantation. 
Kaplan-Meier estimates for transplants ex-
periencing a 1-year creatinine clearance of 
>50 ml/min (solid rule N= 339); 40-50 ml/
min (short dashed rule N= 135); 30-40 ml/
min (long dashed rule N= 79) < 30 ml/min. 





























Delayed graft function in renal transplantation
103
Figure.7 Creatinin clearances of 
grafts with and without DGF du-
ring fi ve years follow-up. 
a: At 3,6,12,24 and 60 months grafts expe-
riencing DGF had lower creatinin clearances 
than grafts that did not.
b: After correction for the initial TFS value, the 
curves were superimposable.
( dashed rule ,IGF ;solid rule, DGF).
















































a: Values of the tubular function slope (TFS) 
in the groups with and without DGF (14). Af-
ter correction for the initial TFS value, the curves 
were superimposable, (p = 0.85) indicating that 
the differences between the two groups were 
determined by the differences already present in 
the early post transplant 99mTc-MAG3 renograp-
hies ( dashed rule, IGF ;solid rule, DGF).
b: Creatinine clearances at 3,6,12 and 36 
months after transplantation. The values ten-
ded to be lower in patients that experienced DGF 
but did not reach statistical difference ( dashed 
rule, IGF ;solid rule, DGF).



































Therefore we expanded the groups with a population of seven hundred and ninety reci-
pients of cadaveric renal transplants in the era 1983 until 1997 from a former study and 
analyzed creatinine clearances in a the IGF group and DGF group during a 5 years follow 
up period. This analysis confi rmed that grafts with DGF had lower creatinine clearances 
than grafts that experience IGF, which was present during the whole period of follow-up 
(p < 0.0001). After correction for the initial difference in creatinine clearance between the 
2 groups, the curves show a identical pattern over time (p = 0.58). There was a decrease in 
creatinine clearance at 5 years follow up, which was mainly present in the IGF group. The 
relatively better results in the DGF group at 5 years are presumably caused by the lower 
number of grafts in the DGF group after 5 years, and the loss of badly functioning grafts at 
that moment (Fig.7)
Vulnerability and DGF
Damage versus protection 
The MAG-3 study gave us insight in the possible role of DGF in long-term graft function. We 
found that all grafts irrespective whether they develop DGF or not, experience an episode 
shortly after transplantation of impaired tubular extraction of MAG-3 that recovers within 
3 weeks. This initial deprivation is caused by ischemia and subsequent tubular dysfunction, 
apoptosis and necrosis characteristic for the initiation phase of acute tubular necrosis (15) 
and are identical for grafts with and without DGF. However, the reason why a graft responds 
to this initial peri-transplantation injury with anuria, remains to be explained: Kidneys have 
a capacity to resist or to recover from ischemic or chemical induced tubular necrosis. These 
protective and repair mechanisms are characteristic for the maintenance and recovery 
phase of acute renal failure in native kidneys. Well known enzymes that are involved in 
tissue protection against ischemia and reperfusion injury are the (SODs)(75) and the he-
moxygenase-1 (HO-1)(76,77). Theoretically grafts experiencing DGF have less protective 
and recovering capacity and therefore are more vulnerable to ischemic damage. A possible 
explanation for the difference between grafts reacting with DGF and grafts with immediate 
graft function lies in their ability to protect itself against ischemic and other damage during 
the whole transplantation procedure.
We therefore compared the expression of superoxide dismutases between grafts with and 
without DGF. We found that when manganese SOD was present, DGF occurs less frequent-
ly (Fig 8), whereas the presence of Cupper/Zinc and extra-cellular SOD had no effect. No 
relations were found between the incidence of the histological presence of ATN and the 
occurrence of DGF. However the presence of ATN correlated with a more extensive pre-
sence of active caspase-3 staining. These fi ndings support the idea that the way a kidney 
reacts on ischemia and reperfusion injury depends on the quality of the transplanted tis-
sue, which is represented by its protective enzymes. However, clinical trials with the use of 
rh-SOD in humans have been disappointing with respect to the incidence of DGF (32,78). 
Nevertheless a protective effective effect of treatment with Rh-SOD on long-term graft sur-
vival was found(78). Also a protective effect of hemo oxygenase-1 (HO-1) in rats has been 
found in vivo models with rats (79,80). 
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Calcium and calcium channel blockers and DGF
The role of calcium channel blockers in the protection against DGF is controversial (81-85). 
The protective role of CCB’s against DGF is thought to be due to its vasodilatory capacity, 
which counteracts the vasoconstrictive effects of the calcineurin inhibitors, cyclosporine 
A or tacrolimus. Disturbance of calcium homeostasis is important in the pathogenesis of 
ATN. 
Cytosolic calcium is a co-factor in the activation of cystein proteases like calpain and ca-
spase-3 (86-88), enzymes that have an important role in the process of ATN. Acute renal 
failure in native kidneys has been reported in patients with serum calcium levels above 3.5 
mmol/L. In native kidneys, acute renal failure due to hypercalcemia is describer in the milk 
alkali syndrome (89), severe hyperparathyroidism or PTH-related proteins (PTHrP) associa-
ted conditions(90) or multiple myeloma (91) and vitamin D intoxication (92). Little is known 
about the effects of hypercalcemia on the initial function of renal allografts. Torregosa et al. 
and Traindl et al. (69,70) reported a signifi cant effect of elevated PTH levels on the incidence 
of DGF, whereas serum vitamin D levels and serum calcium levels did not differ between 
the group with immediate graft function and the group with DGF.
The underlying mechanism explaining how calcium causes acute renal failure remains un-
resolved, but nephrocalcinosis may play a role. In animal models 3 types of nephrocalci-
nosis can be distinguished: chemical nephrocalcinosis, microscopic nephrocalcinosis and 
macroscopic nephrocalcinosis (93). The latter is characterized by gross calcium deposits 
found on radiographic investigations. Microscopic nephrocalcinosis is characterized by 
microscopic calcium deposits, mainly located in the lumen of the tubules. It is supposed to 
be a transitional phase between chemical and macroscopic nephrocalcinosis. Microscopic 
nephrocalcinosis is associated with increased calcium x phosphate product and with chro-
nic renal failure. Its effect on renal function is thought to be caused by tubular obstruction 
and tubular back-leak. Chemical nephrocalcinosis, assumed when macroscopic and mi-
croscopic are excluded, affects glomerular fi ltration rate by vasoconstriction and natriuresis 
Figure 8 
Distal tubular localization of Mn SOD in the presence (A) and absence (B) of DGF. Note the increased 
staining intensity of Mn SOD (red) in biopsies with DGF (right arrow). (Counter staining: anti-cubu-
lin (brown), identifying the brush border of proximal tubules. p, proximal tubules; d, distal tubules. 
Original magnifi cation: 400x) 
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induced volume constriction (94).It is histological characterized by areas of focal necrosis 
in the distal tubules and medullary collecting duct. High calcium content of the medullary 
area was found and the functional substrate was characterized by impaired function of 
the distal tubules. The role of cytoplasmatic calcium as an intracellular messenger in many 
important cell functions might explain these functional changes associated with the high 
cytoplasmatic calcium content. Calcium dependent enzymes that were analyzed in vitro in 
this respect are the cystein proteases, like calpaine and the caspases (20).
We therefore performed a study in which we analyzed the role of hypercalcemia in the 
occurrence of DGF. Serum calcium levels were correlated with the incidence of DGF in rela-
tion to other well known risk factors for DGF like donor age and cold ischemia time Further-
more the presence of calcium deposits in renal biopsies were correlated with the presence 
of DGF and serum calcium levels.
We found that hypercalcemia was an independent risk factor for DGF and that the pre-
transplant use of calcium channel blockers had a protective effect on the incidence of DGF. 
DGF was not associated with the presence of calcium deposits in renal biopsies, suggesting 
calcium infl uences tubular function by chemical nephrocalcinosis (95). This also suggested 
that the protective effect of calcium channel blockers is not only due to the formerly men-
tioned mechanisms but also by the prevention of the uncontrolled infl ux of calcium into 
tubular cells and subsequent activation of cystein proteases.
DGF as a herald rather than a risk factor for poor long term outcome
DGF in renal transplantation is a syndrome that is caused by ischemia and reperfusion in-
jury. This syndrome of acute renal failure is a result of the interaction between the defense 
mechanisms of the graft on the one hand and the ischemic insults during the whole trans-
plantation procedure on the other hand. Because these ischemic insults do not fully ex-
plain the graft’s reaction upon transplantation, the differences in the defense mechanisms, 
which can be translated as differences in quality of the graft, probably are the key to the 
explanation why a graft reacts with DGF or not.
The often found relation between DGF and poor graft outcome therefore should also be 
explained in this scope of differences in quality of the graft, rather than that DGF is an 
independent risk factor for long-term graft outcome. The following fi ndings support this 
hypothesis: First of all, we found that DGF was associated with a low intercept rather than 
with a negative slope in the curves that describe the evolution of graft function over time. 
Furthermore we showed during a follow up of 5 years that grafts from heart beating donors 
(HBD) reacting with DGF have an inferior long term graft function than grafts that do not 
react with DGF. Because this discrepancy was already present shortly after transplantation, 
we presume that differences in graft quality are also responsible for this phenomenon. The 
quality of the graft in essence determines, the full functional potentials of the graft which 
are determined by traditional risk factors for DGF, of which donor age and donor gender 
are important determinants. We found other arguments for our hypothesis in a MAG-III 
renography study in which a determinant of the functional renal mass, the tubular function 
slope (TFS), was found to be signifi cantly lower during a follow up period of 3 years, in 
the DGF group compared to the non-DGF group. This difference was also already present 
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shortly after transplantation. In an immuno-histochemical study we found a higher tissue 
expression of Mn SOD, a protective enzyme against ischemia and reperfusion injury and a 
possible marker of graft quality, in grafts experiencing immediate function. 
Other risk factors like cold ischemia time, brain death of the donor, the use vaso-active 
agents in the procurement of the donor and warm ischemia time represent the amount 
of ischemic insults that the graft must resist. When these ischemic insults are large enough 
also a graft with a good quality ultimately will react with DGF. However when the graft 
overcomes this insult, its function should recover to a level that corresponds with its in-
trinsic quality. Findings in non-heart beating donations (NHBD) in which warm ischemia 
is prolonged as a representative of the intensifi ed ischemic insults, illustrate that unless a 
high incidence of DGF, long term graft function and survival is equal in the NHBD and HBD 
group. Strikingly in the NHBD group donor age was lower and male gender more frequent. 
This may explain the comparable outcomes between the two groups, because this is de-
termined by organ quality is guaranteed (1,2). In heart beating donations we showed that 
the difference in function expressed as creatinine clearance between grafts experiencing 
DGF or not, is already present shortly after transplantation. Therefore it is not amazing that 
grafts experiencing DGF have a lower function during follow up. This means that DGF is an 
expression of poor quality rather than a cause of this graft deterioration.
Conclusion
DGF in renal transplantation is a syndrome that depends largely on the quality of the trans-
planted organ. Because the number of nephrons or the functional renal mass that is trans-
planted is determined at the time of the transplantation, the frame work within which graft 
function develops is set in the early post-transplant period. This functional renal mass is 
determined by factors like donor age and donor gender and this explains why these tradi-
tional risk factors are related with graft outcome. The occurrence of DGF is determined by 
the balance between ischemia reperfusion injury on the one hand and the functional renal 
mass and its protective mechanisms on the other hand. 
Renal function is inversely correlated with the incidence of cardio vascular events and the 
main cause of patient death on hemo- and peritoneal dialysis is cardio vascular disease, 
this is of extreme importance in our search to solve the problem of organ donor shortage. 
Despite increased donor awareness and actions, the actual number of organ donors has 
not increased to any meaningful extend. This disparity has led to an increased interest in 
the use marginal donors, including donors at the extremes of age, donors with a history 
of hypertension or diabetes and non heart beating donations. To use these donors in an 
appropriate way in order to achieve a high percentage of transplantation in patients with 
end stage renal disease and above all good graft function, the quality of the graft should be 
assessed at the time of donation. Separate from a strict risk stratifi cation in the case of non 
heart beating donation (96) and the use of histo-morphological criteria (97), measurement 
of MnSOD in the pretransplant biopsy might be of additive value to determine the quality 
of the graft. After having assessed this quality to some extend the ischemic insults to grafts 
with inferior function should be minimized. This can be done by minimizing the ischemic 
insults limiting cold and warm ischemia time and the use of a proper immunosuppressive 
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regimen. The peri-operative use of calcium channel blockers within the framework of is-
chemia reperfusion injury should be reevaluated. On the other hand interventions should 
be developed to augment the intrinsic resistance against ischemic reperfusion injury. The 
application of protective enzymes like manganese Super Oxide Dismutase (Mn-SOD) and 
Heme-Oxygenase-1 (HO-1) should be considered.
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Delayed graft function (DGF) in renal transplantation remains enigmatic. Progress in the re-
search after the etiology and consequences of DGF are hampered because DGF is a poorly 
defi ned syndrome and the clinical consequences of DGF on long term graft function have 
been diffi cult to ascertain. In general renal biopsies are not taken to document the cause 
of DGF but to exclude latent acute rejection episodes. Large biopsy studies on DGF are not 
consistently available. The interest in DGF has gained renewed interest with the increased 
use of marginal donors, including non-heart-beating donors, donors at the extremes of 
age, and donors with hypertension or diabetes. This group of donors experience DGF more 
frequently, with reported incidences of upto 50%.
Our knowledge on DGF is mainly based on studies in experimental animals and on clinical 
data on acute renal failure in native kidneys (Chapter 1). This comparison has major fl aws, 
since the risk factors and clinical setting for acute renal failure in the transplantation set-
ting are substantially different from the risk factors for acute renal failure in native kidneys. 
In the transplant setting the kidney suffers from cold ischemia after the graft is harvested 
from the donor and cold perfusion is started. This procedure can last as long as 48 hours. 
Furthermore after the transplantation procedure ATN can be complicated by an increased 
likelihood of acute rejection episodes or drug-related nephrotoxicity.
Pathogenesis of DGF
Despite the above mentioned fl aws, the underlying mechanism of DGF is considered to be 
related to ischemic and reperfusion damage, resulting in acute tubular necrosis. 
In the pathogenesis of acute tubular necrosis, 3 stages can be recognized. The fi rst stage is 
the ischemic phase in which ischemic and reperfusion injury (IRI) takes place and in which 
renal epithelial and endothelial cells are subjected to lethal insults leading to apoptosis 
and /or necrosis. The maintenance phase represents a phase of equilibrium between in-
jury and intrinsic or up regulated defense mechanisms, events leading to cellular repair, 
proliferation and redifferentiation. This may lead to the recovery phase in which epithelial 
en endothelial function improve, leading to the recovery of renal function.
Lack of consistency in defi nition of DGF and its consequences for risk factors long term conse-
quences
Risk factors for DGF are well known. These comprise older donor age, prolonged cold is-
chemia time and female gender of the donor. However there is debate on the impact of 
DGF on late graft outcome. Some authors reported an effect of DGF on renal allograft sur-
vival, while others only found inferior graft survival in patients who also experienced acute 
rejection episodes. 
One possible explanation for this apparent difference in outcome may be the defi nition 
of DGF that is used. In most studies DGF is defi ned as the need of dialysis treatment in the 
fi rst week after renal transplantation. This is a criterion that is easy to register and to ob-
tain from large databases. However, dialysis during the fi rst week after transplantation is 
also performed for other reasons than DGF, such as hyperkaliemia and / or fl uid overload. 
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Another fl aw in this defi nition is the inability to exclude acute rejection and calcineurin 
inhibitor toxicity as an additional cause of impaired graft function. To study risk factors for 
DGF and its clinical consequences, it is therefore important to use a defi nition of DGF, in 
which the contribution of ischemia and reperfusion injury is stressed. 
In this thesis we analyze the risks and consequences of delayed graft function, using a func-
tional defi nition in which acute rejection and calcineurin inhibitor toxicity was excluded 
and the ischemic origin of DGF was stressed: 
In this thesis we use a functional defi nition of DGF: We diagnosed DGF retrospectively, 
when serum creatinine level increased, remained unchanged or decreased less than 10% 
per day immediately after surgery during three consecutive days for more than one week 
excluding acute rejection when anti rejection treatment was started within this fi rst week. 
Grafts that never functioned, ultimately leading to graft nephrectomy, were also exclu-
ded.
 
The above mentioned introduction is a summary of chapter 1 of the thesis
In chapter 2 we analyzed the risk factors for the occurrence of DGF in a cohort of 734 
patients transplanted between 1983 and 1997. We found that the presence of DGF was as-
sociated with classical risk factors such as older donor age, a prolonged cold ischemia time 
and a low mean arterial blood pressure of the recipient. The impact of DGF was restricted 
to the quality of renal function (creatinine clearance) within the fi rst year after transplanta-
tion but was not associated with inferior long term graft outcome. Besides the occurrence 
of DGF, one year renal allograft function was associated with older donor age, female gen-
der of the donor and the occurrence of acute rejection episodes. Moreover, graft function 
after this fi rst year is mainly determined by the quality of allograft function at one year and 
not with a history of DGF or acute rejection.
Using these fi ndings, we hypothesized that, since graft function is correlated with the num-
ber of functioning nephrons (functional renal mass), DGF and long term graft function are 
related with each other through this functional renal mass. As it is known from literature 
that renal mass is infl uenced by age and gender, this functional mass might be the con-
necting link that explains the relation between DGF and poor graft outcome.
In chapter 3 we tested this hypothesis in a study that correlated the renal functional mass 
with long-term graft outcome. The functional renal mass was determined using the tubu-
lar function slope (TFS), a parameter in 99mtechnetium mercaptoacetyltriglycine (99mMAG-
3) scintigraphy. In a group of 42 grafts, 14 experienced DGF and had a signifi cant lower 
functional renal mass than 28 grafts without DGF. This difference persisted during the total 
follow up period of 3 years. When the creatinine clearances were analyzed in the group of 
734 patients described in chapter 2, the creatinine clearances in the DGF group were signi-
fi cantly lower during follow up period as compared with patients with immediate function 
of their transplanted kidney.
Another striking fi nding was that, in the DGF group as well as in the PF group, the functi-
onal renal mass was severely reduced directly after transplantation. Recovery took place 
within 1 month after transplantation and was identical for both groups. From these fi n-
dings we conclude that ischemia and reperfusion injury leads to injury that is identical for 
all grafts. Its effect on functional renal mass of the graft disappeared within 1 month.
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Chapter 7
Hypercalcemia is frequently seen in patients on renal replacement treatment. This is cau-
sed by the use of calcium containing phosphate binders and vitamin D analogues, in order 
to prevent hyperparathyroidism and related bone disease. However studies on the effect 
of hypercalcemia on DGF are lacking in literature. Hypercalcemia can result in renal failure 
in native kidneys (nephrocalcinosis), but the exact mechanism of how hypercalcemia leads 
to renal failure is not well known. 
In experimental models 3 types of nephrocalcinosis are recognized:
1. Macroscopic nephrocalcinosis is characterized by calcium deposits that are recog-
nized by ultrasound.
2. Microscopic nephrocalcinosis is characterized by the presence of calcium contai-
ning deposits in tubules, recognized by light microscopy.
3. Chemical nephrocalcinosis, is assumed when no calcium deposits are found in the 
presence of hypercalcemia and acute renal failure. Chemical nephrocalcinosis might 
be associated with high cytosolic calcium levels, that activate enzymes associated 
with necrosis and apoptosis.
In chapter 4 we described, to our knowledge, for the fi rst time the relation between hyper-
calcemia and the occurrence of DGF in a group of 585 recipients of a cadaveric graft. We 
also looked for an anatomical substrate in 71 renal biopsies that were taken within the fi rst 
week after transplantation. The presence of calcium crystals and signs of tubular necro-
sis did not correlate with serum calcium levels, suggesting that chemical nephrocalcinosis 
could be a determinant of DGF.
Another striking fi nding was that the use of calcium channel blockers (CCBs) protected 
against the occurrence of DGF. In the past these CCBs were frequently studied with the 
idea that its vasodilatory characteristics protected against calcineurin inhibitor toxicity. 
The results of these studies were not uniform and therefore CCB’s are not used in clinical 
practice to prevent calcineurine inhibitor toxicity on a regular base. We found in a group 
of patients in which by defi nition calcineurin toxicity was excluded as a cause of DGF that 
the use of CCBs protected against the occurrence of DGF. This is probably explained by the 
prevention of high cytosolic calcium levels and subsequent activation of enzymes involved 
in the process of necrosis and apoptosis, like calpaines and caspases, involved in the pa-
thogenesis of ATN.
Whether DGF develops in the allograft, depends on the balance between apoptosis and 
necrosis inducing factors on the one hand and protective factors on the other hand. In 
our opinion these protective factors are important determinants the quality of the graft 
and consequently long term graft outcome. The superoxide dismutases (SOD) are enzy-
mes that act as scavengers of radicals that are produced upon ischemia and reperfusion 
damage. 
In chapter 5 markers that are representative of the three stages in the development of ATN 
are studied in renal biopsies from grafts with and without DGF. Damage factors that domi-
nate the initiation phase were visualized by morphological examination and by staining for 
active caspase 3, which is a major effector enzyme in the process of apoptosis. The protec-
tive response, that is important in the maintenance phase, was visualized by manganese 
SOD (Mn SOD). Signs of regeneration and proliferation, characteristic for the regeneration 
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phase are characterized by vimentin and Ki-67 staining respectively. We found that grafts 
without DGF had a more intensive staining for Mn SOD. The presence of tubular necrosis 
was, as expected, associated with active caspase-3 staining. The presence of vimentin and 
Ki 67 was associated with recovery of renal function but these data do not reach the level 
of signifi cance. These fi ndings support the hypothesis that the occurrence of DGF was the 
resultant of the balance between protective and damaging factors. Since the occurrence 
of DGF is associated with older donor age and female gender of the donor, the connecting 
link between these epidemiological and immunohistochemical factors, probably is the 
quality in terms of functioning nephrons of the graft. We propose that the presence of 
Manganese SOD in a pre-transplant biopsy can help to determine graft quality. Supple-
mentation of Manganese SOD to grafts might be a method to diminish the occurrence of 




Het vertraagd op gang komen van een nier die net getransplanteerd is, of te wel delayed 
graft function (DGF), wordt in de literatuur met een frequentie tot 50% van de getrans-
planteerde nieren beschreven. De klinische implicatie van dit fenomeen is dat patiënten 
na de transplantatie vaak alsnog gedialyseerd moeten worden en dat er weefselmonsters 
(biopten) uit de getransplanteerde nier moeten worden genomen om bijvoorbeeld acute 
afstoting (rejectie) of de bijwerking van geneesmiddelen uit te sluiten. Hierdoor verblijven 
patiënten met een vertraagd op gang komende nier gemiddeld langer in het ziekenhuis 
dan patiënten van wie de nier wel direct na de transplantatie goed functioneert. De nieren 
met DGF komen uiteindelijk altijd op gang en uiteindelijk hoeft de getransplanteerde pa-
tiënt niet meer gedialyseerd te worden.
Als onderliggend mechanisme voor DGF wordt zgn. ischemie- en reperfusie (I/R)schade 
verondersteld. Deze treedt tijdens de transplantatieprocedure m.n. op als de bloedvoor-
ziening van de transplantaatnier wordt hersteld, wanneer de donornier bij de ontvanger 
wordt geïmplanteerd. Donornieren worden over het gehele Eurotransplant gebied ver-
spreid, waardoor het transport van een orgaan door Europa soms tot 40 uur kan oplopen. 
Hierdoor ontstaat een periode van bloed- en zuurstofl oosheid, die ischemie- en reperfusie-
schade veroorzaakt. Als gevolg van de I/R schade worden de verzamelbuizen van de nier 
(tubuli) beschadigd. Dit wordt acute tubulus necrose (ATN) genoemd, waarna de functie 
van de nier uiteindelijk weg valt. De kennis over de ontwikkelingsfasen bij ATN is met name 
gebaseerd op gegevens uit dierexperimenteel onderzoek en op een vergelijkbaar ziekte-
beeld bij niet-getransplanteerde patiënten, die op een Intensive Care afdeling worden op-
genomen en van wie de nieren niet meer werken ten gevolge van ATN. 
In deze modellen worden 3 fasen onderscheiden bij de ontwikkeling van acute tubulus 
necrose. Deze fasen kunnen gelijktijdig naast elkaar voorkomen. De eerste fase is de is-
chemische fase, een fase waarin als gevolg van het tekort aan zuurstof celdood optreed. Bij 
het optreden van deze celdood zijn enzymen betrokken zoals de calpainen en caspases die 
voor hun activiteit afhankelijk zijn van de aanwezigheid van calcium. De tweede fase is de 
fase waarbij een evenwicht bestaat tussen de bovengenoemde beschadigende factoren en 
de in de nier aanwezige beschermende factoren. Als uiteindelijk het herstel de overhand 
krijgt boven de beschadigende factoren, blijkt de nier een opmerkelijke mogelijkheid te 
hebben tot regeneratie. Deze derde fase van herstel wordt op weefselniveau gekenmerkt 
door snel delende cellen (mitoses) die kapotte dode cellen vervangen. Deze sneldelende 
cellen zijn waarschijnlijk stamcellen uit het nierweefsel of wellicht zelfs uit het beenmerg. 
Ze vertonen in deze korte tijd kenmerken van de gehele embryonale ontwikkeling van de 
nier, alvorens als volgroeide niercel te kunnen functioneren.
Over DGF bij de mens is in de transplantatie literatuur slechts weinig bekend. De bovenge-
noemde dierexperimentele kennis is niet zonder meer naar de humane situatie te vertalen, 
omdat er bij de transplantatiegeneeskunde veel oorzaken zijn waardoor een nier na de 
transplantatie niet op gang komt. Zo kan een acute rejectie (afstoting) of bijwerkingen van 
de immunosuppressiva (calcineurine remmer toxiciteit) een bijkomende oorzaak zijn voor 
het vertraagd op gang komen van de nier. Het is van belang om onderscheid te maken tus-
sen de eerder genoemde I/R schade en deze twee laatste omstandigheden (acute afstoting 
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en bijwerkingen van immunosuppresiva), omdat aan de laatste specifi eke therapeutische 
consequenties verbonden zijn: Zo moet een acute afstoting behandeld worden en moet 
in het geval van calcineurine remmer toxiciteit de dosering van het geneesmiddel worden 
aangepast. Daarom worden er in de vroege periode na transplantatie met enige regelmaat 
biopten uit de net getransplanteerde nier genomen.
De betekenis van het optreden van DGF voor het functioneren van de getransplanteerde 
nier op de middellange en lange termijn is niet duidelijk. Zo zijn er onderzoekers die con-
cluderen dat DGF geen effect heeft op duur dat de getransplanteerde nier functioneert 
(transplantaatoverleving). Anderen concluderen daarentegen dat DGF alleen van invloed 
op de transplantaatoverleving is als het in het beloop gevolgd wordt door het optreden 
van een acute afstoting reactie (rejectie). Weer anderen vinden dat als een nier na de trans-
plantatie meer dan 1 week niet functioneert, de nier aanmerkelijk minder lang werkt dan 
als hij direct of binnen een week op gang komt (primaire functie (PF). 
De reden dat er zo veel uiteenlopende meningen over de betekenis van DGF voor de lange 
termijn transplantaat overleving bestaan, is tweeërlei. In de eerste plaats bestaat er in de 
literatuur geen duidelijke en eenduidige defi nitie voor het syndroom DGF. Veel onderzoe-
kers houden als criterium aan, of een patiënt na de transplantatie al dan niet gedialyseerd 
moet worden. Het nadeel van deze defi nitie is dat een getransplanteerde patiënt om een 
heel aantal andere redenen dan het niet op gang komen van de nier, gedialyseerd kan 
moeten worden. Zo komt het nogal eens voor dat een patiënt na de transplantatie dialyse 
behandeling behoeft vanwege een teveel aan vocht dat is toegediend tijdens de operatie 
of een te hoog kalium of fosfaat gehalte van het bloed. Zoals eerder gezegd kan het ook zo 
zijn dat een nier niet direct op gang komt vanwege het optreden van een acute afstoting of 
een te hoge dosering van de immunosuppressieve medicatie. Omdat dit allemaal aandoe-
ningen zijn met verschillende oorzaken en toch allemaal worden aangeduid als DGF, is het 
niet verbazingwekkend dat de uitkomsten van verschillende onderzoeken niet eenduidig 
zijn.
In de tweede plaats was de interesse voor het klinische probleem van DGF nooit erg groot 
omdat het een aandoening is die in het algemeen vanzelf weer over gaat. Onderzoek 
naar de oorzaak van DGF werd om die reden dan ook zelden gedaan. Nierbiopten werden 
slechts genomen om acute afstoting of calcineurine remmer toxiciteit aan te tonen en niet 
om het onderliggende mechanisme voor het ontstaan van DGF te bestuderen. Hierdoor is 
er maar weinig menselijk weefsel voor onderzoek naar DGF beschikbaar. 
De interesse voor DGF is de laatste jaren echter toegenomen. Dit komt omdat de wachtlijst 
voor een niertransplantatie aanzienlijk is verlengd, als gevolg van een dramatische afname 
van het aantal postmortale donoren de afgelopen 8 jaar. Daarom wordt er momenteel ge-
zocht naar mogelijkheden om dit donortekort aan te vullen. Naast een toename van het 
aantal levende donaties, waarbij een familielid, vriend of kennis een nier aan een dialysepa-
tiënt afstaat, wordt een deel van het probleem opgelost door de criteria voor het selecteren 
van een potentiële postmortale nierdonor aan te passen. Oudere donoren (dwz. donoren 
ouder dan 70 jaar) of donoren die een hoge bloeddruk of suikerziekte hebben, komen nu 
ook, onder bepaalde strikte voorwaarden, in aanmerking voor donatie. Daarnaast wordt 
er uitgebreid onderzocht of potentiële donoren die niet alleen hersendood maar ook een 
hartstilstand hebben gehad (non heart beating donation), in aanmerking komen voor do-
natie. Bij deze laatste twee groepen van donoren is het opvallend dat het aantal malen dat 
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DGF optreedt aanzienlijk hoger is dan in de groep van bijvoorbeeld de bij leven gedoneer-
de nieren of de nieren die bij het constateren van de hersendood van de donor worden 
getransplanteerd (heart beating donation). We worden dus meer met DGF geconfronteerd 
en daarom is het opportuun om DGF en ATN in de humane situatie te onderzoeken.
Bovenstaande inleiding over delayed graft function bij niertransplantatie is een samenvat-
ting van hoofdstuk 1 van dit proefschrift. Het doel van het vervolg van dit proefschrift is 
om met een duidelijke defi nitie van DGF, waarbij de I/R schade centraal staat en waarbij 
acute rejectie en calcineurine remmer toxiciteit zoveel mogelijk als oorzaak voor DGF zijn 
uitgesloten, de risicofactoren voor en de gevolgen van DGF voor het functioneren van de 
nier op de korte en lange termijn te defi niëren. Op die mannier kunnen we uiteindelijk tot 
een hypothese komen over het mechanisme van DGF en hoe uiteindelijk de invloed van 
DGF is op de korte en lange termijn transplantaat functie.
In hoofdstuk 2 wordt een onderzoek beschreven waarbij in een cohort van 734 patiënten 
die tussen 1983 en 1997 werd getransplanteerd de risicofactoren voor het optreden van 
DGF werden vastgesteld. Het blijkt dat klassieke risicofactoren zoals een donorleeftijd bo-
ven de 50 jaar, een lage bloeddruk van de acceptor ten tijde van de transplantatie en een 
koude ischemie duur (KIT) van meer dan 28 uur, met name bepalen of een nier reageert 
met DGF. Een belangrijke bevinding is verder dat de duur dat een nier op de lange termijn 
functioneert, vooral afhankelijk is van de functie die na 1 jaar na de transplantatie is verkre-
gen. Deze 1 jaars transplantaat functie blijkt m.n. afhankelijk te zijn van de leeftijd van de 
donor, het optreden van DGF en het aantal acute rejectie episodes die in dit eerste jaar zijn 
opgetreden. Dus de verdere ontwikkeling van de transplantaat functie na het eerste jaar 
blijkt verder niet afhankelijk te zijn van het optreden van DGF of het optreden een acute 
afstoting, maar alleen van de functie die na een jaar na transplantatie is bereikt.
Met deze gegevens is de hypothese opgesteld dat de nierfunctie bepaald wordt door de 
hoeveelheid functionerend nierweefsel (functionele renale massa). DGF en de nierfunctie 
op de lange termijn zij beide een uiting van nier functie en dus indirect ook een resultante 
van de functionele renale massa. Omdat uit de literatuur bekend is dat de renale massa 
wordt beïnvloed door factoren als leeftijd en geslacht zou het begrip ‘functionele renale 
massa’ de relatie tussen DGF en lange termijn transplantaat functie kunnen verklaren.
Om deze hypothese te toetsen wordt in hoofdstuk 3 een studie beschreven waarin de 
hoeveelheid functionerend nierweefsel wordt onderzocht in relatie tot het optreden van 
DGF en de lange termijn uitkomst. De hoeveelheid functionerend nierweefsel wordt mid-
dels een techniek uit de nucleaire geneeskunde (99mtechnetium mercaptoacetyltriglycine 
(99mMAG-3) scintigrafi e) vast gelegd. In een groep van 42 getransplanteerde nieren blijken 
de 14 nieren die met DGF reageren, direct na de transplantatie een kleinere hoeveelheid 
functionerend nierweefsel te hebben dan de 28 nieren die direct op gang komen (primaire 
functie). Dit verschil blijft gedurende een follow-up periode van drie jaar bestaan. 
Wanneer de creatinineklaring wordt berekend, als maat voor de transplantaatfunctie, blijft 
dit verschil ook gedurende deze follow-up periode van drie jaar , maar de signifi cantie is 
net niet te bereiken. Daarom werd de analyse in de grotere groep die in hoofdstuk 1 is be-
studeerd, opnieuw uitgevoerd. In deze groep bleek het verschil in creatinineklaring tussen 
de DGF en de PF groep, gedurende de gehele drie jaar follow-up, wél signifi cant te zijn. 
Een ander opvallende bevinding is dat de functionele renale massa direct na de transplan-
tatie in beide groepen (DGF én PF) verlaagd is en dat in beide groepen een identiek herstel 
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patroon te zien is die na 3 tot 4 weken zijn volledige beslag heeft gekregen. Hieruit kan 
geconcludeerd worden dat de I/R schade voor alle getransplanteerde nieren hetzelfde is 
en er dus een zelfde periode van 3 a 4 weken nodig is om hier volledig van te herstellen.
Een verhoogd serum calcium (hypercalciaemie) leidt bij niet getransplanteerde nieren tot 
nierfunctiestoornissen. Het precieze mechanisme hier achter is niet geheel duidelijk. Calci-
um is een ion dat in het lichaam in grote hoeveelheid aanwezig is De grootste hoeveelheid 
bevindt zich in het bloed, deels gebonden aan eiwitten en deels als vrij calcium en in de 
botten. De functie van calcium is gelegen in de bot op- en ombouw en daarnaast heeft het 
een belangrijke bijdrage in het op peil houden van de zuurgraad van het lichaam.. Verder 
is calcium werkzaam als een zogenaamde co-factor bij de activatie van tal van enzymen in 
het lichaam. Een groep van enzymen waar calcium een belangrijke co-factor voor is, zijn de 
enzymen die betrokken zijn bij het ontstaan van celdood (necrose) en geprogrammeerde 
celdood (apoptose), zoals calpaine en de caspases.
In dierexperimenteel onderzoek worden drie vormen van door calcium veroorzaakte nier-
functiestoornissen beschreven:
1. macroscopische nefrocalcinose, gekenmerkt door calciumzout neerslagen in het nier-
weefsel die middels echografi e geïdentifi ceerd kunnen worden.
2. microscopische nefrocalcinose, gekenmerkt door de aanwezigheid van calciumzouten 
op microscopisch niveau.
3. chemische nefrocalcinose, wanneer in het geheel geen calciumzout neerslagen in het 
nierweefsel worden waargenomen. Deze laatste vorm van calcium gerelateerde nier-
functie stoornis wordt mogelijk veroorzaakt doordat calcium enzymatische proces-
sen onderhoudt, die uiteindelijk acute tubulus necrose veroorzaken. 
Hypercalciaemie (te hoge calcium gehalte in het bloed) komt frequent voor bij patiënten 
die worden gedialyseerd. Dit heeft te maken met het frequente gebruik van calciumhou-
dende medicijnen (fosfaatbinders) en vitamine D. Deze medicijnen worden gebruikt om 
de nadelige gevolgen van te hard werkende bijschildklieren (hyperparathyreoidie) op bot-
ten en bloedvaten te verminderen. Deze hyperparathyreoidie treedt op als de nieren min-
der of niet meer werken. Echter, studies naar het verband tussen hypercalciaemie en het 
optreden van DGF na niertransplantatie zijn nooit gepubliceerd. 
In hoofdstuk 4 beschrijven wij de voor het eerst in de literatuur gevonden relatie tussen 
het bestaan van hypercalciaemie en het ontstaan van DGF. Een andere opvallende bevin-
ding is dat het gebruik van medicijnen die de calcium opname in cellen remt (calcium 
channel blockers (CCB’s)), bescherming biedt tegen het optreden van DGF. Deze CCB’s zijn 
in het verleden onderzocht met het idee dat zij door het verbeteren van de doorbloeding 
van de nier de nadelige werking van cyclosporine, een calcineurine remmer, konden te-
gengaan. De resultaten van deze studies zijn echter niet eenduidig. In de door ons onder-
zochte groep, waarin per defi nitie calcineurine remmer toxiciteit was uitgesloten, hebben 
deze CCB’s wel een betekenis. Wellicht komt dit doordat CCB’s voorkómen dat er hoge 
calciumconcentraties in de cel ontstaan waardoor chemische nefrocalcinose, en in aanslui-
ting DGF, wordt voorkomen.
Daarnaast beschrijven wij in hoofdstuk 4 ons onderzoek naar een anatomisch substraat 
voor DGF en deze serum calciumwaarden in nierbiopten. Daartoe onderzochten wij 71 bi-
opten die in de eerste week na transplantatie waren genomen en waarin geen acute rejec-
tie of calcineurine remmer toxiciteit aanwezig was, op de aanwezigheid van calciumfosfaat 
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kristallen. Deze bevindingen correleerden we met de serum calciumwaarden en tekenen 
van ATN. Wij vonden geen correlatie tussen de aanwezigheid van calciumneerslagen in het 
nierweefsel en de hoogte van de serum calciumwaarden. Dit ondersteunt de hypothese 
dat het calcium een andere rol heeft bij het ontstaan van DGF dan door de vorming van 
calcium zout neerslagen die meestal vermoed worden.
Om de balans tussen necrose en apoptose inducerende mechanismen aan de en kant en 
de aanwezigheid van beschermende factoren aan de andere kant te bestuderen, hebben 
wij in hoofdstuk 5 nierbiopten, die in de eerste week na transplantatie werden genomen, 
van patiënten met en zonder DGF, bestudeerd. De aanwezigheid van apoptose werd met 
behulp de markers TUNEL en caspase-3, gevisualiseerd. Daarnaast keken we of de aan-
wezigheid van beschermende factoren, zoals mangaan superoxide dismutase (Mn-SOD) 
geassocieerd is met het minder optreden van DGF of het vinden van ATN in deze biopten. 
Ten slotte keken wij of de aanwezigheid van vimentine en Ki 67, beide markers voor de 
regeneratie en het herstel van de nier, geassocieerd was met het optreden van DGF of de 
aanwezigheid van ATN. Wij vonden dat de expressie van actief caspase-3 verhoogd was 
als meer ATN in de biopten gevonden werd. Biopten uit transplantaten van patiënten die 
geen DGF hadden, vertoonden een hogere expressie van Mn-SOD dan die van patiënten 
met DGF. Deze bevindingen steunen onze hypothese dat een balans tussen beschadigen-
de en beschermende factoren bepaalt of een getransplanteerde nier direct functioneert of 
niet. Het zou zo kunnen zijn dat de mate van aanwezigheid van Mn SOD een uiting is van 
de kwaliteit van het getransplanteerde orgaan en dat het niet alleen geassocieerd is met 
het minder optreden van DGF maar ook met een betere transplantaat overleving.
Hoofdstuk 6 is een review over DGF bij niertransplantatie, waarbij de huidige inzichten 
over pathofysiologie en klinische betekenis zijn weergegeven.
Samenvattend is onze hypothese dat delayed graft function (DGF) in de niertransplan-
tatie een syndroom is dat voor het grootste deel bepaald wordt door de kwaliteit van het 
getransplanteerde orgaan. Omdat het aantal nephronen, of te wel de functionele renale 
massa, die initieel getransplanteerd wordt al bepaald is ten tijde van de transplantatie, zijn 
de grenzen waarbinnen de nierfunctie zich kan ontwikkelen al ten tijde van de ingreep 
en in de vroege periode hierna bepaald. De functionele renale massa is geassocieerd met 
determinanten zoals de leeftijd en geslacht van de donor. Daarom zijn deze risicofactoren 
niet alleen gerelateerd aan DGF maar ook aan het uiteindelijke lot van het transplantaat op 
de lange termijn.
Het optreden van DGF wordt bepaald door de balans tussen aan de ene kant ischemie- en 
reperfusieschade en de beschermende factoren aan de andere kant. De aanwezigheid van 
de beschermende factoren, die van nature aanwezig zijn of opgereguleerd worden zoals 
de superoxide dismutasen (SOD) kan worden samengevat als de kwaliteit van het orgaan 
en zou in de toekomst als leidraad kunnen fungeren bij de verdeling en toewijzing (alloca-
tie) van organen. Zo kunnen de schaarse organen zo goed mogelijk worden gealloceerd, 
waardoor zo veel mogelijk mensen zo effi ciënt mogelijk geholpen kunnen worden met 
een goed en langdurig werkend niertransplantaat.
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